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Abstract
Frontotemporal lobar degeneration (FTLD) is a fatal neurodegenerative disease with presenile
onset. Clinically, it mainly presents with language disorders or personality and behavioural
changes whereas pathologically patients show atrophy of the frontal and temporal lobes of the
brain. Like in other neurodegenerative disorders, abnormal protein deposition can be detected
in the aﬀected areas of the brain nervous system. However, several diﬀerent proteins have been
identiﬁed to be the main component of these inclusions accordingly leading to the diﬀerentia-
tion of so far ﬁve distinct types of FTLD, namely FTLD-tau, FTLD-TDP (TAR DNA-binding
protein 43), FTLD-FUS (Fused in Sarcoma), FTLD-DPR (dipeptide repeat protein) and FTLD-
UPS (ubiquitin-proteasome system). FTLD-TDP comprises 45 % of all FTLD cases and thus
represents one of the two main pathological subtypes of FTLD.
In the last few years, tremendous progress has been made in the identiﬁcation of the genetic
causes for FTLD-subtypes; among them, the identiﬁcation of mutations in the progranulin
(GRN ) gene in FTLD-TDP. Interestingly, even though haploinsuﬃciency of progranulin was
demonstrated to be causative for FTLD-TDP, the same GRN mutation could present with dif-
ferent ages of disease onset in diﬀerent patients. This argued for additional factors that might
modulate disease onset. In order to identify such genetic factors, a genome-wide association
study was performed in genetically or pathologically conﬁrmed FTLD-TDP cases. Thereby,
twelve single-nucleotide polymorphisms mapped to a 68 kb interval located on chromosome
7p21.3 implicating that this might be a common genetic susceptibility locus for FTLD-TDP. This
region only comprised one gene encoding for the transmembrane protein 106B (TMEM106B).
Interestingly, the risk allele of TMEM106B was especially associated with FTLD risk in patients
carrying a GRN mutation which suggested a functional relationship between those two proteins.
However, TMEM106B was an uncharacterized protein of unknown function. Thus, the motiva-
tion of my study was to investigate the biochemical features of TMEM106B, followed by exam-
ining the relationship between TMEM106B and GRN and ﬁnally, by investigating TMEM106B
function.
In the ﬁrst part of this study, membrane orientation, cellular localization and the glycosylation
status of TMEM106B were determined and tools developed. By sequential inactivation of the ﬁve
predicted N-glycosylation motifs, TMEM106B was demonstrated to be a type II transmembrane
protein that is N-glycosylated at the amino acid positions 146 (N1), 152 (N2), 165 (N3), 184 (N4)
and 257 (N5). Moreover, only N4 and N5 proved to be complex glycosylated whereas N1, N2 and
N3 did not. By immunoﬂuorescence, TMEM106B was determined to be a lysosomal protein.
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Interestingly, mutants where one of the two complex glycosylation motifs was deleted showed
a diﬀerent intracellular localization whereas deleting the non-complex glycosylation motifs did
not change TMEM106B localization. This indicated that complex glycosylation was essential
for correct TMEM106B positioning in the cell.
In the second part of this study, the inﬂuence of TMEM106B expression on GRN levels was
analysed in various cell lines. However, neither overexpression nor knockdown of TMEM106B
changed intracellular or secreted GRN levels indicating that both proteins probably do not in-
ﬂuence each other directly. However, interestingly, baﬁlomycin A1 (BafA1) treatment which in-
hibits lysosomal acidiﬁcation and thus lysosomal function increased both GRN and TMEM106B
protein levels suggesting that both proteins might act in a common pathway or might be lo-
cated in the same compartment. Since treatment with proteasomal inhibitors did not increase
TMEM106B levels, this observation further indicated that TMEM106B is mainly degraded by
the lysosome.
In the third part of this study, the endogenous function of TMEM106B was investigated us-
ing siRNA-mediated TMEM106B knockdown in a cell culture model. Thereby, TMEM106B
knockdown was shown to change lysosomal positioning as lysosomes clustered tightly at the
microtubule-organizing center instead of being distributed throughout the cell. A rescue expe-
riment, where endogenous TMEM106B was knocked down ﬁrst and then, additionally, either a
control vector or exogenous TMEM106B was transfected, proved that lysosomal clustering was
the result of TMEM106B loss and not a side eﬀect of siRNA transfection.
Furthermore, lysosomal clustering upon TMEM106B knockdown was shown to be dependent
on functional retrograde transport and an intact microtubule network. In addition, lysosomes
were demonstrated to be still acidic and, in principle, functional upon TMEM106B knock-
down. Interestingly, however, lysosomal and autophagosomal protein levels increased signiﬁ-
cantly upon TMEM106B knockdown, suggesting that the autophagic pathway might be aﬀected
by TMEM106B levels. Since GRN had been implicated in playing an important role for lyso-
somal function and thus in the autophagic pathway, the ﬁnding that TMEM106B also has an
impact on this pathway might explain why TMEM106B polymorphisms are especially associ-
ated with GRN mutation carriers but also why TMEM106B is a general risk factor for FTLD.
Changes in the autophagic pathway seem to be common in neurodegenerative disorders as for
example in Alzheimer’s, Parkinson’s and Huntington’s disease, the autophagic pathway has been
reported to be impaired in the course of disease. My ﬁndings would support the notion that
also in FTLD, autophagy plays an essential part in disease progression.
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Zusammenfassung
Frontotemporale lobäre Degeneration (FTLD) ist die zweithäuﬁgste Ursache präseniler Demenz.
Klinische Symptome beinhalten vor allem eine Veränderung der Persönlichkeit und des sozialen
Verhaltens sowie Sprachstörungen. Auf pathologischer Ebene ist die Krankheit durch eine
Atrophie der Frontal- und Temporallappen des Gehirns gekennzeichnet. Außerdem können,
ähnlich wie bei anderen neurodegenerativen Erkrankungen, in den betroﬀenen Bereichen des
Nervensystems unnatürliche Proteinablagerungen festgestellt werden. Interessanterweise wur-
den allerdings mehrere unterschiedliche Proteine als Hauptkomponente dieser Einschlusskör-
per identiﬁziert. Dies führte zur Unterscheidung von fünf verschiedenen FTLD-Untergruppen:
FTLD-Tau, FTLD-TDP (TAR DNA-bindendes Protein 43), FTLD-FUS (“Fused in Sarcoma”),
FTLD-DPR (“dipeptide repeat” Protein) und FTLD-UPS (Ubiquitin-Proteasom System). Mit
45 % stellt FTLD-TDP neben FTLD-Tau die größte pathologische FTLD-Untergruppe dar.
In den letzten Jahren wurden große Fortschritte bei der Identiﬁzierung der genetischen Ur-
sachen dieser FTLD-Untergruppen gemacht. So wurden auch Mutationen im Progranulin-Gen
(GRN ) als Ursache für FTLD-TDP entdeckt, die zu einer Haploinsuﬃzienz führen. Jedoch ist
immer noch unklar, weshalb Patienten mit der gleichen GRN -Mutation in unterschiedlichem
Alter erkranken. Es ist allerdings sehr wahrscheinlich, dass dies auf weitere Faktoren, die sich
auf das Erkrankungsalter auswirken, zurückzuführen ist. Deshalb wurde eine Genom-weite
Assoziationsstudie mit pathologisch veriﬁzierten FTLD-TDP-Fällen durchgeführt, um zusätz-
liche genetische Faktoren zu ermitteln. Dabei wurde ein 68 kb-großer Bereich auf Chromosom
7p21.3 als gemeinsamer genetischer Suszeptibilitätslokus identiﬁziert. Diese Region beinhaltet
nur ein Gen, welches das bisher nicht charakterisierte Transmembranprotein 106B (TMEM106B)
kodiert. Des weiteren zeigte das Risikoallel von TMEM106B (T/T) eine besonders starke Assozi-
ation zum Erkrankungsrisiko bei FTLD-Patienten, die zusätzlich eine GRN -Mutation aufwiesen,
was auf einen funktionalen Zusammenhang zwischen diesen beiden Proteinen schließen lässt.
Allerdings war zu diesem Zeitpunkt noch nichts über die Eigenschaften des Proteins TMEM106B
bekannt. Das Ziel dieser Studie bestand deshalb darin, die Rolle von TMEM106B in FTLD-
TDP zu untersuchen. Dafür wurden zunächst dessen biochemische Charakteristika untersucht,
gefolgt von dem Einﬂuss von TMEM106B auf GRN und schließlich seine Funktion.
Im ersten Teil dieser Arbeit wurden deshalb die Membranorientierung, die zelluläre Lokalisierung
und der Glykosylierungsstatus von TMEM106B bestimmt sowie Methoden und Antikörper
etabliert. Durch sequenzielle Inhibierung der durch Computeranalysen prognostizierten N-
Glykosylierungsmotive konnte gezeigt werden, dass es sich bei TMEM106B um ein Typ-II-
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Transmembranprotein handelt, das an den Aminosäurepositionen 146 (N1), 152 (N2), 165 (N3),
184 (N4) and 257 (N5) N-glycosyliert ist. Dabei sind N4 und N5 komplex glykosyliert, während
bei N1, N2 und N3 keine komplexen Glykosylierungen nachgewiesen werden konnten. Durch
Immunﬂuoreszenzversuche wurde ersichtlich, dass es sich bei TMEM106B um ein lysosomales
Protein handelt. Interessanterweise änderte sich die zelluläre Lokalisierung von TMEM106B-
Mutanten, bei denen eines oder beide der komplex glykosylierten Arginine deletiert wurden,
wohingegen die Mutantion der nicht-komplex glykosylierten Motive keinen Einﬂuss auf die
Lokalisation von TMEM106B ausübte. Dies deutet darauf hin, dass die komplexe Glykosylierung
von TMEM106B die Positionierung von TMEM106B in der Zelle maßgeblich beeinﬂusst.
Im zweiten Teil der Studie wurde unter Verwendung verschiedener Zelllinien der Einﬂuss von
TMEM106B auf GRN ermittelt. Allerdings veränderten sich nach Überexpression oder Her-
abregulation von TMEM106B durch RNA-Interferenz weder die intra- noch die extrazellulären
GRN-Proteinmengen, was darauf hindeutet, dass sich TMEM106B und GRN auf Expression-
sebene wahrscheinlich nicht gegenseitig beeinﬂussen. Interessanterweise aber führte die Behand-
lung mit Baﬁlomycin A1 (BafA1), einer Chemikalie, die die lysosomale Ansäuerung und damit
die lysosomale Funktion inhibiert, sowohl zu einem Anstieg der GRN- als auch der TMEM106B-
Proteinmenge. Dies könnte darauf hinweisen, dass beide Proteine in einem gemeinsamen Sig-
nalweg agieren oder sich im gleichen zellulären Kompartiment beﬁnden. Da eine Behandlung
mit proteasomalen Inhibitoren die TMEM106B-Mengen nicht erhöhte, deutet diese Beobach-
tung außerdem darauf hin, dass überschüssiges TMEM106B vor allem über den lysosomalen
Abbauweg degradiert wird.
Im dritten Teil dieser Arbeit wurde mit Hilfe eines Zellkulturmodells, bei welchem TMEM106B
durch RNA-Interferenz herunterreguliert wurde, die endogene Funktion von TMEM106B un-
tersucht. Interessanterweise führte dabei die Herabregulation von TMEM106B zu einer Verän-
derung der Lokalisierung von Lysosomen in der Zelle: Statt sich über das gesamte Zellvolumen
zu verteilen, sammelten sich die Lysosomen hauptsächlich in Form eines engen “Clusters” am
Zentrosom. Dieses Phänomen wurde durch ein “Rescue”-Experiment bestätigt. Hierbei konnte
gezeigt werden, dass Zellen, in welchen endogenes TMEM106B durch RNA-Interferenz herab
reguliert und in welche zusätzlich exogenes TMEM106B transﬁziert worden war, eine normale
Verteilung der Lysosomen aufwiesen.
Außerdem wurde gezeigt, dass das Clustern der Lysosomen nach der Herabregulation von
TMEM106B sowohl von einem intakten Mikrotubuli-Netzwerk also auch von einer funktionalen
retrograden Transportmaschinerie abhängig ist. Darüber hinaus wurde nachgewiesen, dass nach
TMEM106B-Herabregulation Lysosomen nach wie vor einen sauren pH-Wert aufweisen und
prinzipiell funktionell sind. Allerdings waren nach TMEM106B-Herabregulation sowohl lysoso-
male als auch autophagosomale Proteinmengen signiﬁkant erhöht, was darauf hindeutet, dass
der lysosomale Abbauweg durch TMEM106B beeinﬂusst wird.
Es wird vermutet, dass GRN eine wichtige Rolle für die Funktion von Lysosomen und damit
für Autophagie spielt. Dass TMEM106B wahrscheinlich ebenfalls diesen Abbauweg beeinﬂusst,
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könnte erklären, warum TMEM106B-Polymorphismen in besonderer Weise mit GRN -Muta-
tionsträgern assoziiert sind und warum TMEM106B einen allgemeinen Risikofaktor für FTLD
darstellt.
Veränderungen im lysosomalen Abbauweg sind ein häuﬁges Erscheinungsbild in neurodegenera-
tiven Erkrankungen. So konnte beispielsweise ab einem bestimmten Zeitpunkt des Krankheitsver-
laufs sowohl bei Alzheimer- als auch bei Parkinson- oder Huntington-Erkrankten eine Hemmung
des Autophagie-Signalwegs festgestellt werden. Die Ergebnisse dieser Arbeit deuten darauf
hin, dass auch bei der FTLD-TDP Autophagie eine wesentliche Rolle für das Fortschreiten der
Krankheit spielen könnte.
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1.1 Frontotemporal lobar degeneration (FTLD)
1.1.1 Epidemiology and clinical phenotypes of FTLD
In 1892, Arnold Pick was the ﬁrst to describe lobar atrophy in a patient with presenile dementia
and aphasia [217]. Accordingly, the disease has been called Pick’s Disease, a term which had
become to represent a class of clinical syndromes with symptoms attributed to frontal and
temporal lobe dysfunction. More than a century later, it has been renamed frontotemporal
lobar degeneration. Nowadays, the term Pick’s Disease is only used for a subtype of FTLD with
speciﬁc histopathological features like round inclusions of tau ﬁlaments, also called Pick bodies
[239, 227, 217].
FTLD is a comprehensive term for a clinically, genetically and pathologically heterogeneous
group of dementias characterized by a relatively selective and progressive atrophy of the frontal
and temporal lobes of the brain [315, 270, 239] (ﬁgure 1.1 a). It is the second most common
form of presenile dementia after Alzheimer’s disease (AD) and accounts for about 20 % of cases
with an onset before the age of 65 years [192, 233]. FTLD has an incidence of about 3.5 cases
per 100,000 person-years compared to 4.2 cases for AD in a group with the age range of 45 to
64 years in the United Kingdom (UK) [182]. The exact prevalence of FTLD is uncertain as only
few studies were conducted with estimates between 3.6 (in the Netherlands) and 15 per 100,000
persons (in the UK), depending on the age range [264, 246, 233]. According to the Oﬃce of Rare
Diseases (ORD) of the National Institutes of Health (NIH) and the Ophanet, FTLD is listed
to be a so called “rare disease” which means that only 1 in 2,000 persons is aﬀected. However,
still more than an estimated 50,000 to 60,000 Americans suﬀer from this disease. Moreover, the
symptoms of FTLD are often misinterpreted as symptoms of a midlife crises or a psychiatric
disorder. Therefore, the true number of individuals suﬀering from FTLD could be even higher
[143, 106, 290, 54, 30]. FTLD can start as early as in the third decade of life but also late onsets
in the eighth decade have been reported. The mean age-at-onset is about 58 years [126] and the
median survival is estimated at six to eleven years from symptom onset and three to four years
from diagnosis [225]. This means that often people are aﬀected before they are retired which
places an additional heavy burden not only on the family of the patients but also on economics
[290].
Two clinical syndromes of FTLD, namely language disorders (primary progressive aphasia, PPA)
or personality and behavioural changes (behavioural variant frontotemporal dementia, bvFTD),
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are described [225]. People suﬀering from bvFTD, the most common FTLD syndrome [126,
130, 270], show loss of empathy, apathy, neglect of personal hygiene and impaired regulation of
personal conduct that could present, among others, with increased aggressiveness, inactivity to
overactivity and pacing [130, 232, 274, 270, 13, 264, 193]. The language syndrome of FTLD is
subdivided into the semantic variant PPA (svPPA), the nonﬂuent variant PPA (nfvPPA) and
the logopenic variant PPA (lvPPA) [23]. The characteristics of the semantic variant PPA are a
gradual loss of the semantic memory, i.e. a loss of word meaning, whereas speech remains ﬂuent
[315, 239, 193]. In contrast, nonﬂuent variant PPA presents with a dominant agrammatism
and eﬀortful non-ﬂuent speech [23]. The third language variant, lvPPA, is characterized by an
impairment of speech comprehension and diﬃculty with repetition probably due to a disorder in
the phonological loop function [23]. However, as this classiﬁcation is a very recent development,
the terminology and criteria for the three subtypes is still inconsistent across institutions what
makes the comparison of studies diﬃcult [23].
1.1.2 Molecular Pathology
Not only the syndromes of FTLD are heterogeneous, but also the molecular pathology. Like in
other neurodegenerative disorders, FTLD shows abnormal protein aggregation in the aﬀected
parts of the nervous system [307]. However, the nature of the aggregates is not as uniform as
for example in AD where the pathology is dominated by amyloid-β plaques and neuroﬁbrillary
tangles [93, 307]. In FTLD, diﬀerent proteins have been identiﬁed to be the main component of
the inclusions that were found in the nervous system. A major component to be identiﬁed was
hyperphosphorylated tau, a microtubule-associated protein that accumulated in neurons and glia
(ﬁgure 1.1 b) [239, 171]. In 1998, mutations in the microtubule-associated protein tau (MAPT)
gene, were found to be causative for the disease which has been termed FTLD-tau accordingly
[116, 276] (ﬁgure 1.3). Pick’s disease, characterized by round inclusions of tau ﬁlaments (ﬁgure
1.1 c), belongs to this pathological subgroup [307]. The remaining group of FTLD pathology
mainly comprised tau-negative, but ubiquitin-positive inclusions and ﬁrstly has been named
FTLD-U for ubiquitin. In 2006, Neumann et al. were able to identify the TAR-DNA binding
protein 43 (TDP-43) as the major component of ubiquitin-positive inclusions in the majority of
FTLD-U cases (ﬁgure 1.1 d) [195] that were subsequently termed FTLD-TDP (ﬁgure 1.3). Only
a total of 5 to 20 % of all FTLD-U cases were negative for TDP-43. Of these, about 9 % stained
positive for a protein called Fused in Sarcoma (FUS) (FTLD-FUS) [196] (ﬁgure 1.1 e and 1.3).
For the remaining FTLD cases, the major component of their inclusions has not been identiﬁed,
yet [173, 225, 307]. However, as in these cases, inclusions are positive for ubiquitin, they are
termed FTLD-UPS (ubiquitin-proteasome system) (ﬁgure 1.3) [173, 225, 307]. Interestingly,
in 2013, Mori et al. described an FTLD-UPS patient with a C9orf72 repeat expansion which
showed inclusions that mainly contained the dipeptide species poly-GA [187] hinting that FTLD-
DPR (for dipeptide-repeat proteins) might be another important pathological subtype of FTLD
(see also section 1.1.3.1.3, page 14). In the same year, Mori’s ﬁnding was conﬁrmed by Ash et al.
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who also examined C9orf72 -repeat expansion-positive cases of FTLD and amyotrophic lateral
sclerosis (ALS), a motor neuron disease closely related to FTLD, for their immunoreactivity
with generated dipeptids [5] (ﬁgure 1.3).
Thus, until today, ﬁve or even six major pathological subtypes of FTLD can be distinguished:
FTLD-tau (45 % of all FTLD cases), FTLD-TDP (45 % of all FTLD cases), FTLD-FUS (9 % of
all FTLD cases), FTLD-UPS (about 1 % of all FTLD cases), FTLD without inclusions (number
unknown) [199] and probably also FTLD-DPR (included in number of FTLD-TDP and FTLD-
UPS cases) [171, 270, 162, 64] (ﬁgure 1.2).
c
ed
ba
Figure 1.1: Pathological features of FTLD
(a) Severe atrophy of the frontal and temporal lobes of a patient with Pick’s disease [197]. (b) Neuronal
and glial tau pathology in the frontal cortex of an FTLD-tau patient [197]. (c) Pick bodies labelled with tau
[20]. (d) Staining of TDP-43-positive inclusions (arrowheads) in hippocampal dentate granule neurons of an
FTLD-TDP patient. Note that nuclei are cleared of TDP-43 (arrow) in neurons with inclusions compared to
normal neurons (*) [195]. (e) Neuronal cytoplasmic inclusions in the dentate granule cells of the hippocampus
of an FTLD-FUS patient [196] (modiﬁed from [196, 195, 197, 20]).
1.1.3 Molecular Genetics
In FTLD, approximately 40 to 50 % of patients have a family history, of which 10 % to 30 % show
an autosomal dominant inheritance pattern [239, 225] highlighting the important contribution
of genetic factors in this disease [61]. In the last few years, tremendous progress has been made
in the identiﬁcation of the genes involved in FTLD. In the following sections, the role of causal
genes and genetic risk factors for FTLD will be discussed.
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Figure 1.2: Overview of the pathological subtypes of FTLD
The percentages of the pathological subtypes of FTLD are shown according to the major protein accumulated
[199, 171, 270, 162, 64](modiﬁed from [162]).
1.1.3.1 Autosomal dominant genes
1.1.3.1.1 Microtubule-associated protein tau
The ﬁrst gene discovered to be causative for FTLD was MAPT, encoding for tau. Already
in 1994, frontotemporal dementia with parkinsonism had been linked to chromosome 17q21.1
(FTLD-17). Four years later, in 1998, tau was identiﬁed as the most probable candidate gene
[116] of which today, more than 60 diﬀerent mutations have been detected in FTLD patients [2,
270]. Tau is mainly expressed in neurons of the central and peripheral nervous system [293, 226],
but can also be found in astrocytes and oligodendrocytes [163]. It is a microtubule-associated
protein whose main function is to stabilize microtubules and promote microtubule assembly by
binding to tubulin [110]. Moreover, tau has been shown to tune kinesin-mediated transport of
vesicles and organelles along microtubules depending on its isoforms and relative amounts [258,
65, 63, 311]. In total, six major isoforms of tau are produced by alternative splicing of exons 2,
3 and 10 of the MAPT gene (reviewed in [226, 308]).
Mutations in MAPT perturb the subtle equilibrium between cytoskeletal assembly and disassem-
bly by destabilizing microtubules leading to impaired axonal transport and neuronal plasticity
and promoting pathological tau ﬁlament aggregation [239, 270]. Furthermore, the ratio of tau
isoforms is usually altered in disease, favouring tau aggregation [308, 245]. Deposition of hyper-
phosphorylated tau is a hallmark for several neuropathological diseases also termed tauopathies
[275]. These include corticobasal degeneration (CBD), AD and FTLD [226]. Of all familial
cases, FTLD-tau accounts for about 45 % and is mainly associated with bvFTD [239, 270].
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Figure 1.3: Classiﬁcation of FTLD
Pathologically, FTLD and FTLD/ALS are considered as diﬀerent diseases of probably one FTLD-ALS spectrum
and can be divided into diﬀerent clinical subtypes in regard to the deposited protein found in the nervous system
of the patient. The disease-causing genes are indicated in italic letters of which the very rare genes are shown
in parenthesis. Only one disease modifying or risk gene is known for FTLD and has been associated with
FTLD-TDP patients carrying a GRN mutation or are C9orf72 expansion carriers (modiﬁed from [64]).
1.1.3.1.2 Progranulin (GRN)
Concerning all families with autosomal dominant FTLD linked to chromosome 17q21, there
were still some that did not harbour a mutation in the MAPT gene [76] pointing to another
gene to be responsible for the disease. Therefore, systematic mutation analysis of all remaining
genes within the candidate region was performed leading to the identiﬁcation of mutations in
the progranulin (GRN ) gene [9, 52]
Progranulin, with a molecular weight of 68.5 kDa, is a 593-amino-acid-long-secreted glycoprotein
composed of seven and a half tandem repeats of 12-cysteinyl motifs, separated by linker regions
[9, 312] (ﬁgure 1.4).
G F B A C D EPN C
Figure 1.4: Schematic protein structure of GRN
GRN consists of seven and a half cystein-rich tandem repeats, also called granulin (grn) domains, which are
represented by the lettered boxes (grnP (P), grnG (G), grnF (F), grnB (B), grnA (A), grnC (C), grnD (D)
and grnE (E)). N and C represent the N- and C-terminus of the protein (modiﬁed from [138]).
It is ubiquitously expressed, but can mainly be found in hematopoietic and epithelial cells
as well as in neurons and especially in activated microglia (reviewed in [138]). Full-length
progranulin can be proteolytically cleaved into 6 kDa granulin peptides by neutrophil elastase
and proteinase-3, a process that can be inhibited by secretory leukocyte protease inhibitor
(SLPI) [105, 135, 329]. GRN and its granulin peptides (ﬁgure 1.4) are involved in the regulation
of inﬂammatory reactions whereas the full-length protein exerts an anti-inﬂammatory function
and granulin peptides are probably pro-inﬂammatory [329, 138]. Furthermore, progranulin
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also plays an essential part in other cellular processes including proliferation, development, cell
motility and wound repair (reviewed in [138]). Interestingly, whereas decreased GRN levels
lead to neurodegeneration, increased levels are associated with accelerated tumor growth and
tumorigenesis [104].
Mutations in GRN account for 5 to 10 % of all FTLD cases and up to 20 % of all familial
cases [171, 9, 52]. Neuropathologically, GRN mutation carriers consistently show TDP-43- and
ubiquitin-positive, lentiform neuronal intranuclear inclusions (NII) in the neocortex and striatum
[170, 3, 195]. Furthermore, hippocampal sclerosis and irregular dystrophic neurites as well as
extensive astrogliosis and loss of myelin in the underlying white matter can be observed [308]
(reviewed in [138]). Biochemically, TDP-43 C-terminal fragments accumulate in aﬀected brain
regions [195].
Until now, more than 60 pathogenic mutations that are evenly distributed throughout the gene
were described [21]. As most of the GRN mutations are loss-of-function mutations, which
reduce functional protein levels, or mutations that lead to reduced GRN secretion [80, 9, 52,
268], haploinsuﬃciency seems to be the most probable pathomechamism [272, 228]. Thus,
increasing GRN levels in GRN mutation carriers by increasing the production from the still
intact wild-type (wt) allele of GRN was suggested to be beneﬁcial for preventing the disease
[138]. In 2011, Capell et al. demonstrated that alkalizing agents and v-ATPase inhibitors such as
baﬁlomycin A1 (BafA1) and chloroquine (CQ) could restore GRN levels in patient lymphoblasts
with loss-of-function mutations in GRN [37]. For treating FTLD-TDP patients carrying a GRN
mutation, CQ seems to be the most promising drug, as it is already used in treating malaria
and has been reported to be able to cross the blood-brain-barrier, at least to some extent [37].
However, as increased GRN levels are also implicated in tumorigenesis, it is absolutely crucial
to further study and monitor possible side eﬀects of GRN elevation and titrate GRN levels very
carefully.
GRN is ubiquitously expressed and even though overall expression levels in the brain are very low
compared to other tissues like skin and gut, GRN is highly expressed in speciﬁc subsets of adult
neuronal cells, notably cortical neurons, Purkinje cells of the cerebellum and granule cells of the
hippocampus [56]. Importantly, GRN levels in microglia seem to be higher than in neurons and
increase rapidly and excessively (approximately 500-fold) upon microglial activation implicating
that GRN plays a crucial role in neuroinﬂammatory processes [216]. Moreover, it was suggested
that GRN is neuroprotective [78], involved in the function or maintenance of mature neurons
[216] and that it promotes neurite outgrowth [300, 78].
Very recently, another aspect of progranulin came into focus, namely its role in lysosomes. In
2012, Smith et al. described two siblings that suﬀered from adult-onset neuronal ceroid lipo-
fuscinosis (NCL), a lysosomal storage disorder, which resulted from a homozygous mutation
in GRN [273]. The patients were in their twenties and showed mild cerebellar ataxia, early
cognitive deterioration and retinal dystrophy [273]. The reported frameshift mutation resulted
in the premature termination of GRN translation and had already been described in patients
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suﬀering from FTLD-TDP, however, they had only been heterozygous for this mutation [320].
Therefore, apparently, GRN mutations can present with two diﬀerent phenotypes depending on
whether they are homozygous (NCL) or heterozygous (FTLD-TDP) which suggests a role for
GRN in lysosomal function [273]. Already in 2011, GRN was included in the top ranked genes
of a transcriptional gene network inference study to identify human disease genes that may have
a role in lysosomal function and organization [15]. The authors validated their hit and found
that, indeed, GRN responded to sucrose treatment, a known inducer of lysosomal biogenesis,
by a two-fold increase in GRN mRNA levels. Moreover, upon overexpression of GRN, levels
of lysosome-associated membrane protein 1 (LAMP1) and lysosome-associated membrane pro-
tein 2 (LAMP2), two lysosomal marker proteins, increased concomitantly supporting a lysosomal
involvement of GRN [15]. In 2013, Tanaka et al. observed co-localization of GRN and LAMP1
in activated microglia after experimental induction of traumatic brain injury (TBI) [286]. Fur-
thermore, lysosomal marker protein CD68 and microglial marker Iba1 were more dramatically
increased in activated microglia of Grn knockout than of control mice [286]. Concomitantly,
the authors found the activity of mammalian target of rapamycin complex 1 (mTORC1) to be
decreased which would explain the increased expression of lysosomal genes [286]. mTORC1 is
a protein complex located on the lysosomal membrane that is responsible for transcription fac-
tor EB (TFEB) phosphorylation [243]. The phosphorylation of TFEB prevents it from nuclear
translocation and thus from inducing lysosomal biogenesis [254] (see also ﬁgure 1.13 and for
detailed description of this pathway section 1.3.4, page 33).
In addition, exacerbated neuronal damage was observed supporting the authors hypothesis that
due to GRN deﬁciency, lysosomal biogenesis increases which subsequently leads to exacerbated
neuronal damage after TBI [286]. In accordance with these ﬁndings, Götzl et al. also found
lysosomal proteins like LAMP1, LAMP2 and cathepsin D to be increased in a homozygous Grn
knockout mouse model as well as in brain lysates of GRN-associated FTLD patients [87]. As
in the mouse model, the changes in lysosomal protein levels occurred long before pathological
signatures of FTLD-TDP, like microgliosis or phosphorylation of TDP-43, were detected, Götzl
et al. concluded that lysosomal dysfunction seems to be a primary and early cause for neurode-
generation [87]. However, also proteins that were reported to play a role in NCL like saposin D
were elevated [87]. Interestingly, in CTSD (gene encoding cathepsin D) knockout mice, a model
for NCL, not only lysosomal proteins but also phospho-TDP-43, a hallmark for FTLD-TDP,
was found to be increased along with GRN levels [87]. These ﬁndings suggest that lysosomal
storage disorders, like NCL, and GRN-associated FTLD-TDP share common features and that
lysosomal dysfunction might be a general process in neurodegeneration [286, 87].
1.1.3.1.3 C9orf72
The most common genetic abnormality causing FTLD and ALS has only been discovered re-
cently, in 2011, by DeJesus-Hernandez et al. and Renton et al. [61, 238]. They found an uncom-
mon hexanucleotide repeat expansion located in the non-coding promoter region of the C9orf72
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gene causative for chromosome 9p21-linked ALS-FTD as well as familial FTLD (11 to 21 %) and
familial ALS (23 to 37 %) [238, 61, 227]. Patients that harbour the hexanucleotide expansion
have at least 60 units, but the number of repeats can also increase to up to 1600 compared to
less than 26 in healthy individuals [61, 238, 84, 303]. So far, the pathomechanism has not been
elucidated even though several diﬀerent ones have been proposed. Firstly, a loss of C9orf72
protein function due to incorrect splicing because of the length of the repeat expansion might
cause the disease. This hypothesis is supported by the ﬁndings of DeJesus-Hernandes et al.,
Gijselink et al. and van der Zee et al. who reported decreased C9orf72 mRNA expression levels
and decreased transcriptional activity of the C9orf72 promoter [61, 84, 303]. Moreover, essential
RNA-binding proteins like hnRNP A3 seem to be trapped by the formation of RNA foci causing
RNA toxicity [61, 186]. However, by so far the most unusual disease mechanism has been pro-
posed by Mori et al. [187] and Ash et al. [5]. They hypothesized that the repeat region might be
translated into dipeptides via a mechanism called non-ATG-initiated translation. This would
result in ﬁve (poly-GA, -GP, -GR, -AP and -PR) diﬀerent dipeptide-repeat proteins (DPRs)
due to the translation of the sense as well as the antisense strand of the expanded GGGGCC
repeats [185, 187, 5] (ﬁgure 1.5).
sense
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anti-sense
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GGGGCC
Figure 1.5: Scheme of C9orf72 repeat expansions and resulting dipeptides
The repeat region (GGGGCC)n can be translated into ﬁve diﬀerent DPRs due to repeat-associated non-ATG
(RAN) translation of the sense and antisense strand [5, 185, 187].
Mori et al. and Ash et al. [5] were able to show that indeed these DPRs are formed and found
in the inclusions of FTLD and ALS patients carrying a C9orf72 hexanucleotide expansion [185,
187]. Especially poly-GA and poly-GP proteins that are extremely hydrophobic are the main
component of these aggregates [187]. Currently, there is evidence for all of these three scenarios
and it is quite conceivable that they may all occur in parallel.
Functionally, C9orf72 was identiﬁed to be a potential DENN-type guanine nucleotide exchange
factor (GEF) [324] and was shown to co-localize with the Ras-related proteins (Rabs) Rab1,
Rab5, Rab7 and Rab11 [70]. Accordingly, C9orf72 was found to play an important role in
regulating endosomal traﬃcking [70] and seems to facilitate both autophagy and endosomal
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transport [70]. This suggests that disease pathology might also result from haploinsuﬃciency
of C9orf72 leading to impaired intracellular membrane traﬃc. Interestingly, in motor neurons
from C9orf72 ALS patients, increased co-localization between C9orf72 and Rab7 and Rab11 was
observed compared to controls [70].
1.1.3.1.4 Charged multivesicular body protein 2B (CHMP2B)
In 2005, linkage analyses in a Danish FTLD family identiﬁed a mutation on chromosome 3 in
the acceptor splice site of exon 6 in a gene called CHMP2B [271]. This mutation was predicted
to disrupt the processing of CHMP2B mRNA [271] leading to a C-terminally truncated protein
[271] that results from the two aberrant transcripts. Three years later, van der Zee et al. re-
ported a Belgian familial FTLD patient with a nonsense mutation in exon 5 of the CHMP2B
gene. Interestingly, this mutation also resulted in a C-terminally truncated protein that, upon
overexpression in a cellular system, caused an enlarged endosomal phenotype similar to the one
that was observed when the splice site mutants of the Danish FTLD family were overexpressed
[304, 271]. CHMP2B is part of the endosomal sorting complex required for transport (ES-
CRT) III complex (ﬁgure 1.6, left panel). Usually, its acidic C-terminus auto-inhibits CHMP2B
protein function via intramolecular interaction with the basic N-terminus [304] (ﬁgure 1.6, left
panel). However, mutant CHMP2B that lacks its C-terminus is permanently activated and re-
mains bound in ESCRT-III complexes that accumulate on the endosomal membrane arguing for
a toxic gain-of-function mechanism [201, 83] (ﬁgure 1.6, right panel). In addition, the truncated
protein does not contain the coiled-coil domain located at the C-terminus of CHMP2B. This
domain is important for the binding of the VPS4 AAA-ATPase that mediates active dissociation
of the ESCRT complex (ﬁgure 1.6, right panel).
VPS4
active
inactive
wt CHMP2B
VPS4
VPS4
VPS4
constantly active
truncated CHMP2B
X
ESCRT III
ESCRT III
wt mutant
VPS4
coiled-coil domain
basic N-terminus
acidic C-terminus
VPS4 AAA-ATPase
CHMP2B:
ESCRTIII complex
Figure 1.6: Scheme of wt and mutant CHMP2B
On the left, wt CHMP2B is depicted which still contains the coiled-coil domain (grey) which allows for VSP4-
ATPase binding. After dissociation from the ESCRT III complex (purple), the acidic C-terminus (pink) binds
to the basic N-terminus (blue) of wt CHMP2B and thus auto-inhibits the protein. On the right, mutant
CHMP2B lacking the coiled-coil domain as well as the C-terminus is depicted. As the VPS4 AAA-ATPse
(green) cannot bind to CHMP2B any more, CHMP2B remains bound to the ESCRT III complex. Moreover,
due to the missing C-terminus, mutant CHMP2B remains constantly active [304, 201, 83].
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Together, this blocks the invagination process and intraluminal vesicle formation that is essen-
tial for multivesicular body formation (see also section 1.3.2, page 26) subsequently resulting
in endosomal dysfunction [304, 296]. Moreover, the constitutive binding of mutant CHMP2B
prevents the recruitment of proteins necessary for endosome-lysosome fusion, like Rab7, a key
member of the fusion machinery [120, 294]. Hence, autophagy is likewise impaired leading to
the accumulation of p62- and ubiquitin-positive aggregates [71]. However, Rab7 is also impli-
cated in long-range retrograde axonal traﬃcking [60] and thus, not only endosomal function
and autophagy but also axonal transport could be perturbed by the FTLD-linked CHMP2B
mutations [83]. Indeed, axonal swellings containing mitochondria and vesicles from the endo-
lysosomal and autophagy pathways are observed in transgenic CHMP2B mutant mice, along
with inclusion formation and gliosis [83]. Moreover, Belly et al. found that dendritic spine de-
velopment was heavily impaired in cultured hippocampal neurons of CHMP2B mutants [17],
further supporting the role of CHMP2B in causing neurodegeneration.
1.1.3.1.5 Valosin containing protein (VCP)
Mutations in VCP are relatively rare with a mutation frequency of less than 1 % of all familial
FTLD cases [239, 270] and are associated with FTLD-TDP. They cause a rare autosomal domi-
nant disorder with disabling muscle weakness called inclusion body myopathy (IBM) associated
with Paget’s disease of the bone (PDB) and FTLD, in short IBMPFD [316, 307]. However, also
familial ALS can result from VCP mutations [125]. VCP is a highly conserved AAA+-ATPase
that is implicated in multiple cellular processes especially the ubiquitin-regulated ones i.e. the
degradation pathways [292, 317, 313]. Thereby, VCP facilitates the extraction of endoplasmic
reticulum (ER)-associated degradation (ERAD) substrates, like misfolded proteins, from the ER
(ﬁgure 1.7). Moreover, it is also involved in their subsequent ubiquitination, and in the delivery
of ubiquitinated proteins (ERAD substrates but also cytosolic proteins) to the proteasome for
degradation [317] (ﬁgure 1.7). Futhermore, VCP promotes perinuclear aggresome formation
[131, 32] and seems to play an important role in endosomal traﬃcking [32, 241] (ﬁgure 1.7).
Also, VCP has been implicated to be required for correct dendrite pruning through inﬂuenc-
ing mRNA metabolism thereby highlighting its importance during neuronal develompent [249]
(ﬁgure 1.7). In 2009, Ju et al. reported that VCP was essential for autophagy and that loss of
VCP activity leads to autophagosome accumulation due to impaired autophagosome maturation
as well as impaired autophagic ﬂux. Interestingly, they also found that subsequently, TDP-43
accumulated in the cytoplasm [131]. Tresse et al. additionally showed that VCP is essential for
autophagosome-lysosome fusion [292] (ﬁgure 1.7). Although it is still controversially discussed,
impairment of lysosomal degradation in the autophagic pathway rather than proteasomal im-
pairment seems to be the most relevant disease pathomechanism, as no evidence was found that
mutations of VCP also impaired the ubiquitin-dependent degradation by the proteasome [292].
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Figure 1.7: Scheme of VCP functions
The AAA+-ATPase VCP is implicated in many cellular processes [292, 317, 313, 131, 32, 241, 249] (modiﬁed
from [183]).
1.1.3.1.6 TAR-DNA binding protein 43 (TDP-43) and Fused in Sarcoma (FUS)
Only very few TARDBP (three) and FUS (one) mutations have been found in FTLD patients
indicating that even though they are a major cause for ALS, they only play a limited role in
the genetic etiology of FTLD [307, 172]. TDP-43, encoded by the TARDBP gene, is a highly
conserved RNA-binding protein (ﬁgure 1.8) with apparently several thousand targets in the brain
(reviewed in [19]). It can continuously shuttle between the nucleus and the cytosol, however,
its predominant localization is in the nucleus (reviewed in [19, 172]). Moreover, TDP-43 seems
to be involved in further RNA regulation processes namely control of RNA splicing, microRNA
processing, local translation in dendritic spines and RNA stability (reviewed in [227, 19]).
FUS belongs to the FUS, Ewing sarcoma breakpoint region 1 (EWS) and TATA-binding protein-
associated factor 2N (TAF15) (FET) protein familiy and is a multifunctional DNA/RNA-binding
protein (reviewed in [227, 172]; ﬁgure 1.8). Like TDP-43, it shuttles between the cytosol and the
nucleus and can bind a large number of RNA targets (reviewed in [227, 172]). Among others, it
is involved in mRNA transport, cell proliferation, DNA repair, RNA and microRNA processing
and neuronal plasticity (reviewed in [227, 19, 172]).
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Figure 1.8: Schematic domain structure of TDP-43 and FUS
The N-terminal domain of TDP-43 contains the nuclear localization signal (NLS). Then, two RNA recognition
motif (RRM) domains follow of which the second one contains the nuclear export signal (NES). The C-terminal
part of TDP-43 consists of a glycine (GC)-rich domain. The N-terminus of FUS is a serine-tyrosine-glycine-
glutamine-rich (SYGQ)-rich domain which is followed by three arginine-glycine-glycine (RGG) domains, an
RRM domain and a zinc-ﬁnger (ZnF) domain. The proline-tyrosine (PY)-motif at the C-terminal end of FUS
serves as NLS [19] (modiﬁed from [19]).
In summary, in the last few years, major progress has been made in the identiﬁcation of the
genes that are causative for familial FTLD. In addition to the MAPT gene encoding for tau,
GRN, VCP, CHMP2B and, to a minor exent, TARDBP and FUS mutations as well as C9orf72
hexanucleotide repeat expansions were found to be crucially involved in the development of
FTLD. However, still 23 % of familial FTLD-TDP cases are not caused by any of the known
disease genes indicating the presence of other genetic factors that still remain to be elucidated
[84].
1.1.3.2 Risk factors
1.1.3.2.1 Triggering receptor expressed on myeloid cells 2 (TREM2)
One of these risk factors might be TREM2, an innate immune receptor [46]. Homozygous
loss-of-function mutations of TREM2 are causative for the so-called Nasu-Hakola disease [211]
characterized by multiple bone cyst-like lesions and progressive neurodegeneration predomi-
nantly aﬀecting the frontal and temporal lobes [210]. Moreover, recently, TREM2 mutations
were identiﬁed in patients with Alzheimer’s disease [128, 91], Parkinson’s disease [237], and
ALS [35] suggesting a broader role for TREM2 in neurodegeneration. Interestingly, homozygous
TREM2 mutations have also been described in patients with early-onset dementia without bone
cysts [42] and with bvFTD [91, 85] as well as in patients with clinically diagnosed FTLD [237,
24, 55] implying that TREM2 mutations might confer a risk for developing FTLD.
TREM2, a type I transmembrane glycoprotein [46], is expressed on osteoclasts, immature den-
dritic cells, activated macrophages and microglia [46], but not on neurons [113]. It has been
reported to play a role in various signalling events including diﬀerentiation of dendritic cells
and osteoclasts, immune response and phagocytosis [208, 113, 285]. In the brain, TREM2 pro-
motes phagocytosis of apoptotic neurons without eliciting inﬂammation [113, 285]. Mutations in
TREM2 causing FTD-like disease result in decreased surface localization of the protein due to
severe transport deﬁcits and thus impaired TREM2-mediated phagocytosis [139]. Interestingly,
the p.R47H mutation, that represents as a risk factor for AD, only showed a mild eﬀect on
TREM2 maturation compared to the severe phenotype of the p.Y38C and p.T66M mutations
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that are considered causative for FTLD when in a homozygous state [139, 91]. This might be
in line with the p.R47H mutation being a risk factor.
1.1.3.2.2 Transmembrane protein 106B (TMEM106B)
Another factor is TMEM106B, which was discovered in a genome-wide association study (GWAS)
in 2010 designed to identify susceptibility loci for FTLD-TDP [301]. Until then, TMEM106B
was an uncharacterized protein of unknown function. However, while I was working on this
TMEM106B study, results about TMEM106B function in health and disease were achieved
which are presented in the following section.
1.2 Transmembrane protein 106B
GRN mutations have a reduced penetrance and patients show variable ages of disease onset
[301] which indicates that there are additional factors that modulate FTLD disease progression.
Therefore, a GWAS was performed in a homogeneous population of either pathologically or
genetically conﬁrmed FTLD-TDP cases in order to identify new genetic modulators [301, 307].
Thereby, twelve single-nucleotide polymorphisms (SNPs) of which three reached genome-wide
signiﬁcance mapped to a 68 kb interval located on chromosome 7p21.3 implicating that this might
be a common genetic susceptibility locus for FTLD-TDP [301]. Within this region, only one
gene was located namely the gene encoding for the previously uncharacterized transmembrane
protein 106B (TMEM106B). The most signiﬁcantly associated SNPs lay within intron 3 or 5
(rs1020004, rs6966915) or 6.9 kb downstream (rs1990622) of this gene (see also ﬁgure 3.1 a).
Thereby, in FTLD-TDP patients, the frequency of the protective minor allele of the associated
SNPs was signiﬁcantly decreased. In three subsequent studies, TMEM106B could be conﬁrmed
as risk factor for FTLD-TDP [51, 72, 306]. Moreover, another SNP, rs3173615 (C/G), that was
in perfect linkage disequilibrium to the top SNP rs1990622 (T/C) was identiﬁed as a coding
variant in TMEM106B dictating an amino acid change from threonine (disease-associated) to
serine (protective) at position 185 within the TMEM106B gene (p.T185S) (see also ﬁgure 3.1
a) [72, 200].
Apart from these genetic studies, nothing was known about TMEM106B at the beginning of my
studies. However, while working on TMEM106B, results about TMEM106B function in health
and disease were achieved. These are summarized below.
TMEM106B is a highly conserved protein with two paralogues, TMEM106A and TMEM106C,
with a sequence homology of 49 % and 47 %, respectively [257]. Even though more data is needed
to verify their localization, both paralogues probably reside in the lysosomal membrane [26, 277].
Of note, TMEM106A is associated with breast cancer [81] whereas TMEM106C represents a
positional and functional candidate for arthrogryposis multiplex congenita (AMC) [82], a disease
where multiple contractures of the joints and muscle weakness occurs [95].
19
1 Introduction
TMEM106B comprises seven coding exons [66]. Its transcript length is approximately 12.5 kb
and eight diﬀerent splice variants are annotated [66]. The translation length of TMEM106B is
274 amino acids with a predicted molecular weight of 31.12 kDa [66].
1.2.1 Biochemical characteristics of TMEM106B
I found that TMEM106B is a type II transmembrane protein with ﬁve N-glycosylation sites of
which the two most C-terminal ones are complex glycosylated [155] (see also sections 3.2, page
49; 3.2.2, page 51 and 3.4, page 57). In the brain, TMEM106B is highly expressed, especially in
neurons [263, 34, 39] and microglia, but also in cells surrounding blood vessels [34]. Moreover,
it shows a polarized, perikaryal distribution in neurons [34], where TMEM106B localizes to late
endosomes and lysosomes [263, 39], which is also observed in cultured cells [155, 25, 39] (see
also section 3.3, page 53). Interestingly, in FTLD-TDP patients, TMEM106B appeared more
widely distributed throughout the cell body, which was especially prominent in GRN mutation
carriers [39, 34].
Furthermore, TMEM106B seems to be cleaved by lysosomal hydrolases to create a stable N-
terminal fragment (NTF) before it undergoes regulated intramembrane proteolysis (RIP) medi-
ated by SPPL2a and, to a minor extent, by SPPL2b [26]. Thereby, a highly unstable intracel-
lular domain (ICD) is produced which is located in the lysosome implying that RIP processing
probably serves as a quality control system that allows for the removal of excess TMEM106B
thereby controlling TMEM106B levels [26]. Interestingly, the lysosomal degradation rate of the
protective S185 TMEM106B isoform seems to be faster than of the risk variant (T185) [200].
Moreover, TMEM106B has been implicated in lysosomal traﬃcking [263, 277] and might play
a role in lysosomal stress response [277], data which still have to be conﬁrmed. Hence, the
endogenous function of TMEM106B as well as its role in FTLD-TDP disease progression are
still unknown and remain to be elucidated.
1.2.2 The relationship between TMEM106B and GRN
Accumulating evidence suggests a relationship between TMEM106B and GRN [72, 301] as an
increase in TMEM106B mRNA and protein levels was found to be especially associated with
GRN mutation carriers [301, 87]. Moreover, homozygosity of the risk allele of rs1990622 seems
to be associated with decreased levels of GRN in the plasma of patients as well as of healthy
controls arguing for a generally increasing risk for FTLD-TDP in the population and modifying
the age-at-onset in GRN mutation carriers [72, 51]. However, these data have not been con-
ﬁrmed, yet [51]. Additionally, some overexpression studies suggested that increased TMEM106B
levels would subsequently increase GRN levels [39, 200, 25] whereas others could not detect any
correlation between TMEM106B and GRN expression levels [155, 257, 77]. Thus, it is still un-
der debate whether TMEM106B and GRN inﬂuence each other directly or through acting in a
common pathway.
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1.2.3 Interaction partners of TMEM106B
It was suggested that two microRNAs (miRs) of the miR-132 cluster, miR-132 and miR-212,
can bind to the 3’ UTR of TMEM106B thereby repressing its expression [39]. Interestingly, this
miR-cluster seems to be downregulated in FTLD-TDP patients [39].
Moreover, in a yeast-two-hybrid study, the N-terminus of TMEM106B was reported to interact
with a subunit of AP-2 and clathrin [277] as well as with VPS11 [277], a class C protein of the
homotypic fusion and protein sorting (HOPS) complex and the class C core vacuole/endosome
tethering factor (COVERT) [140], and VPS13D [277], which is implicated in the delivery of
proteins to the vacuole [212]. Additionally, the microtubule-associated protein 6 (MAP6), also
known as stable tubule-only polypeptide (STOP), was claimed to be an interaction partner of
TMEM106B [263]. Interestingly, even though these interaction partners of TMEM106B have
not yet been conﬁrmed by others, they indicate that TMEM106B might play a role in endocytic
vesicle maturation, their delivery to lysosomes [277] and late endosomal/lysosomal traﬃcking
[263].
1.2.4 Impact of TMEM106B on cognition
In 2010, it was observed that ALS patients with the protective alleles of TMEM106B were
signiﬁcantly associated with preserved cognition compared to matched controls implying that
TMEM106B might aﬀect cognitive impairment in ALS [309]. Moreover, in vitro studies suggest
that TMEM106B might inﬂuence dendritic branching [263, 277]. Interestingly, a recent study
with asymptomatic carriers of the GRN Thr272fs mutation revealed that TMEM106B polymor-
phism modulates brain connectivity as homozygosity for the risk allele (T/T) was associated
with decreased connectivity within the ventral salience and the left frontoparietal network [224].
In addition, the TMEM106B risk allele of rs1990622 might decrease the volume of temporal
brain regions, especially the left hemisphere, and the interconnectivity of the temporal lobes not
only in FTLD patients but also in healthy elderly aﬀecting structures important for language
[1]. Therefore, the risk allele of rs1990622 is probably associated with cognitive decline which
seems not to be restricted to FTLD-TDP.
1.2.5 TMEM106B in other neurodegenerative diseases
In 2014, TMEM106B has also been found to be a modiﬁer of FTLD with C9orf72 hexanu-
cleotide repeat expansions [77, 299]. Van Blitterswijk et al. reported that homozygozity for
the minor allele of the rs3173615 variant of TMEM106B, a SNP that is in perfect linkage dis-
equilibrium with the top SNP rs1990622, protects carriers of C9orf72 repeat expansions from
developing the disease [299]. Moreover, patients that were homozygous for the protective minor
allele showed a decreased TDP-43 burden compared to those with the risk allele implying that
TMEM106B might also inﬂuence TDP-43 [299]. Gallagher et al. conﬁrmed that TMEM106B
aﬀects risk for FTLD in the C9orf72 expansion carriers to about the same extent than in GRN
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mutation carriers [77]. However, in contrast, Lattente et al. recently reported that the C9orf72
expansion did not correlate with TMEM106B genotypes [156]. Therefore, it is still under debate
whether TMEM106B indeed is also a genetic modiﬁer in FTLD-DPR caused by a hexanucleotide
expansion in C9orf72.
Interestingly, not only FTLD but also ALS and AD seem to be inﬂuenced by TMEM106B.
As already mentioned (see section 1.2.4), TMEM106B might aﬀect cognitive decline in ALS as
protective alleles of TMEM106B were signiﬁcantly associated with preserved cognition [309]. In
AD, patients with TDP-43 pathology revealed a highly signiﬁcant decrease in the frequency of
the minor (protective) allele of TMEM106B compared to cases without TDP-43 pathology [250].
Moreover, the risk allele (T) for rs1990622 was found to be strongly associated with late-onset
AD (LOAD) in apolipoprotein E (APOE)ε4 allele carriers [165]. APOEε4 is a risk factor for
LOAD [259, 282] and has been reported to decrease the age-at-onset in homozygous carriers of
AD as well as FTLD patients [50, 184]. Interestingly, recently, mRNA levels of TMEM106B
have been found to be reduced, and concomitantly, GRN mRNA levels to be increased in AD
patients [257].
1.3 Lysosomal function in protein degradation
Neurodegenerative diseases such as Alzheimer’s, Parkinsons’s and Huntington’s disease as well
as FTLD are proteinopathies characterized by progressive neuronal dysfunction accompanied
by a selective loss of neurons [326] and the presence of aggregates (inclusions) in cells of the
target tissues [235, 79]. In many cases, the accumulation of aggregate-prone mutant protein
correlates with the severity of the disease [235]. Thus, clearance of these proteins and aggregates
is particularly important in post-mitotic cells, which cannot dilute their toxic burden by cell
division [235, 319, 158]. Accordingly, neurons are especially vulnerable to an alteration in
protein degradation which can cause protein accumulation and cytotoxicity ultimately leading
to neurodegeneration [158].
One of the intracellular clearance pathways is the ubiquitin-proteasome system which operates
through the proteasome, a barrel-shaped, multi-protein complex that predominantly degrades
short-lived cytosolic and nuclear proteins as well as retro-translocated, misfolded ER proteins
which usually have been covalently modiﬁed with polyubiquitin [149]. The second one is the
autophagy-lysosome pathway where bulky substrates or substrates with a long half-life are se-
questered by double-layered membranes before being directed to the lysosome where they are
degraded [149].
While examining the biochemical characteristics of TMEM106B, I found that TMEM106B is
a lysosomal transmembrane protein which might be involved in autophagy. Therefore, in the
following sections, the characteristics of lysosomes and their most important components, the two
diﬀerent routes of lysosomal degradation, endolysosomal sorting (heterophagy) and autophagy,
as well as the regulation of lysosomal degradation are described in more detail.
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1.3.1 General information about lysosomes
Lysosomes that have been discovered by Christian de Duve in 1949 (reviewed in [57]) are ubiqui-
tous, membrane-delimited organelles which are primarily involved in recycling and degradation
[148, 251, 252]. However, they are not only the “waste bin” of the endocytic pathway, but are
involved in many diﬀerent physiological processes including metal ion homeostasis [188], intra-
cellular calcium homeostasis [10], bone and tissue remodelling, plasma-membrane wound repair
[179], pathogen defense, cholesterol homeostasis, membrane repair, cell death [252] and immune
response [262]. Aside from their acid pH (≤ 5) and the absence of the mannose-6-phosphate
receptor which distinguishes them from endosomes, lysosomes are characterized by more than
50 soluble acid hydrolases (with a pH optimum below 6 [251]) and over 120 highly glycosylated
lysosomal membrane proteins [27, 252].
Lysosomal hydrolases are activated in the acidic environment of the lysosome by proteolytic
cleavage and are responsible for the degradation of the material that has been targeted to the
lysosome, i.e. proteins, lipids, carbohydrates and nucleic acids [251]. Two examples for typical
lysosomal hydrolases are cathepsin D and B. Cathepsin D is an aspartic endopeptidase with
numerous physiological functions including metabolic degradation of intracellular proteins, ac-
tivation and degradation of polypeptide hormones and growth factors, activation of enzymatic
precursors, processing of enzyme activators and inhibitors, brain antigen processing and reg-
ulation of programmed cell death [18, 47]. Cathepsin B is a cysteine protease with exo- and
endopeptidase function [48]. Like cathepsin D, it plays a role in the apoptosis of immune cells
as reactive-oxygen-species-dependent release of the enzyme into the cytosol results in the acti-
vation of a pro-apoptotic factor [48] leading to T-lymphocyte death. Furthermore, cathepsin B
is required for toll-like-receptor signalling and tumor necrosis factor α (TNFα) production [48].
However, the most abundant lysosomal components are the lysosome-associated membrane pro-
teins LAMP1 and LAMP2. [262]. As both proteins form a continuous carbohydrate lining on
the inner leaﬂet of lysosomes, they were suggested to be important for the maintenance of the
structural integrity of the lysosomal membrane [117]. Furthermore, as LAMP1 and LAMP2
contribute to about 50 % of all lysosomal membrane proteins [67], they are used as lysosomal
markers. Loss-of-LAMP2-protein-mutations in humans can cause a fatal cardiomyopathy and
myopathy associated with mental retardation, called Danon disease, which is characterized by
the accumulation of late autophagic vacuoles in the heart and skeletal muscle which might impair
the turnover of mitochondria [202, 67]. Yet, the most severe phenotype was reported in mice
where both LAMP1 and LAMP2 had been knocked out. They presented with embryonic lethal-
ity along with abnormally high amounts of autophagic vacuoles and accumulated non-esteriﬁed
cholesterol [68] as well as defects in phagosome maturation due to impaired organellar motility
[117]. Moreover, lysosomes were more dispersed and phagosome and lysosome migration towards
the microtubule-organizing center (MTOC) was delayed [248]. These results clearly highlighted
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that both LAMPs are essential for many cellular mechanisms far beyond their initially suggested
role in maintaining the structural integrity of the lysosomal membrane [67].
1.3.2 Lysosomal degradation through endolysosomal sorting
Extracellular macromolecules destined for lysosomal degradation can be ingested by the cell
by several diﬀerent mechanisms. The best studied route is receptor-mediated endocytosis via
clathrin-coated pits. However, there are also non-clathrin-mediated pathways like phagocyto-
sis, caveolae-mediated uptake, macropinocytosis and a constitutive cholesterol-sensitive uptake
pathway carrying lipid rafts to the Golgi complex [167].
Transmembrane proteins targeted for the lysosome are ubiquitinated and reach the lysosome
via multivesicular bodies (MVBs), a morphologically distinctive late endosome that accumulates
internally small membrane vesicles containing the cargo protein (ﬁgure 1.9) [69]. To form these
internal vesicles, the ESCRT machinery binds to the ubiquitin subunits attached to the targeted
molecule and mediates the invagination and constriction of small luminal vesicles (ﬁgure 1.9)
[69].
For cargo transport to the lysosome, four models have been proposed (ﬁgure 1.10). The ﬁrst one
is the maturation model suggesting that endocytic vesicles mature into early endosomes, late
endosomes and subsequently into lysosomes where the cargo molecule is degraded, by the gradual
addition of lysosomal in exchange for late endosomal components (ﬁgure 1.10) [280]. Another
possibility is the formation of an endocytic carrier vesicle that buds from the late endosome
and delivers its content to the lysosome (ﬁgure 1.10) [89, 168]. In the kiss and run model, late
endosomes and lysosomes transiently fuse which allows an exchange of contents between these
organelles before they depart again (ﬁgure 1.10) [28, 281]. The fourth model, so-called direct
fusion or hybrid model, suggests that endosomes and lysosomes permanently fuse to form a
hybrid organelle that contains late endosomal and lysosomal components. By selective retrieval
of late endosomal components, lysosomes are subsequently re-formed (ﬁgure 1.10) [168, 28, 75,
166]. Even though all four models might not be mutually exclusive, the two most probable
means of delivery are kiss and run events and direct fusion [167, 188].
The fusion events between late endosomes and lysosomes occur mainly in the juxtanuclear
region of the cell, also called MTOC where late endosomes and lysosomes are concentrated
[168]. Late endosomal and lysosomal positioning at the MTOC thereby reﬂects the balance of
long-range bidirectional movement of late endosomes and lysosomes on microtubules and short-
range movement on actin ﬁlaments. In both cases, the movement is mediated by motor proteins
and proteins that are required for the optimal attachment of these motors to late endosomes
and lysosomes [168, 177]. Two of these proteins are the small GTPase Rab7, which associates
with late endosomes [322], and the Rab7 eﬀector RAB7-interaction lysosomal protein (RILP).
Both are responsible for the attachment of the dynein-dynactin motor complex that mediates
the retrograde transport of lysosomes [129].
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Figure 1.9: The endocytosis pathway
Surface transmembrane proteins that are destined for degradation are ubiquitinated before being internalized
[69] whereas extracellular molecules are directly endocytosed [167]. To facilitate the degradation of the
transmembrane proteins, the ESCRT machinery assembles (ESCRT0-III) at the endosomal membrane and
mediates their sorting into small luminal vesicles. The resulting multivesicular body can subsequently fuse
with the lysosome followed by the degradation of the vesicles and their cargo proteins by its enzymes [69]
(modiﬁed from [71]).
1.3.3 Lysosomal degradation through autophagy
In eukaryotic cells, intracellular proteins can either be degraded by the ubiquitin-proteasome sys-
tem or by the autophagic pathway that involves degradation through lysosomes [288]. Whereas
the ﬁrst is limited primarily to targeting individual proteins for destruction, larger structures in-
cluding aggregated, misfolded or long-lived proteins, dysfunctional organelles or even pathogens
can be degraded via autophagy (Greek words for “self” and “eating”) [142]. Constitutive, basal
25
1 Introduction
endocytic
vesicle
lysosome hybrid
organelle
late
endosome
early
endosome
maturation vesicular traffic kiss-and-run direct fusion
extracellular permease
hydrolase
target material
plasma membrane
Figure 1.10: Models for cargo transport to the lysosome
Cargo is internalized via endocytosis and subsequently transported to the lysosome, where four diﬀerent
traﬃcking models have been suggested. The maturation model proposes that the endocytic vesicle matures
from an endosome to a late endosome and ﬁnally to the lysosome by changing its protein composition. The
second model postulates that a vesicle buds from the late endosome which delivers the proteins destined for
degradation to the lysosome. In the third model, late endosomes and lysosomes transiently fuse (kiss) to
exchange proteins and subsequently depart again (run). Finally, the fourth model presumes that the late
endosome directly fuses with the lysosome to form a hybrid organelle from which lysosomes can be re-formed
by selective retrieval of late endosomal components [168] (modiﬁed from [168]).
autophagy that occurs under nutrient-rich conditions serves as a quality control mechanism
and maintains cellular homeostasis as it protects cells from the consequences of dysfunctional
organelles and proteins [98, 69]. Furthermore, autophagy can be induced by extra- and in-
tracellular signals like glucose-, amino acid- and serum-starvation, oxidative stress (hypoxia),
growth factors, ceramide and lysosomal or ER stress [288] leading to a massive increase in the
autophagic ﬂux, i.e. the rate at which autophagic vacuoles are processed by lysosomes [221].
Abnormalities in autophagy not only contribute to pathologies like tumorigenesis and certain
muscle diseases, but also to various neurodegenerative diseases because postmitotic cells are
particularly susceptible to the accumulation of defective proteins or organelles as they cannot
dilute their amount by cell division [174, 99, 247, 319].
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There are three diﬀerent types of the autophagic pathway, namely microautophagy, chaperone-
mediated autophagy (CMA) and macroautophagy, the latter of which people are usually referring
to when they talk about autophagy (ﬁgure 1.11) [288].
Microautophagy involves the direct sequestering of cytosolic vesicles by lysosomes without the
formation of nascent vacuoles (ﬁgure 1.11) [288, 221]. CMA is a selective form of autophagy.
It targets cytosolic proteins with a speciﬁc pentapeptide signal sequence called the KFERQ
motif which is recognized by the heat shock cognate protein of 70 kDa (Hsc70), a molecular
chaperone [221, 288]. The substrate-bound Hsc70 subsequently docks on lysosomes via binding
to LAMP2a. This transmembrane protein of the lysosome acts as a receptor for CMA and
participates in the translocation of unfolded proteins into the lysosome (ﬁgure 1.11) [221, 288].
Interestingly, CMA, which plays an important role in quality control but also in stress response,
has only been described in mammals and shows some distinct features [160]. Firstly, it selectively
targets non-essential proteins for degradation to obtain amino acids required for the synthesis of
essential proteins [160]. Secondly, it removes speciﬁc proteins that were damaged under stress
conditions without interfering with the still functional forms of the same protein as the KFERQ
motif is only accessible when the protein is not folded correctly [160]. Notably, as levels of
LAMP2a are limited, the process of translocation can become saturated which makes a tight
regulation of CMA crucial [160].
Macroautophagy, hereafter referred to as autophagy, evolved as both, an adaptation of the eu-
karyotic cell to starvation and a quality control mechanism to protect against damage caused by
dysfunctional proteins and organelles [123, 244]. It involves the bulk sequestration of cytosolic
content including large protein complexes and organelles into autophagic vesicles, so-called au-
tophagosomes (ﬁgures 1.11 and 1.12) [221, 142]. In order to meet this challenge, a high degree
of ﬂexibility and diﬀerent vesicles sizes (0.5 μm to 1.5 μm) are needed [142, 244]. As a ﬁrst step,
a pre-autophagosome or phagophore is formed in the cytosol as a cup-shaped structure (ﬁgure
1.12) [97, 284]. However, the origin of the phagophore still remains elusive [142] as reports state
that the membranes could be either derived from mitochondria, the ER, the plasma membrane
or even from several distinct locations [247]. The nucleation of the phagophore is controlled
by the lipid kinase hVPS34, which forms a complex with ATG14L, beclin-1 and hVPS15 and
produces phosphatidylinositol 3-phosphate (PI3P) that subsequently recruits factors promot-
ing phagophore nucleation [244]. After autophagy initiation, the phagophore double membrane
elongates sequentially, probably via homotypic fusion events, thereby actively engulﬁng its cargo
[142, 247]. This step is regulated by two ubiquitination-like reactions of which the second in-
volves the conjugation of microtubule-associated protein 1 light chain 3 (LC3), GABARAP and
GATE-16 to the phospholipid phosphatidylethanolamine (PE) [247]. LC3 or more precisely its
autophagosome membrane-bound, PE-conjugated form LC3II is a well-known autophagosomal
marker protein as it can be nicely distinguished from its soluble, cytosolic form LC3I [247,
288, 98]. Subsequently, the double membrane structure closes to form the autophagosome (ﬁg-
ure 1.12) [288, 69]. Normally, autophagosomal vesicles that appear randomly throughout the
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Figure 1.11: Lysosomal degradation within the mammalian cell
Proteins destined for degradation are either delivered to the lysosome from the extracellular media (het-
erophagy) or from the intracellular compartment (autophagy). For the latter, three diﬀerent types have been
proposed: macroautophagy, chaperone-mediated autophagy and microautophagy. Whereas lysosomes directly
internalize cargo during microautophagy, in macroautophagy, intracellular components are sequestered in au-
tophagosomes that subsequently fuse with lysosomes. In chaperone-mediated autophagy, substrate proteins
are selectively recognized and transported to the lysosome where they are translocated into the lysosomal
lumen by LAMP2a [176] (modiﬁed from [176]).
cytoplasm, traﬃc, while they are maturating, along microtubules towards the MTOC, where
lysosomes are concentrated [247, 174].
Along the way, autophagosomes may fuse with endosomes to form amphisomes (ﬁgure 1.12)
that are enriched in proteins of early endosomes, like early endosome antigen 1 (EEA1), and
of late endosomes, like mannose 6-phosphate receptors (MPRs) [69]. Finally, either the outer
membrane of the autophagosome or of the amphisome, which is already more acidic than the
autophagosome and represents a pre-lysosomal compartment, fuses with the lysosome (ﬁgure
1.12). Following this autolysosome formation, the inner vesicle containing the sequestered cargo
as well as the cargo itself are degraded by lysosomal hydrolases and the degradation products
are released through membrane permeases (ﬁgure 1.12) [69, 247, 142].
Even though (macro-) autophagy has been considered to be a very unselective process for bulk
sequestration of long-lived proteins and organelles during starvation to restore the energy bal-
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Figure 1.12: The process of macroautophagy
Autophagy is initiated by the formation of a phagophore that expands into an autophagosome while engulﬁng
a portion of the cytosol. During the movement towards the MTOC, autophagosomes can fuse with endosomes
forming amphisomes. Finally, the autophagosome or amphisome fuses with the lysosome which supplies the
acid hydrolases required for the degradation of the inner membrane of the autophagosome or amphisome and
subsequently their content. The resulting macromolecules are released through permeases into the cytosol
[141] (modiﬁed from [141]).
ance of the cell, recently, evidence mounted of selective autophagic degradation operating during
nutrient-rich conditions [244, 123]. Selective autophagy is mediated by speciﬁc autophagic re-
ceptors such as sequestosome-1 (p62/SQSTM1) and neighbour of BrcaI gene (NBR1) which
both show a strong oligomeric potential [244] and recognize their cargo by binding to unfolded
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regions of a protein or to conjugated ubiquitin (Ub), a universal signal for degradation [137,
123].
P62, the ﬁrst described mammalian selective autophagy receptor [22], interacts with ubiquitin,
preferentially mono-ubiquitin (at Lys63), via its Ub-associated (UBA) domain [123]. However,
ubiquitin binding can be inhibited by homo-polymerization of p62 via its Phox and Bem 1p (PB1)
domain [123]. To mediate selective autophagy, the ubiquitinated substrate (protein aggregates,
organelles or pathogens) recruits p62 which sequesters its target into larger units or aggregates,
also called p62 bodies [123, 319]. Subsequently, non-covalent binding of the LC3-interaction
region (LIR) of p62 [244] to LC3 mediates the recruitment of the phagophore. This process
might be further supported by aggregation which itself is a signal for degradation. Following
phagophore recruitment, the autophagosome forms around the aggregated substrate [123].
P62 is involved in many cellular processes like NFκB signalling pathways, bone remodelling,
obesity, oxidative and proteotoxic stress response, cell spreading and cancer development [123].
Furthermore, it was also suggested to aﬀect both pro-survival and pro-apoptotic signalling path-
ways and to play an important role in innate immunity [123].
Like p62, NBR1 is also involved in the recruitment of ubiquitin-positive cargo via cross-linking
[137, 244]. Interestingly, both, p62 and NBR1, accumulate in inclusion bodies upon autophagy
inhibition [137, 244]. Moreover, p62 is detected in most of the cytoplasmic and nuclear protein
aggregates found in human diseases, like FTLD with C9orf72 hexanucleotide expansions [187]
or Huntington’s disease [191]. However, recruitment of p62 is considered to be a secondary
mechanism promoted by the ubiquitination of aggregates which had been induced by other pro-
teins [123, 191]. Interestingly, accumulation of p62 due to impaired autophagy compromises the
ubiquitin-proteasome system. This results in increased levels of proteasome substrates because
p62 competes with other ubiquitinated proteins for delivery to the proteasome [149]. Thus, not
only aggregation-prone proteins but also short-lived regulatory proteins like p53 or β-catenin
accumulate leading to deleterious consequences [149].
1.3.4 Regulation of lysosomal degradation
In 2009, Sardiello et al. identiﬁed a gene network that regulates lysosomal biogenesis and function
[254]. They found that the palindromic GTCACGTGAC motif, they called CLEAR element,
was highly enriched in the promoter region of many lysosomal genes. The transcription factor
TFEB is able to bind to the CLEAR motif thereby upregulating lysosomal and autophagosomal
gene expression, like the expression of cathepsin D or p62, and is thus considered as a master
regulator for genes of the autophagy-lysosome pathway [209, 266].
In resting cells, TFEB is mainly located in the cytoplasm with focal concentrations associated
with lysosomes [243]. Roczniak-Ferguson et al. were able to show that mTORC1, located at the
surface of lysosomes under nutrient-rich conditions, recruits TFEB to lysosomes and mediates
TFEB phosphorylation (ﬁgure 1.13) [243]. In turn, phosphorylated TFEB binds to 14-3-3 pro-
teins in the cytosol whose binding masks the nuclear localization signal (NLS) of TFEB thereby
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preventing its translocation to the nucleus as well as subsequent transcriptional activation of
autophagosomal and lysosomal genes (ﬁgure 1.13) [243, 267].
However, upon cellular stress signals like starvation or an increase of intracellular pH, mTORC1
translocates from the lysosomal surface [150] and hence, TFEB is not phosphorylated and thus
inhibited any longer leading to enhanced accumulation of TFEB in the nucleus (ﬁgure 1.13)
[243, 266, 254].
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Figure 1.13: Model of the TFEB signalling pathway
Under healthy conditions, the mTORC1 complex is localized at the lysosomal membrane and mediates the
phosphorylation (P) of the transcription factor EB (TFEB). Consequently, the 14-3-3 protein is able to bind
to TFEB which masks the nuclear localisation signal (NLS) of TFEB thereby sequestering it in the cytosol
[243]. However, under stress or starvation, mTORC1 detaches from the lysosome resulting in its inactivation.
Thus, TFEB is no longer phosphorylated, 14-3-3 proteins cannot bind and TFEB translocates to the nucleus
where it promotes the transcription of autophagic and lysosomal genes [267] (modiﬁed from [267, 243]).
Moreover, upon starvation and the associated increase in intracellular pH, lysosomes change their
localization and mainly cluster at the MTOC (ﬁgure 1.14) probably due to a pH-dependent loss of
proteins that regulate the anterograde transport of lysosomes [150]. This favours autophagosome-
lysosome fusion which together with an increased synthesis of autophagosomal and lysosomal
proteins enhances autophagy-mediated nutrient release and therefore enables subsequent cell
survival under starvation conditions (ﬁgures 1.13 and 1.14) [150]. Interestingly, lysosomal posi-
tioning was also shown to modulate mTORC1 activity as the overexpression of kinesins KIF2A
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and KIF1B-β, that promote the anterograde transport of lysosomes, as well as of the ARF-like
GTPase ARL8B, which is also involved in lysosomal traﬃcking [7], increased mTORC1 activ-
ity. Conversely, their knockdown decreased peripheral positioning and subsequently mTORC1
activity [150, 223].
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Figure 1.14: Lysosomal positioning modulates autophagy
Under healthy, nutrient-rich conditions, mTORC1 activity is high which blocks lysosome and autophagosome
biogenesis. Moreover, autophagy is inhibited facilitated by the mainly peripheral localization of lysosomes [150].
However, upon lysosomal stress or starvation, mTORC1 activity decreases leading to the activation of lysosome
and autophagosome synthesis. Also, lysosomes cluster at the MTOC which promotes autophagosome-lysosome
fusion [150] (modiﬁed from [150]).
Another pathway in starvation response involves the regulation of membrane protein degradation
[127]. Thereby, during stress conditions or after initiation of autophagy, a speciﬁc set of plasma
membrane proteins that is not essential for survival is increasingly endocytosed [127]. Moreover,
the eﬃciency of MVB sorting is enhanced through the downregulation of increased sodium
tolerance protein 1 (Ist1) which in turn promotes eﬃcient VPS4 recruitment to endosomes, a
protein that is required for the release of the ESCRT machinery from the endosomal membrane
allowing for further MVB formation [127]. These two mechanisms provide an immediate source of
amino acids during the time of acute starvation and enable the synthesis of starvation-response
proteins which are vital for the cell to adapt to stress conditions until the major starvation-
response system, autophagy, is fully active [127]. Therefore, the MVB pathway is essential for
the initial phase of starvation response (ﬁrst one to two hours), but is subsequently replaced by
the long-term starvation response pathway, autophagy [127, 6].
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1.4 Lysosomal dysfunction in neurodegenerative diseases?
Neurons are postmitotic cells and therefore particularly susceptible to lysosomal dysfunction as
they cannot dilute their toxic burden, i.e. aggregated proteins and dysfunctional organelles, by
cell division [319]. Accordingly, the brain is often the most severely aﬀected organ in primary
lysosomal disorders [205] as lost neurons cannot be replaced and the progressive loss ﬁnally
gives rise to the symptoms of neurodegenerative diseases [176]. Moreover, due to the very large
expanses of dendritic and axonal cytosol, neurons need to transport their cellular waste over
long distances towards the cell body, where the majority of lysosomes is located. An impairment
of transport or a slowdown of proteolytic clearance of the autolysosomal substrates is therefore
detrimental to neurons [205].
In 2006, Taichi Hara et al. were able to prove that suppression of basal autophagy in neuronal
cells was already suﬃcient to induce neurodegeneration in mice, even without the presence of
any disease-associated mutant protein [99]. This ﬁnding was conﬁrmed by Komatsu et al. [146,
145]. The generated mice in which two diﬀerent autophagic genes, namely Atg5 or Atg7, were
exclusively deleted in neurons showed progressive neurodegeneration and symptoms of neuro-
logical pathology along with a high number of ubiquitin-positive inclusion bodies in neurons [99,
146, 145]. Interestingly, inclusion bodies only appeared in later phases of autophagy deﬁciency
suggesting that the primary role of autophagy in neurons is the turnover of diﬀuse ubiquitinated,
cytosolic proteins rather than the elimination of inclusion bodies and that these mutant cytosolic
proteins could present the main source of toxicity [99]. However, as impaired autophagy seemed
to aﬀect speciﬁc neuronal cell-types stronger than others, it was speculated that neurons exposed
to high stress levels probably also need higher levels of basal autophagy and are therefore more
vulnerable to defective autophagy than cells that only require low levels of basal autophagy
and are therefore more resistant to impaired autophagy [229]. These studies not only stress the
importance of autophagy for the progression of neurodegenerative diseases, but also show that
under basal, nutrient-rich conditions, autophagy seems to be constantly active in the brain and
is required for neuronal survival [99].
In neurodegenerative diseases, the autophagic pathway has been found to be impaired at all
stages - the initiation of autophagy (even though very rarely), the selection of the autophagic
substrates, the sequestration of the cargo, the transport along microtubules towards the lyso-
somes, the fusion between autophagosomes/amphisomes and lysosomes and ﬁnally the degrada-
tion within the autolysosomal lumen [205]. Clinical manifestations of neurodegeneration include
progressive cognitive decline and changes in behaviour. These phenotypes are also observed
in lysosomal storage disorders (LSDs), diseases that result from mutations in lysosomal genes
[221, 74, 16]. This suggests that lysosomal disturbances play a role in both neurodegeneration
and lysosomal storage disorders [8] and further stresses the importance of lysosomes to proper
nervous system function [203].
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In the following, lysosomal dysfunction in the four diﬀerent neurodegenerative diseases AD,
Parkinson’s and Huntington’s disease as well as in FTLD will be set out in more detail.
1.4.1 Alzheimer’s disease (AD)
AD is a progressive neurodegenerative disease which is pathologically characterized by the oc-
currence of intraneuronal ﬁbrillary tangels (NFTs) consisting of aggregated, abnormally phos-
phorylated tau (see also section 1.1.3.1.1, page 9) [90, 151, 207, 93] and senile plaques composed
of amyloid-β peptide (Aβ) [86]. Amyloid-β is produced by the processing of its precursor, the
β-amyloid precursor protein (APP). Thereby, APP is shedded by β-secretase followed by γ-
secretase cleavage which releases an Aβ peptide (Aβ 38, 40 or 42) [93, 327]. This pathway is
called the amyloidogenic pathway. The major toxic species in AD is considered to be Aβ42 and
has a strong potential to oligomerize [327, 93].
One of the earliest manifestations that can be detected in AD, however, is not the deposition of
Aβ, but an upregulation of the endocytic-lysosomal system [203, 176]. Therefore, it is discussed
whether the endocytic-lysosomal system, including autophagy, is disturbed. Evidence for this
hypothesis are the giant neuritic swellings found in AD brains that mainly contain autolyso-
somes [206] suggesting that autophagic substrate elimination is defective [205]. However, these
swellings might also result from microtubule destabilization caused by tau hyperphosphorylation
subsequently leading to impaired neuronal traﬃcking [204].
Moreover, intracellular transport, which is essential for proper neuronal functioning, might also
be disrupted due to the accumulation of autophagic vacuoles (AVs) as a consequence of impaired
autophagosome-lysosome fusion, another theory which is discussed [206, 176, 321]. Furthermore,
Yu et al. argue that persistent AVs might present as major internal source for Aβ because AVs
contain full-length APP, β-cleaved APP C-terminal fragments as well as its cleaving enzyme
γ-secretase (which is highly enriched in these AVs), proteins that are crucial for the generation
of Aβ [321].
In addition, the toxic and aggregative Aβ42 which is taken up by neurons via endocytosis and
subsequently traﬃcked to lysosomes was shown to be degraded slowly and thus to accumulate
within the lysosome [203]. Lysosomal as well as autophagosomal accumulation of Aβ42 might
then result in a leakage of lysosomal enzymes and of toxic undigested substrates into the cytosol
adding to cellular toxicity and leading to apoptosis [203, 124, 326, 176].
APOE4 is the strongest risk factor for LOAD and encodes a neuronal cholesterol transport
protein [205]. The primary pathway by which it increases the LOAD risk is probably by binding
with high aﬃnity to Aβ which might enhance plaque formation [101]. However, interestingly,
it is discussed whether it might also destabilize lysosomal membranes thereby contributing to
accelerated cell death via apoptosis [205]. Moreover, it has been reported that apoE isoforms
diﬀerentially inﬂuence the neuronal uptake of Aβ, its subsequent traﬃcking to the lysosome and
thus its degradation [159]. Thereby, apoE3 seems to be more eﬃcient to accelerate lysosomal
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degradation than apoE4, another explanation for why Aβ aggregation is promoted in APOE4
carriers [159].
Mature APP can be re-internalized from the cell surface and targeted to endosomes and lyso-
somes where it is processed [92]. Moreover, as β-secretase (BACE) seems to be more active at
mild acidic pH, making endosomes the most likely location for BACE cleavage of APP [136],
internalization of cell surface APP therefore leads to elevated Aβ generation [147, 136]. Thus,
increased endocytosis and impaired lysosomal degradation might result in Aβ accumulation
thereby enhancing the AD phenotype. Accordingly, the risk factor APOE4 as well as mu-
tant forms of APP, APP duplications and elevated amounts of dietary cholesterol interfere with
lysosomal proteolysis via promoting Ras-related protein 5 (Rab5)-upregulation and thereby ac-
celerated endocytosis [203].
Furthermore, Lee et al. claim that mutations in presinilin-1, which is part of the γ-secretase
complex, result in impaired targeting of the a1 subunit of V0-ATPase from the ER to the
lysosome [102, 157]. As the V0-ATPase is essential for lysosomal acidiﬁcation, presinilin-1
mutations might be responsible for the defective proteolysis of autophagic substrates leading to
the accumulation of AVs and, accordingly, of Aβ [102, 157, 194]. However, this mechanism is
controversially discussed as neither Coen et al. nor Zhang et al. could reproduce the ﬁndings
of Lee et al. [328, 45]. Coen et al. argue that endo-lysosomal dysfunction of presenilin-deﬁcient
cells rather results from impaired lysosomal calcium storage and/or release which in turn might
hamper lysosomal-autophagosomal fusion [45]. Zhang et al. report a signiﬁcant increase in
CLEAR network genes in samples of presinilin-1 and -2 knockout mouse brains hinting that
presenilin might inﬂuence lysosomal biogenesis [328]. In 2013, Wolfe et al. reconﬁrmed their
original ﬁndings that lysosomal acidiﬁcation is impaired in AD [157]. Thus, it still remains to
be determined if one of the proposed mechanisms leads to the lysosomal phenotype observed in
AD.
Another evidence for disrupted autophagy in AD are the reduced expression levels of beclin-1
in AD patients [218]. As beclin-1 is a protein that is required for autophagy initiation [244],
its reduction might result in impaired neuronal autophagic activity [218] thereby increasing
Aβ-accumulation and neurodegeneration [102].
To summarize, there is some evidence that, in AD, autophagy might be disrupted at both the
initiation as well as the clearance stage which subsequently might lead to the accumulation
of autophagic vesicles in dystrophic neurites, increased Aβ levels, altered traﬃcking, impaired
degradation of toxic proteins and increased apoptosis adding to neurodegeneration.
1.4.2 Parkinson’s disease (PD)
In Parkinson’s disease, the dompaminergic neurons of the substantia nigra pars compacta and
of the striatum degenerate. One of the main reasons for this degeneration is an α-synuclein
accumulation within inclusions called Lewy bodies [79, 176]. α-synuclein is located in the
presynaptic terminals of neurons and has been implicated in synaptic function [176]. Post-
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translational modiﬁcations of α-synuclein promote the formation of oligomeric protoﬁbril in-
termediates that subsequently progress to insoluble ﬁbrils [176]. However, when α-synuclein
interacts with dopamine, ﬁbrillation is inhibited and α-synuclein accumulates in its soluble toxic
form which makes dopaminergic neurons most susceptible to neurodegeneration [176]. Soluble
α-synuclein is degraded by the proteasome, however, ﬁbrillar α-synuclein gets jammed inside
the proteasome thereby blocking its activity [176, 278]. Moreover, soluble forms can also be
degraded by chaperone-mediated autophagy [53].
However, pathogenic mutants of α-synuclein bind to the CMA receptor LAMP2a with high
aﬃnity thereby inhibiting their translocation into the lysosomal lumen [176, 53]. Even more,
they also compromise the uptake of other CMA substrates resulting in a complete blockage of
CMA [176, 53]. As a consequence of both proteasome and CMA inhibition, macroautophagy
is upregulated rendering the cells very susceptible to stressors and stress conditions [176, 53].
Over time, the autophagic system probably becomes overloaded which results in its failure
subsequently leading to neurodegeneration [176, 53].
Along with α-synuclein (SNCA) mutations, leucine-rich repeat kinase 2 (LRRK2 ) mutations
that have been linked to defects in endosomal-lysosomal traﬃcking, lysosomal pH and calcium
regulation as well as CMA, have also been reported to cause autosomal-dominant PD by an as
yet unidentiﬁed mechanism [220, 176, 175].
Furthermore, autosomal-recessive PD is associated with two genes that play an important role
in mitophagy, the removal of damaged mitochondria by autophagy, namely PINK and PARK2,
encoding Parkin [102]. During mitophagy, Parkin is selectively recruited to damaged mitochon-
dria due to the accumulation of PINK at the outer mitochondrial membrane [220]. Subsequently,
Parkin mediates the ubiquitination of the mitochondrial surface which allows for the recruitment
of the autophagic machinery [220]. Thus, mutant PINK or Parkin contribute to mitochondrial
dysfunction and thereby increase oxidative stress which further damages the cell and promotes
neurodegeneration [176].
Another gene that causes autosomal-recessive PD is ATP13A2, encoding a lysosomal trans-
membrane protein [230]. Loss-of-function mutations of ATP13A2 result in impaired lysosomal
acidiﬁcation, subsequent decreased proteolytic processing of lysosomal enzymes and reduced
degradation of lysosomal substrates leading to an accumulation of autophagosomes and enlarged
lysosomes as well as neuronal toxicity [297, 59].
Interestingly, mutations in the glucocerebrosidase (GBA) gene which cause Gaucher disease, a
lysosomal storage disorder, increase the risk for developing PD when only one allele is aﬀected
[169, 256]. Probably, glucosylceramide accumulation leads to decreased lysosomal degradation
resulting in an accumulation of α-synuclein which promotes oligomer formation and neurotoxic-
ity [178]. In addition, α-synuclein accumulation impairs the traﬃcking of GBA thereby further
decreasing lysosomal GBA activity resulting in a positive feedback loop that may lead to a
self-propagating disease [178, 58].
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Together, in PD, the proteasome and CMA as well as autophagy in the clearance stage were
reported to be disrupted. Thereby, it was claimed that either the degradation of mitochondria,
lysosomal function or traﬃcking was compromised resulting in the accumulation of autophago-
somes and toxic protein species like soluble α-synuclein and increased oxidative stress due to
dysfunctional mitochondria promoting the progression of neurodegeneration.
1.4.3 Huntington’s disease (HD)
Huntington’s disease is an autosomal-dominant polyglutamine-repeat disorder [8] caused by an
abnormally long CAG repeat expansion in the N-terminal region of the huntingtin protein [176,
291]. Huntingtin plays a multifunctional role in various cellular processes like gene transcription,
signalling and intracellular traﬃcking and interacts with other proteins through its N-terminus
[176]. Therefore, huntingtin-interacting proteins are usually co-sequestered into the huntingtin
inclusion bodies that are formed upon mutant huntingtin expression, amplifying the loss of
function [176]. However, inclusion bodies seem to be cytoprotective [4, 289]. Whereas the
amount of diﬀuse intracellular huntingtin together with the polyglutamine expansion length
predicts neuronal death [4], inclusion body formation correlates with improved survival as the
levels of diﬀuse huntingtin are reduced [4]. During formation of the inclusion bodies, huntingtin
ﬁlaments are formed that inhibit the ubiquitin-proteasome system [62] which makes autophagy
the essential mechanism for mutant huntingtin degradation [229]. Indeed, autophagy was found
to be upregulated in response to huntingtin aggregate formation and contributes to the removal
of huntingtin aggregates [255, 133].
Interestingly, one of the proteins sequestered by mutant huntingtin inclusion bodies is the mam-
malian target of rapamycin (mTOR) [236]. As a consequence of sequestration, mTOR kinase
activity is inhibited which in turn induces autophagy [236]. Moreover, inhibition of the UPS
might also cause autophagy induction [176]. Of note, increased cathepsin D activity has been de-
tected in aﬀected areas of HD brains. This might enhance the degradation of mutant huntingtin
that is more resistant to cathepsin D degradation than the wild-type protein [326].
Mutant huntingtin also recruits beclin-1, which is an important factor for phagosome nucleation,
and thereby impairs the turnover of long-lived proteins [269]. Moreover, beclin-1 sequestration
reduces autophagic degradation of mutant huntingtin thereby promoting its further accumula-
tion and mediating disease progression [269]. An age-dependent decline in beclin-1 expression
may add to the reduction of autophagic activity thereby accelerating disease progression with
age [269]. In part, this might explain the failure of autophagy in advanced stages of the disease
[176].
Treatment of a ﬂy model of HD with rapamycin, an mTOR inhibitor and autophagy stimulator,
protected against neurodegeneration and provided evidence for the importance of autophagy for
clearing cells from mutant huntingtin [236].
Moreover, huntingtin was reported to link cargo to actin and to coordinate the switching between
actin- to microtubule-based movement [88]. Disruption of huntingtin thus was demonstrated to
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cause peripheral accumulation of all endocytic compartments consistent with impaired dynein-
dependent traﬃcking [38].
In summary, in HD, autophagy was found to be upregulated due to UPS inhibition. However,
during disease progression, co-sequestering of an important nucleation factor for phagophore for-
mation inhibits autophagy at the initiation stage resulting in reduced autophagic activity which
accelerates neurodegeneration. Moreover, sequestration of huntingtin might inhibit retrograde
traﬃcking of cargo destined for lysosomal/autophagic degradation.
1.4.4 Frontotemporal lobar degeneration (FTLD)
Only recently, evidence accumulated that also in FTLD, dysfunction in the endosomal-lysosomal-
autophagic pathway plays an important role in disease development and progression.
For instance, VCP was found to inﬂuence the autophagic pathway. Upon VCP loss or ex-
pression of mutant VCP, diﬀerent stages of autophagy like autophagosome maturation and
autophagosome-lysosome fusion were shown to be impaired [292, 131] (for more details see
also section 1.1.3.1.5, page 17). Moreover, CHMP2B mutations, which cause a block in MVB
formation, impair Rab7 recruitment to endosomes [295] which is essential for autophagosome
maturation and endosome-lysosome fusion [118]. Thus, CHMP2B mutations also inﬂuence lyso-
somal function by inhibiting lysosomal degradation (for more details see also section 1.1.3.1.4,
page 16).
In 2011, GRN appeared among the best hits of a transcriptional gene network inference study
which investigated human disease genes connected to lysosomal function and organization [15].
Furthermore, alkalizing agents as well as v-ATPase inhibitors were shown to restore GRN levels
in patient lymphoblasts with GRN mutations [37]. Strikingly, one year later, homozygous GRN
mutations were described to be causative for NCL [273], a lysosomal storage disorder, a ﬁnding
which strongly supported a linkage between GRN and lysosomal function. As heterozygous GRN
mutations cause FTLD, a gene dosage eﬀect was suggested [273]. In addition, lysosomal proteins
were demonstrated to be increased in Grn knockout mice [87, 286] along with a decreased
mTORC1 activity [286] at early stages of disease progression, i.e. before neuroinﬂammation
became apparent [87]. Together, this suggested that loss-of-function mutations in GRN might
result in lysosomal dysfunction leading to neurodegeneration (for more details see also section
1.1.3.1.2, page 12).
To summarize, in FTLD, autophagy was found to be impaired in VCP and CHMP2B mutation
carriers resulting in autophagosome accumulation and subsequent neurodegeneration. Moreover,
GRN mutations were implicated in causing lysosomal dysfunction, however, the exact disease
mechanism has not been elucidated, yet.
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The motivation of my study was to investigate how TMEM106B could confer a risk for developing
FTLD-TDP and/or how it might inﬂuence disease progression.
Since very little was known about this protein at the time when I started my studies, the ﬁrst
aim was to characterize TMEM106B in regard to its location, its orientation in the membrane
and its glycosylation status.
The second aim was to ﬁnd out whether TMEM106B levels could directly inﬂuence GRN expres-
sion. GRN mutation carriers were found to be especially associated with increased TMEM106B
mRNA and protein levels [301, 87] suggesting a direct functional relationship between GRN and
TMEM106B [72, 301]. To know whether TMEM106B might have a direct impact on GRN lev-
els is crucial as a reduction in GRN levels causes FTLD-TDP [9, 52]. Moreover, the knowledge
of whether and how TMEM106B might inﬂuence GRN expression levels could provide an ap-
proach to overcome GRN haploinsuﬃciency in GRN mutation carriers, namely by manipulating
TMEM106B expression.
The third aim of my study concentrated on elucidating the endogenous function of TMEM106B
in order to understand how malfunctioning of TMEM106B might increase the risk for devel-
oping FTLD. Thus, I analysed whether TMEM106B knockdown had any inﬂuence on cellular
structures or organelles in order to elucidate whether TMEM106B might aﬀect one or several
cellular structures as well as to get some information about its possible endogenous function.
Moreover, as TMEM106B proved to be a lysosomal protein, I examined whether lysosomal
function was inﬂuenced by TMEM106B. Since it is known that lysosomal dysfunction might
result in neurodegeneration, an impact of TMEM106B on lysosomal function would explain how
it contributes to FTLD-TDP disease progression. Finally, I investigated whether TMEM106B
plays a role in the autophagic pathway which is aﬀected in many neurodegenerative disorders
and is known to accelerate disease progression (see also section 1.4, page 35).
Together, an understanding of TMEM106B’s characteristics, the knowledge of its interaction
partners as well as in which molecular pathway it is involved will aid the development of a
therapeutical approach against FTLD-TDP, a disease where still no cure exists.
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3 Results1
3.1 Establishment of a method for analysing TMEM106B on
immunoblot
At the time when I started this study, little was known about the biochemical features of
TMEM106B. Only predictions based on its DNA (ﬁgure 3.1 a and b) and protein sequence
(ﬁgure 3.1 c) were made. The TMEM106B gene comprises eight or nine exons of which seven
are protein-coding (ﬁgure 3.1 a). In the longest variant, the transcript length is 12.5 kb whereas
the TMEM106B complementary DNA (cDNA) comprises 825 nucleotides (ﬁgure 3.1 b). The
TMEM106B gene is translated into a protein of 274 amino acids (ﬁgure 3.1 c) with a predicted
molecular weight of 31.12 kDa. Moreover, by the bioinformatic prediction programmes for tans-
membrane helices TMHMM 2.0 and TMpred, TMEM106B was predicted to be a transmembrane
protein with one or two transmembrane domains (ﬁgure 3.1 c).
To analyse TMEM106B, human TMEM106B cDNA was ampliﬁed from the IMAGE full length
clone IRAT p970G1031D. An N-terminal human inﬂuenza haemagglutinin (HA)-tag was added
by PCR (see section 5.1.2, page 115)in order to be able to detect TMEM106B with an anti-
HA antibody as, at the time, no anti-TMEM106B antibody was available. Subsequently, the
construct was cloned into both a pcDNA6/V5-HisA and a pcDNA4/TO/myc vector backbone
(see section 5.1.3, page 116). The latter construct was used for generating a stable N-terminally
HA-tagged TMEM106B expressing T-RExTM293 cell line. It was produced because transient
overexpression of TMEM106B resulted in variable TMEM106B expression levels which also
inﬂuenced the intracellular localization of TMEM106B, i.e. heavily overexpressed TMEM106B
resulted in its surface localization or its localization within the lumen of lysosomes. Occasionally,
HA-tagged TMEM106B was also found to be retained in the ER (data not shown).
The use of single, TMEM106B-expressing cell clones enables a homogeneous expression pattern
of TMEM106B. Moreover, especially for immunoﬂuorescence, cell lines with low expression levels
of HA-tagged TMEM106B were chosen to avoid overexpression artefacts and to better mimic
endogenous TMEM106B expression. In the following study, clone number 18 was used as it
presented with the lowest expression of HA-tagged TMEM106B (ﬁgure 3.2). All results were
conﬁrmed with other cell clones (data not shown).
1Parts of the results presented in this study have already been published in Lang et al. [155], Schwenk et al.
[263] and Götzl et al. [87].
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2nd predicted transmembrane domain
1st predicted transmembrane domain 
 
predicted N-glycosylation motifs
disease-associated mutation
c)
1 11 21 31 41
51
101 111 121 131 141
151 161 171 181 191
201 211 221 231 241
251 261 271
61 71 81 91
MGKSLSHLPL HSSKEDAYDG VTSENMRNGL VNSEVHNEDG RNGDVSQFPY 
VEFTGRDSVT CPTCQGTGRI PRGQENQLVA LIPYSDQRLR PRRTKLYVMA 
SVFVCLLLSG LAVFFLFPRS IDVKYIGVKS AYVSYDVQKR TIYLNITNTL
NITNNNYYSV EVENITAQVQ FSKTVIGKAR LNNITIIGPL DMKQIDYTVP
TVIAEEMSYM YDFCTLISIK VHNIVLMMQV TVTTTYFGHS EQISQERYQY
VDCGRNTTYQ LGQSEYLNVL QPQQ
ATG GGA AAG TCT CTT TCT CAT TTG CCT TTG CAT TCA AGC AAA GAA GAT GCT TAT GAT GGA GTC 
ACA TCT GAA AAC ATG AGG AAT GGA CTG GTT AAT AGT GAA GTC CAT AAT GAA GAT GGA AGA AAT 
GGA GAT GTC TCT CAG TTT CCA TAT GTG GAA TTT ACA GGA AGA GAT AGT GTC ACC TGC CCT ACT 
TGT CAG GGA ACA GGA AGA ATT CCT AGG GGG CAA GAA AAC CAA CTG GTG GCA TTG ATT CCA TAT 
AGT GAT CAG AGA TTA AGG CCA AGA AGA ACA AAG CTG TAT GTG ATG GCT TCT GTG TTT GTC TGT 
CTA CTC CTT TCT GGA TTG GCT GTG TTT TTC CTT TTC CCT CGC TCT ATC GAC GTG AAA TAC ATT 
GGT GTA AAA TCA GCC TAT GTC AGT TAT GAT GTT CAG AAG CGT ACA ATT TAT TTA AAT ATC ACA 
AAC ACA CTA AAT ATA ACA AAC AAT AAC TAT TAC TCT GTC GAA GTT GAA AAC ATC ACT GCC CAA 
GTT CAA TTT TCA AAA ACA GTT ATT GGA AAG GCA CGC TTA AAC AAC ATA ACC ATT ATT GGT CCA 
CTT GAT ATG AAA CAA ATT GAT TAC ACA GTA CCT ACC GTT ATA GCA GAG GAA ATG AGT TAT ATG 
TAT GAT TTC TGT ACT CTG ATA TCC ATC AAA GTG CAT AAC ATA GTA CTC ATG ATG CAA GTT ACT 
GTG ACA ACA ACA TAC TTT GGC CAC TCT GAA CAG ATA TCC CAG GAG AGG TAT CAG TAT GTC GAC 
TGT GGA AGA AAC ACA ACT TAT CAG TTG GGG CAG TCT GAA TAT TTA AAT GTA CTT CAG CCA CAA 
CAG TAA 
chromosome 7: 12,250,867-12,282,993
base pairs: 12,539
cDNA nucleotides: 825
rs1020004 rs6966915
T185S (rs3173615)
rs1990622
a)
b)
Figure 3.1: cDNA and protein sequences of TMEM106B
a) The gene structure of the longest TMEM106B variant is depicted. Empty boxes represent non-protein-
coding exons or the 3’ UTR, black boxes represent protein-coding exons. In red, the location of the SNPs
found in the GWAS in 2010 [301] is depicted (modiﬁed from [305]). b) The cDNA sequence of the longest
TMEM106B variant is depicted. In the cDNA sequence, start and stop codons are underlined. c) The protein
sequence of TMEM106B is shown. Predicted transmembrane domains and glycosylation sites are highlighted
in diﬀerent colours (ﬁgure legend). The disease-associated mutation site is underlined (T185S).
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Figure 3.2: Stable expression of HA-tagged TMEM106B in diﬀerent cell clones of HA-tagged wild-
type (wt) TMEM106B-transfected T-RExTM293 cells
T-RExTM293 cells stably expressing N-terminally HA-tagged wt TMEM106B were generated and a pool as
well as single cell clones were isolated (number of cell clones see ﬁgure). HA-TMEM106B expression was
induced with 0.2 μg/ml tetracycline and cell lysates were analysed for HA-tagged TMEM106B by SDS-PAGE
and subsequent immunoblotting with the anti-HA antibody 3F10. Untransfected T-RExTM293 cells served
as negative control (ctrl) and β-actin as loading control. The asterisk (*) marks putative HA-TMEM106B
aggregates.
At the beginning of my studies, I established conditions for SDS-PAGE and immunoblotting of
TMEM106B. Since HA-tagged TMEM106B showed a high tendency to aggregate upon SDS-
PAGE separation (data not shown), I chose to use urea-SDS gels instead to reduce TMEM106B
aggregation. Moreover, better results were gained when non-reducing urea Laemmli buﬀer
(without β-mercaptoethanol) was used (data not shown; also compare to results see ﬁgure 3.3).
For endogenous TMEM106B detection, Anja Capell 2, Elizabeth Kremmer 3 and I started to
raise and test monoclonal antibodies against TMEM106B peptide. After selecting a hybridoma
cell clone producing an antibody suitable for immunoblotting (anti-TMEM106B antibody 6F2;
see also section 5.1.8, page 123 and section 5.1.9, page 125), I investigated whether urea-SDS-
PAGE followed by immunoblotting was also an applicable method for endogenous TMEM106B
protein detection. Furthermore, I tested whether indeed non-reducing conditions lead to better
results than reducing ones. In addition, I varied the incubation temperature of the protein
samples in their appropriate Laemmli buﬀer (ﬁgure 3.3).
The speciﬁcity of the antibody was shown by knocking down endogenous TMEM106B with
small interfering RNAs (siRNAs) (ﬁgure 3.3; see lanes marked with KD). As upon TMEM106B
knockdown, both the band at about 75 kDa, a potential dimer, as well as the band at about
40 kDa disappeared, both bands are considered to be speciﬁc for TMEM106B.
2Dr. Anja Capell, Ludwig-Maximilians-University Munich, Adolf Butenandt Institute, Munich, Germany
3Dr. Elisabeth Kremmer, Institute of Molecular Immunology, Helmholtz Center, Munich, Germany
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Interestingly, TMEM106B showed a molecular weight band proﬁle which was dependent on the
conditions used for the denaturation of the proteins, namely temperature and reducing conditions
(ﬁgure 3.3). Furthermore, the addition of urea to the SDS gel as well as to the Laemmli buﬀer
reduced TMEM106B aggregation.
TMEM106B
HA-TMEM106B
TMEM106B
HA-TMEM106B
kDa KD KD KD OEOEOEOE ---- KD
4°C 25°C 65°C 95°C
98
148
250
64
36
50
TMEM106B
TMEM106B
HA-TMEM106B
HA-TMEM106B
98
148
250
64
50
no
n-
re
du
ci
ng
 c
on
di
tio
ns
(w
/o
 ?
-m
er
ca
to
et
ha
no
l; 
ur
ea
-S
D
S
)
re
du
ci
ng
 c
on
di
tio
ns
(w
ith
 ?
-m
er
ca
to
et
ha
no
l; 
S
D
S
)
Figure 3.3: Running behaviour of TMEM106B on immunoblot, depending on temperature and re-
ducing conditions
SH-SY5Y cells were transfected with an siRNA pool against TMEM106B (KD), with an N-terminally HA-
tagged wt TMEM106B construct (OE) or with non-targeting siRNA as control (-). Before loading on the
urea-SDS gel, samples were incubated in urea Laemmli buﬀer without β-mercaptoethanol for 30min at 4 ◦C
or at 25 ◦C, for 15min at 65 ◦C or for 5min at 95 ◦C. Equal amounts of the same samples were incubated for
the same time ranges and temperatures in “normal” Laemmli buﬀer with β-mercaptoethanol and loaded on an
SDS gel. Subsequently, TMEM106B variants were separated by SDS-PAGE and detected by immunoblotting
with the anti-TMEM106B antibody 6F2.
Under non-reducing conditions (no β-mercaptoethanol), at 4 ◦C and 25 ◦C, only one band ap-
peared at about 75 kDa. However, at 65 ◦C and 95 ◦C, the band at about 75 kDa increasingly
decreased whereas a band at about 40 kDa was detected. Furthermore, a large amount of protein
does not seem to be detectable any longer. HA-tagged TMEM106B ran at a higher molecular
weight than expected possibly because the HA-tag interferes with the running behaviour of the
TMEM106B protein. Thus, on immunoblot, HA-tagged TMEM106B was detected at about
100 kDa and 55 kDa.
Notably, the TMEM106B band with the higher molecular weight was more prominent in case of
HA-tagged than of endogenous TMEM106B. This might indicate that HA-tagged TMEM106B
is more prone to aggregation than endogenous TMEM106B. However, the fact that at lower
temperatures, only the 75 kDa band of endogenous TMEM106B is visible might also imply that
TMEM106B dimerizes.
Strikingly, under reducing conditions, the band at about 40 kDa was not changed in regard
to diﬀerent temperatures. However, the band at about 75 kDa increasingly disappeared with
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increasing temperatures and, at 95 ◦C, was almost undetectable. Moreover, comparing both
reducing conditions (using Laemmli buﬀer with β-mercaptoethanol) and non-reducing conditions
(using urea Laemmli buﬀer without β-mercaptoethanol), it became apparent that even though
equal amounts of protein were loaded, less protein was detected in case of the reducing conditions.
Since it was not clear whether the band at about 75 kDa represented a natively-existing
TMEM106B dimer or whether it was just an artefact due to protein aggregation, and as un-
der non-reducing conditions, I could detect higher levels of TMEM106B protein, I decided to
use urea-SDS gels with pre-heating of the protein lysates at 65 ◦C in Laemmli buﬀer without
β-mercaptoethanol for detecting TMEM106B.
3.2 TMEM106B is a highly glycosylated type II
transmembrane protein
3.2.1 TMEM106B is a glycosylated integral membrane protein
To determine whether TMEM106B was a transmembrane protein as predicted or just membrane-
attached, a membrane preparation followed by carbonate extraction was performed with T-
RExTM293 cells stably expressing N-terminally HA-tagged wild-type TMEM106B (ﬁgure 3.4
a). As TMEM106B was recovered in the membrane/membrane-associated protein fraction and,
upon further fractionation, in the pellet of the carbonate extraction, TMEM106B was conﬁrmed
to be an integral membrane protein (ﬁgure 3.4 a). However, the molecular weight of the protein
detected on western blot was about 55 kDa and not the predicted 31.12 kDa, which could not
only be explained by the added HA-tag of the overexpressed protein.
Interestingly, the consensus sequence for N-glycosylation, N-X-T/S, was found to appear ﬁve-
times in the amino acid sequence of TMEM106B (ﬁgure 3.1 c, yellow highlights). Bioinformatic
tools (NetNGlyc 1.0 and NetOGlyc 4.0, ﬁgure 3.1) conﬁrmed the presence of ﬁve possible N-
glycosylation sites at amino acid positions 146 (N1), 152 (N2), 165 (N3), 184 (N4) and 257
(N5). Thus, it was investigated whether the diﬀerent molecular weight of TMEM106B could be
explained by glycosylation. Indeed, upon treatment with either N-glycosidase F, to remove N-
linked glycans, or endoglycosidase H, to only remove non-complex sugars, the molecular weight
of TMEM106B shifted towards a smaller size suggesting that TMEM106B is both non-complex
and complex glycosylated (ﬁgure 3.4 b).
Of note, on immunoblot, TMEM106B appeared as a double band which was especially promi-
nent after deglycosylation. However, this phenomenon cannot be attributed to phosphorylation
as after treatment with okadaic acid, a drug that inhibits protein serine/threonine phosphatases,
the double band was still present (data not shown). Therefore, another post-translational mod-
iﬁcation of TMEM106B might be responsible for the doublet. Alternatively, it might be a
methodological problem as without β-mercaptoethanol and without boiling, TMEM106B might
not be fully reduced and/or denatured.
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Figure 3.4: TMEM106B is a glycosylated integral membrane protein
a) Tetracycline-induced T-RExTM293 cells stably expressing N-terminally HA-tagged wt TMEM106B were
subjected to cellular fractionation. Total membranes, cytosol and carbonate-extracted membranes (carb.
supernatant (sup.) which is the membrane-associated protein fraction; carb. pellet which is the integral
membrane fraction) were subsequently analysed for TMEM106B by SDS-PAGE and immunoblotting with the
anti-HA antibody 3F10. Calnexin served as a control for an integral membrane protein, 14-3-3-β as control
for a cytosolic soluble protein, respectively. The asterisk (*) marks putative TMEM106B aggregates. b)
Lysates of tetracycline-induced T-RExTM293 cells stably expressing N-terminally HA-tagged wt TMEM106B
were treated for 16 h with either N-glycosidase F (F) to remove all N-linked glycans or with endoglycosidase H
(H) to only remove non-complex glycans. Controls were incubated in the appropriate buﬀer, but without the
enzyme. The asterisk (*) marks putative TMEM106B aggregates [155].
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3.2.2 TMEM106B is a type II transmembrane protein
The suggested existence of one or two transmembrane domains within TMEM106B together with
a robust molecular weight shift due to N-glycosylation would result in two possible topologies of
the protein (ﬁgure 3.5). If both transmembrane domains were utilized, TMEM106B would be
inserted into the membrane as hairpin-like structure with its N- and C-termini located within
the cytosol (see model on the left side of ﬁgure 3.5). However, if only the more N-terminal trans-
membrane domain (which was predicted with a higher probability) was inserted, TMEM106B
would be type II-oriented, with its C-terminus in the lumen and the N-terminus in the cytosol
(see model on the right side of ﬁgure 3.5).
The predicted ﬁfth glycosylation site at position 257 (N5) is C-terminal of the second predicted
transmembrane domain (ﬁgure 3.5). Accordingly, if TMEM106B is a type II tansmembrane
protein, N5 would be glycosylated, however, if it adopts a hairpin-like structure and thus its
C-terminus is located in the cytosol, N5 would not be glycosylated.
N1
N2
N3
N4
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Figure 3.5: The two possible topologies of TMEM106B
On the left, the hairpin-like structure that TMEM106B would adopt if both predicted transmembrane domains
were used is depicted. On the right, the model of TMEM106B as a type II transmembrane protein is shown.
The N-glycosylation sites are marked as N1 to N5 (modiﬁed from [155]).
Therefore, in order to determine the membrane orientation of TMEM106B, the ﬁve predicted
N-glycosylation sites were sequentially inactivated by mutating the asparagines (N) to serines
(S) (ﬁgure 3.6 a). Indeed, sequential deletion of the predicted N-glycosylation sites resulted in a
gradual reduction of the molecular weight of TMEM106B, and importantly, also after deleting
the last (N5) glycosylation site, a further reduction of the molecular weight could be noticed
(ﬁgure 3.6 a).
To verify the result, only the N5-glycosylation site was mutated and compared to wild-type
TMEM106B (ﬁgure 3.6 b and c). As a control, also N4 and N3 were singly mutated. Again,
deletion of N5 resulted in a decreased molecular weight which was comparable to the decreased
weight in the N3 and N4 mutants (ﬁgure 3.6 b and c). As the HA-tag might interfere with
the membrane orientation, the experiment was performed with both an N- (ﬁgure 3.6 b) and
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Figure 3.6: TMEM106B is a type II transmembrane protein
a) The asparagines of the ﬁve N-glycosylation motifs of TMEM106B were sequentially mutated to serines to
abolish glycosylation. Each mutant contains an additionally deleted glycosylation site (N1mut to N1-5mut).
The mutated cDNA constructs were transiently transfected into HEK293T cells. To control for migration of
fully glycosylated and unglycosylated TMEM106B in SDS-PAGE, HEK293T cells were transfected with the
HA-TMEM106B wt construct and treated with solvent or 10 μg/ml tunicamycin for 16 h. HA-TMEM106B
variants were separated by SDS-PAGE and detected by immunoblotting with the anti-HA antibody 3F10. The
asterisk (*) marks putative TMEM106B aggregates. Note that both the treatment with tunicamycin and
the deletion of all ﬁve glycosylation sites lead to the same molecular weight shift and that in both cases,
reduced expression levels can be observed probably due to impaired folding and thus increased degradation
[155]. b) & c) TMEM106B constructs either tagged N- (b) or C-terminally (c) were subjected to site-directed
mutagenesis to only mutate the single glycosylation motifs at N3, N4 or N5. The resulting constructs N3mut,
N4mut and N5mut and, as a control, the wt construct were transiently transfected into HEK293T cells. Lysates
were analysed for TMEM106B expression by SDS-PAGE and subsequent immunoblotting with the anti-HA
antibody 3F10. The asterisk (*) marks putative TMEM106B aggregates. Importantly, the HA-tag does not
interfere with glycosylation at N5 and thus with the membrane orientation of TMEM106B [155].
a C-terminally (ﬁgure 3.6 c) tagged construct. Both led to consistent results proving that
TMEM106B is indeed a type II transmembrane protein (ﬁgure 3.7).
Moreover, deletion of all glycosylation sites (N1-5) resulted in a shift of the molecular
weight equal to the one observed after treatment with tunicamycin, a drug that abolishes N-
glycosylation (ﬁgure 3.6 a). Hence, the ﬁve examined N-glycosylation sites of TMEM106B are
the only ones utilized.
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Figure 3.7: Topology of TMEM106B
The model of TMEM106B as a type II transmembrane protein is shown. The N-glycosylation sites are marked
as N1 to N5 (modiﬁed from [155]).
3.3 TMEM106B is localized to the late endosomal/lysosomal
compartment
To determine the localisation of TMEM106B within the cell, immunoﬂuorescence experiments
were performed with various marker antibodies against diﬀerent cellular structures. As at
the beginning of my studies no TMEM106B antibody was available, experiments were exe-
cuted in tetracycline-induced T-RExTM293 cells stably expressing N-terminally HA-tagged wt
TMEM106B at low levels to avoid overexpression artefacts. Thereby, TMEM106B predomi-
nantly co-localized with the lysosomal marker protein LAMP1, but did not or only to a minor
amount co-localize with the ER marker binding immunoglobulin protein (BiP) and the Golgi
marker giantin (ﬁgure 3.8 a). Treatment with BafA1, a drug that inhibits lysosomal acidiﬁcation,
further increased the lysosomal co-localization of TMEM106B (ﬁgure 3.8 a).
To further specify TMEM106B localization, either tetracycline-induced T-RExTM293 cells sta-
bly expressing N-terminally HA-tagged wt TMEM106B (ﬁgure 3.8 c) or HeLa cells transiently
transfected with N-terminally HA-tagged wt TMEM106B (ﬁgure 3.8 d) were co-transfected with
diﬀerent Rab-green ﬂuorescent protein (GFP) constructs and subjected to immunoﬂuorescence.
TMEM106B wt-positive cells thereby showed a clear co-localization with Rab7-GFP-positive
vesicles, i.e. late endosomes or lysosomes [323]. However, TMEM106B did not or only to a mi-
nor extent co-localize with Rab4a-, Rab5- or Rab11-GFP-positive vesicles, i.e. early or recycling
endosomes [323].
Thus, TMEM106B seems to be mainly localized to the late endosomal/lysosomal compartment,
a ﬁnding, that was later also conﬁrmed by staining endogenous TMEM106B using an anti-
TMEM106B antibody whose speciﬁcity is shown by the absence of staining in the TMEM106B
knockdown (ﬁgure 3.8 b).
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Figure 3.8: TMEM106B is localized to the late endosomal/lysosomal compartment
a) Tetracycline-induced T-RExTM293 cells stably expressing N-terminally HA-tagged wt TMEM106B at very
low levels were grown on coated coverslips and TMEM106B expression was induced with 0.2 μg/ml tetracycline
for 16 h. One set of cells was additionally treated with 25 nM BafA1 for 16 h. Then, cells were ﬁxed with PFA
and stained for TMEM106B with an anti-HA antibody (green). The co-staining (red) was executed with the
use of the indicated cell marker antibodies (anti-BiP for ER, anti-giantin for Golgi, anti-LAMP1 for lysosomes)
[155].
50
3.3 TMEM106B is localized to the late endosomal/lysosomal compartment
c)
magnification
LAMP1 poly3F10 (HA-TM)
Rab7-GFP
Rab5a-GFP3F10 (HA-TM)
3F10 (HA-TM)
merge/DAPI
merge/DAPI
merge/DAPI
3F10 (HA-TM) Rab11-GFP merge/DAPI
scale bar: 20 μm scale bar: 5 μm
d)
magnification
scale bar: 20 μm scale bar: 5 μm
Rab7-GFP
Rab5a-GFP
Rab4-GFP merge/DAPI
merge/DAPI
merge/DAPI
merge/DAPIRab11-GFP
3F10 (HA-TM)
3F10 (HA-TM)
3F10 (HA-TM)
3F10 (HA-TM)
Figure 3.8 (continued): TMEM106B is localized to the late endosomal/lysosomal compartment
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Figure 3.8 (continued): TMEM106B is localized to the late endosomal/lysosomal compartment
b) HEK293T cells were grown on coated coverslips and subsequently stained for TMEM106B with an anti-
TMEM106B antibody (green) and co-stained with the monoclonal lysosomal marker antibody anti-LAMP1
(red). Additionally, one set of cells had been transfected with an siRNA pool against TMEM106B to knockdown
the protein and one set had been treated for 16 h with 25 nM BafA1 before being stained. Note that the
TMEM106B staining is abolished in the siRNA-transfected cells proving the speciﬁcity of the antibody [155].
c) Tetracycline-induced T-RExTM293 cells stably expressing N-terminally HA-tagged wt TMEM106B at very
low levels were grown on coated coverslips and transiently transfected with carboxy-terminal GFP fusion
cDNA constructs of Rab4, Rab5a, Rab7 or Rab11 as indicated. 8 h after transfection, TMEM106B expression
was induced for 16 h. Subsequently, TMEM106B was stained with an anti-HA antibody (red). Note that
TMEM106B co-localizes best with the late endosome marker Rab7, but hardly co-localizes with early endosome
markers Rab4 and Rab5a or with the recycling endosome marker Rab11 [155]. d) HeLa cells were grown on
coverslips and co-transfected with N-terminally HA-tagged wt TMEM106B cDNA and the indicated Rab-
GFP constructs. Cells were ﬁxed in PFA and stained for TMEM106B with an anti-HA antibody and for
lysosomes with an anti-LAMP1 antibody. Note that like in the stable T-RExTM293 cells (c), TMEM106B
mainly co-localizes with Rab7 and LAMP1, but not with Rab5a or Rab11.
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3.4 Complex glycosylation of TMEM106B is required for its
cellular transport
To analyse which of the ﬁve N-glycosylation motifs of TMEM106B is complex glycosylated,
HEK293T cells were transfected with the already mentioned glycosylation site mutants (N1mut
to N1-5mut, see section 3.2.2, page 51) as well as the single glycosylation site mutants N4mut and
N5mut and the double-mutant N4+5mut. Subsequently, cells were lysed and treated with either
N-glycosidase F or endoglycosidase H (ﬁgure 3.9 a). Interestingly, combined mutation of the
ﬁrst three glycosylation motifs (N1-3mut) resulted in an endoglycosidase H-resistant TMEM106B
variant suggesting that the fourth and the ﬁfth glycosylation site are complex glycosylated
whereas the ﬁrst to the third are non-complex glycosylated (ﬁgure 3.9 a and b).
As glycosylation might play a role in cellular transport, I investigated the localization of the
TMEM106B glycosylation variants in immunoﬂuorescence. Thereby, abolishing non-complex
glycosylation did not present with any obvious impact on TMEM106B localization shown by
co-localization of N1-3mut with the lysosomal marker LAMP2 (ﬁgure 3.9 c). However, additional
deletion of one (N1-4mut) or both (N1-5mut) complex glycosylation sites resulted in an accumu-
lation of TMEM106B in the ER and an impaired transport to late endosomes/lysosomes (ﬁgure
3.9 c and d). To further investigate whether and which complex glycosylation site is responsible
for cellular traﬃcking of TMEM106B, HeLa cells were transfected with either N4mut, N5mut or
N4+5mut (ﬁgure 3.9 c and d). As the deletion of both complex glycosylation sites (N4+5mut)
led to a similar phenotype than N1-4mut or N1-5mut, complex glycosylation indeed seems to play
a role in cellular traﬃcking of TMEM106B (ﬁgure 3.9 c and d). Interestingly, whereas muta-
tion of the ﬁfth glycosylation site (N5) resulted in a strong lamellipodia-like staining suggesting
prominent cell surface localization, mutation of the fourth glycosylation site only (N4) led to
ER retention of TMEM106B and thus impaired forward transport to late endosomes/lysosomes
(ﬁgure 3.9 c and d). Accordingly, complex glycosylation seems to be important for correct
TMEM106B localization within the cell.
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Figure 3.9: Localization of TMEM106B is inﬂuenced by complex glycosylation
a) Lysates of HEK293T cells transiently transfected with the indicated N-terminally HA-tagged TMEM106B
glycosylation mutants were treated with either N-glycosidase F (F) or endoglycosidase H (H) for 16 h before
separation by SDS-PAGE and immunoblotting with an anti-HA antibody. Controls were incubated in the
appropriate buﬀer without the enzyme [155]. b) Model of TMEM106B depicting the non-complex glycosylation
sites (in dark blue) and the complex ones (in light blue). c & d) HeLa cells were transiently transfected with the
indicated N-terminally HA-tagged TMEM106B glycosylation mutants and subjected to immunoﬂuorescence.
Thereby, the cells were stained for TMEM106B with an anti-HA antibody (red) and either co-stained with the
lysosomal marker anti-LAMP2 (c) or the ER marker anti-BiP (d) (green) [155].
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3.5 TMEM106B and GRN do not inﬂuence each other directly
TMEM106B risk variants were found to be especially associated with GRN mutation carri-
ers [301] (see also section 1.2.2, page 22). Moreover, van Deerlin et al. claimed that risk
carriers showed higher TMEM106B expression and that in FTLD-TDP cases, TMEM106B
mRNA levels were 2.5-fold increased compared to controls [301]. Together, this suggested a
direct relationship between GRN and TMEM106B expression levels. Therefore, I investigated
the inﬂuence of TMEM106B overexpression and knockdown on GRN in a cell culture model.
For TMEM106B overexpression, tetracycline-induced T-RExTM293 cells stably expressing N-
terminally HA-tagged wt TMEM106B were used (ﬁgure 3.10 a and b). As control served non-
induced stable cells as well as non-transfected T-RExTM293 cells. However, neither on mRNA
nor on protein level (media and lysate), any changes of GRN could be observed (ﬁgure 3.10
a and b). The same applied to SH-SY5Y cells transiently transfected with N-terminally HA-
tagged TMEM106B (ﬁgure 3.10 c). Next, the inﬂuence of TMEM106B knockdown on GRN
was examined with the use of the anti-TMEM106B antibody 6F2 (validation of the antibody
see Material and Methods 5.1.9), but even though the TMEM106B knockdown eﬃciency was
more than 90 % (on mRNA level), no diﬀerences on either GRN mRNA or on protein levels
were observed in both HEK293T and SH-SY5Y cells (ﬁgure 3.11). Thus, TMEM106B and GRN
probably do not interact directly, but may inﬂuence each other indirectly through a common
pathway.
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Figure 3.10: TMEM106B overexpression does not inﬂuence GRN levels
a) T-RExTM293 cells stably expressing N-terminally HA-tagged wt TMEM106B were (+Tet) and were not
(-Tet) tetracycline-treated for 16 h. As a control served untransfected and non-induced T-RExTM293 cells.
Conditioned media and lysates were analysed for GRN and TMEM106B expression by SDS-PAGE and subse-
quent immunoblotting where β-actin served as loading control. The bar graph represents the quantiﬁcation
of TMEM106B expression by measuring the chemiluminescence on the immunoblot. Data are shown as fold
change normalized to non-induced cells, means ± S.D. (n=3) are depicted (***: p < 0.001 and not signiﬁcant
(n.s.) by one-way ANOVA post hoc Dunnett’s test) [155]. b) Bar graphs represent the quantiﬁcation of GRN
protein levels from the immunoblot by chemiluminescence and from the media by ELISA. GRN mRNA levels
were quantiﬁed by real-time PCR. Data are shown as fold change in GRN levels after TMEM106B induction,
means ± S.D. (n= 3) are depicted (n.s. by one-way ANOVA post hoc Dunnett’s test) [155]. c) SH-SY5Y
cells were transiently transfected with N-terminally HA-tagged wt TMEM106B and TMEM106B and GRN
levels were detected by SDS-PAGE and subsequent immunoblotting. β-actin served as loading control. The
bar graph represents the quantiﬁcation of GRN levels by measuring the chemiluminescence of the immunoblot.
Data are shown as fold change normalized to mock-treated control cells, means ± S.D. (n=3) are depicted
(n.s. by unpaired student’s t-test).
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Figure 3.11: TMEM106B knockdown does not inﬂuence GRN levels
a) HEK293T cells were either transfected with an siRNA pool against TMEM106B or with non-targeting
control siRNA. 72 h after transfection, conditioned media of the last 16 h of siRNA transfection was collected,
and total RNA or cell lysates prepared. TMEM106B and GRN expression were analysed by SDS-PAGE and
subsequent immunoblotting. The bar graphs represents the quantiﬁcation of TMEM106B and GRN expression
by measuring the chemiluminescence on the immunoblot. Data are shown as fold change normalized to non-
targeting siRNA-treated cells, means ± S.D. (n=3) are depicted (***: p < 0.001 and n.s. by unpaired
student’s t-test) [155]. b) Bar graphs represent the quantiﬁcation of GRN protein levels from the media
by ELISA. GRN and TMEM106B mRNA levels were quantiﬁed by real-time PCR. Data are shown as fold
change normalized to non-targeting siRNA-treated cells, means ± S.D. (n= 3) are depicted (n.s. by unpaired
student’s t-test) [155]. c) SH-SY5Y cells were transfected with an siRNA pool against TMEM106B or with
non-targeting control siRNA and cell lysates were analysed 72 h post transfection. The bar graph represents
the quantiﬁcation of TMEM106B and GRN levels by measuring the chemiluminescence of the immunoblot.
Data are shown as fold change normalized to non-targeting control siRNA-treated cells, means ± S.D. (n=3)
are depicted (***: p < 0.001 and n.s. by unpaired student’s t-test) [155].
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3.6 Impaired acidiﬁcation increases TMEM106B protein levels
In 2011, Capell et al. showed that GRN deﬁciency, which is associated with FTLD-TDP, can be
rescued by inhibiting the vacuolar H+-ATPase with BafA1, a drug that compromises lysosomal
acidiﬁcation [37]. Moreover, as Van Deerlin et al. suggested a relationship (even though probably
indirect) between TMEM106B and GRN [301] and TMEM106B seems to be localized in BafA1-
sensitive compartments, i.e. in lysosomes, I examined whether TMEM106B is required for the
elevation of GRN levels after BafA1 treatment and whether inhibition of the H+-ATPase had
an impact on TMEM106B levels.
Indeed, upon induction of TMEM106B expression in T-RExTM293 cells stably expressing N-
terminally HA-tagged wt TMEM106B and subsequent BafA1 treatment, a signiﬁcant increase
in TMEM106B levels could be observed (ﬁgure 3.12 a). However, even though GRN levels
increased upon BafA1 treatment, the increase was not inﬂuenced by TMEM106B overexpression
(ﬁgure 3.12 a). Next, TMEM106B and GRN levels were analysed under TMEM106B knockdown
conditions with and without BafA1 treatment. Again, the increase in GRN levels after BafA1
treatment was not inﬂuenced by TMEM106B (ﬁgure 3.12 b), but interestingly, endogenous
TMEM106B levels were elevated dramatically upon H+-ATPase inhibition (ﬁgure 3.12 b). Thus,
even though GRN and TMEM106B did not inﬂuence each other directly, BafA1 treatment had
an impact on both proteins hinting that they may act in a common pathway.
Analysing TMEM106B mRNA levels revealed a slight increase (1.5-fold) upon BafA1 treatment,
however, to a much lesser extent than on protein level (ﬁgure 3.12 c). Therefore, I tested whether
either impaired transcription or translation could abolish the increase in TMEM106B protein
levels after BafA1 treatment. Interestingly, whereas treatment with actinomycin, a drug that
inhibits transcription, did not impair the increase in TMEM106B levels after BafA1 treatment,
treatment with cycloheximide, which compromises translation, strongly reduced the BafA1 eﬀect
on TMEM106B levels (ﬁgure 3.13 a). Thus, protein stabilization alone probably cannot account
for the elevated protein levels of TMEM106B after BafA1 treatment. Supporting this ﬁnding,
cells treated with lysosomal protease inhibitors did not result in elevated TMEM106B levels
comparable to BafA1 treatment (ﬁgure 3.13 b). Also, inhibition of proteasomal degradation
by epoxomicin did not inﬂuence TMEM106B expression levels to the same extent than BafA1
(ﬁgure 3.13 b). In summary, these data therefore suggest a predominant post-transcriptional
mechanism to be involved in the BafA1-mediated increase in TMEM106B protein levels.
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Figure 3.12: TMEM106B accumulates in lysosomes upon BafA1 treatment
a) TMEM106B expression was induced with 0.2 μg/ml tetracycline in T-RExTM293 cells stably expressing
N-terminally HA-tagged wt TMEM106B and cells were either treated or not treated with BafA1 for 16 h. As
a control, T-RExTM293 cells were also treated or not treated with BafA1. Cells were lysed and TMEM106B
and GRN expression were analysed by SDS-PAGE and subsequent immunoblotting and quantiﬁed via chemi-
luminescence. β-actin served as loading control. Data are shown as fold change normalized to the untreated
controls, means ± S.D. (n=3) are depicted (n.s. and *: p < 0.05 by one-way ANOVA post hoc Tukey’s test
and unpaired student’s t-test) [155]. b) HEK293T cells were either transfected with an siRNA pool against
TMEM106B or with non-targeting siRNA as a control and treated with or without BafA1 for 16 h. Cell lysates
were subjected to SDS-PAGE and immunoblotting to analyse TMEM106B and GRN expression levels. β-actin
served as loading control. Subsequently, TMEM106B and GRN levels were quantiﬁed by chemiluminescence.
Data was normalized to untreated cells, and depicted as means ± S.D. (n=3; ***: p < 0.001 and n.s. by
one-way ANOVA post hoc Tukey’s test) [155]. c) TMEM106B mRNA levels of BafA1- and control-treated
cells were analysed by real-time PCR. Data are normalized to control cells and depicted as means ± S.D.
(n=3; *: p < 0.05 by unpaired student’s t-test) [155].
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Figure 3.13: Stabilization of TMEM106B alone cannot account for the increase in protein levels after
BafA1 treatment
a) HEK293T cells were either treated with actinomycine (to inhibit transcription) or cycloheximide (to inhibit
translation) during treatment with/without BafA1. Cell lysates were analysed on immunoblot for TMEM106B
expression with an anti-TMEM106B antibody. β-actin served as loading control [155]. b) HEK293T cells
were treated with BafA1, a mixture of lysosomal protease inhibitors (leupeptin, E64, antipain), leupeptin or
epoxomicin, a proteasomal inhibitor. Cell lysates were analysed on immunoblot for TMEM106B expression
with an anti-TMEM106B antibody. β-actin served as loading control [155].
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3.7 Lysosomal positioning changes upon TMEM106B
knockdown
3.7.1 Upon TMEM106B knockdown, lysosomes cluster in the perinuclear
region of the cell
For analysing TMEM106B function, I focused on knockdown experiments. Before I started to
examine the eﬀects of TMEM106B knockdown, however, I established the conditions for further
experiments. Thus, to test the knockdown eﬃciency of the TMEM106B siRNAs used in this
study (see also Material and Methods, section 5.1.4, page 118), mRNA levels of TMEM106B were
analysed by real-time PCR after knocking down TMEM106B with TMEM106B siRNA (ﬁgure
3.14 a and b). Thereby, TMEM106B #17 (#17) siRNA showed a TMEM106B knockdown
eﬃciency of only less than 25 % (in HEK293T cells), whereas the other siRNAs presented with
a very good knockdown eﬃciency (siRNA pool: 96 %; TMEM106B #2 (#2): 95 %; TMEM106B
#3 (#3): 94 %; TMEM106B #4 (#4): 87 % in HEK293T cells; TMEM106B #3 (#3): 90 % in
HeLa cells). The knockdown eﬃciency was also analysed on protein level by immunoblotting,
where the remaining TMEM106B levels were 33 % (siRNA pool), 17 % (#2), 27 % (#3),
27 % (#4) and 63 % (#17) of TMEM106B levels detected in the non-targeting siRNA treated-
cells, respectively (ﬁgure 3.14 c). Of note, cells treated with TMEM106B #2 siRNA seemed
to die to a much greater extent than cells that were treated with the other siRNAs (data not
shown). Thus, for the following experiments, TMEM106B knockdown was performed with
TMEM106B #3 siRNA as it presented with the best knockdown eﬃciency compared to the
remaining TMEM106B siRNAs.
Strikingly, knocking down TMEM106B resulted in a change in lysosomal positioning, namely
lysosomal clustering in the perinuclear region of the cell (ﬁgure 3.15 a). This phenotype was
especially prominent in HeLa cells (ﬁgure 3.15 b, left panel) but could also be observed in SH-
SY5Y cells where lysosomes did not predominantly cluster at one site near the nucleus, but
were found to be arranged in a ring-like form around the nucleus (ﬁgure 3.15 b, right panel).
Thus, for the following experiments, I chose HeLa cells to further investigate this clustering
phenotype. To exclude that lysosomal clustering was due to side eﬀects of the siRNAs used, I
transfected not only the siRNA pool against TMEM106B, but also the single siRNAs of the pool,
namely TMEM106B #2, TMEM106B #3, TMEM106B #4 and TMEM106B #17. Whereas the
transfection of TMEM106B #2 siRNA was too toxic for the cells as evidenced by a large amount
of cell death (data not shown), transfection of either TMEM106B #3 or TMEM106B #4 siRNA
resulted in pronounced lysosomal clustering (ﬁgure 3.15 b). However, cells transfected with
TMEM106B #17 only showed a very mild clustering phenotype, if at all (ﬁgure 3.15 b). These
observations correlate well with the knockdown eﬃciencies of the respective siRNAs (see ﬁgure
3.14) thus hinting that lysosomal clustering might indeed be caused by TMEM106B knockdown
and not be the result of siRNA side eﬀects.
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Figure 3.14: TMEM106B knockdown eﬃciencies
a) HEK293T cells were transfected with either non-targeting control (ctrl) siRNA, an siRNA pool against
TMEM106B (pool) or with the single siRNAs against TMEM106B, TMEM106B #2 (#2), TMEM106B #3
(#3), TMEM106B #4 (#4) and TMEM106B #17 (#17). Subsequently, real-time PCR was performed
to measure TMEM106B mRNA levels. Data are normalized to control-treated cells according to the ΔΔCt
method and depicted as means ± S.D. (n=3; **: p < 0.01 and n.s. by unpaired student’s t-test). b) HeLa cells
were transfected with either non-targeting control (ctrl) siRNA or with TMEM106B siRNA TMEM106B #3
(#3). TMEM106B mRNA levels were quantiﬁed by real-time PCR. Data are normalized to control-treated
cells and depicted as means ± S.D. (n=3; ****: p < 0.0001 by unpaired student’s t-test). c) HEK293T cells
were transfected with either non-targeting control (ctrl) siRNA, an siRNA pool against TMEM106B (pool) or
with the single siRNAs against TMEM106B, TMEM106B #2 (#2), TMEM106B #3 (#3), TMEM106B #4
(#4) and TMEM106B #17 (#17). Cell lysates were analysed on immunoblot for TMEM106B expression with
an anti-TMEM106B antibody. β-actin served as loading control. The bar graph represents the quantiﬁcation
of the immunoblot by chemiluminescence. Data are normalized to control siRNA-treated cells and depicted
as means ± S.D. (n=3; ****: p < 0.0001, ***: p < 0.001, **: p< 0.01 by unpaired student’s t-test).
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Figure 3.15: Lysosomal clustering upon TMEM106B knockdown
a) HeLa cells were transfected with either non-targeting control siRNA or an siRNA pool against TMEM106B
and immunostained with antibodies against LAMP2 (green) and β-catenin (red) to visualize the cell size.
Note the tight clustering of lysosomes in the perinuclear region of TMEM106B siRNA-treated cells [263].
b) HeLa (left panel) and SH-SY5Y (right panel) cells were transfected with control (ctrl), non-targeting
siRNA, an siRNA pool against TMEM106B and with the single siRNAs against TMEM106B, TMEM106B #3,
TMEM106B #4 and TMEM106B #17. Cells were immunostained with an antibody against LAMP1.
Note that lysosomes clustered in the perinuclear region in cells transfected with either TMEM106B #3,
TMEM106B #4 or the siRNA pool against TMEM106B, whereas the lysosomal phenotype in TMEM106B
#17 siRNA-transfected cells resembled the one in control siRNA-treated cells.
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3 Results
To establish the experimental set-up for TMEM106B knockdown experiments, HeLa cells were
transfected with TMEM106B siRNA TMEM106B #3 on day 0 and ﬁxed at day 1, day 2 and
day 3 after transfection in order to ﬁnd the optimal conditions for analysing the clustering
phenotype (ﬁgure 3.16). On day 1, lysosomes were still distributed throughout the whole cell
with only a mild clustering at the perinuclear region. However, the phenotype became more
obvious the longer the knockdown period lasted and was best at day 3 (ﬁgure 3.16, right panel).
Therefore, for the following experiments, cells were harvested or ﬁxed on day 3, which was 72 h
post transfection.
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Figure 3.16: Lysosomal clustering phenotype increases with TMEM106B knockdown duration
On day 0, HeLa cells were transfected with either non-targeting control siRNA (control) or with TMEM106B
siRNA TMEM106B #3 and ﬁxed on day 1, day 2 or day 3 post-transfection. Subsequently, cells were immuno-
stained for lysosomes with an anti-LAMP1 antibody. Note that in control cells, lysosomes remain distributed
throughout the whole cell whereas in TMEM106B siRNA-treated cells, lysosomes increasingly cluster in the
perinuclear region.
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3.7.2 Lysosomal clustering upon TMEM106B knockdown can be rescued by
overexpressing wt TMEM106B
To verify that the lysosomal clustering phenotype resulted from the lack of TMEM106B pro-
tein and was not caused by side eﬀects of the TMEM106B siRNAs, a resuce experiment was
performed (ﬁgure 3.17). Thereby, HeLa cells were either transfected with non-targeting con-
trol siRNA or with TMEM106B #3 siRNA to knockdown TMEM106B. Two days after siRNA
transfection, either an empty control vector or a vector carrying a TMEM106B #3 siRNA-
resistant, N-terminally HA-tagged TMEM106B wt construct was transfected. Importantly, to
avoid overexpression artefacts, TMEM106B levels were carefully titrated. The TMEM106B #3
siRNA-resistant N4 glycosylation TMEM106B variant served as an additional control as this
protein variant has been shown to be retained in the ER (see section 3.4, page 57). Accord-
ingly, the N4 variant would not reach the lysosome and thus not be able to rescue the clustering
phenotype. On day 3 after siRNA transfection, cells were subjected to immunoﬂuorescence.
In control siRNA-transfected cells expressing HA-tagged TMEM106B, lysosomes were dis-
tributed throughout the cell with a tendency to be more localized to the tips (ﬁgure 3.17).
In TMEM106B #3 siRNA transfected cells, lysosomes clustered in the perinuclear region and
transfection of the empty vector did not inﬂuence this phenotype (ﬁgure 3.17). However, in
TMEM106B #3 siRNA transfected cells that expressed HA-tagged wt TMEM106B, lysosomes
were almost normally distributed throughout the cell, suggesting a successful rescue of the
clustering phenotype (ﬁgure 3.17). As there was no good antibody available for the stain-
ing of TMEM106B, I did not co-stain for endogenous TMEM106B expression to verify the
TMEM106B knockdown. However, TMEM106B knockdown eﬃciency in general is very high
and in TMEM106B #3 siRNA-transfected cells, almost every cell shows lysosomal clustering.
Thus, TMEM106B knockdown had very likely been successful and, accordingly, the observed
spreading of lysosomes in the rescue set-up was due to exogeneous TMEM106B wt expres-
sion. This was further supported by the fact that overexpression of the siRNA-resistant N4
TMEM106B construct could not rescue the lysosomal clustering phenotype (ﬁgure 3.17).
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Figure 3.17: Lysosomal clustering upon TMEM106B knockdown can be rescued by the overexpression
of wt TMEM106B
HeLa cells were reversly transfected with either non-targeting control siRNA (control) or with TMEM106B
siRNA TMEM106B #3 (#3). After two days of siRNA transfection, TMEM106B #3 siRNA-resistant HA-
TMEM106B (wt TMEM106B) and N4 (fourth glycosylation site of TMEM106B deleted) were transfected.
The empty vector pcDNA3.1 served as a control. On day 3 after siRNA transfection, cells were subjected
to immunoﬂuorescence and stained with antibodies against LAMP2 (lysosomal marker, green) and HA (red)
to mark exogeneous TMEM106B. Note that lysosomal clustering could be rescued by overexpressing the N-
terminally HA-tagged wt TMEM106B construct [263], but not by overexpression of the glycosylation mutant
N4.
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3.7.3 Lysosomes cluster at the microtubule-organizing center
From the literature, it is known that lysosomes traﬃc along microtubules and tend to cluster
at the microtubule-organizing center [31, 177]. Hence, I investigated whether upon TMEM106B
knockdown, lysosomes were indeed concentrated at the MTOC. Therefore, I transfected HeLa
cells with TMEM106B siRNA TMEM106B #3 and analysed lysosomal clustering by immunoﬂu-
orescence. Lysosomes were co-stained with γ-tubulin, a marker for the MTOC (ﬁgure 3.18). In
fact, lysosomes clustered at the MTOC suggesting a role for lysosomal transport along micro-
tubules in lysosomal clustering mediated by TMEM106B knockdown.
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Figure 3.18: Upon TMEM106B knockdown, lysosomes cluster at the micrutubule-organizing center
HeLa cells were transfected with either non-targeting control siRNA (control) or with TMEM106B siRNA
TMEM106B #3 and immunostained with antibodies against LAMP1 (red) and γ-tubulin (marker for the
MTOC, green). The arrowheads point towards the MTOC [263].
3.7.4 Quantiﬁcation of lysosomal positioning after TMEM106B knockdown
To quantify lysosomal clustering, automated quantitative image analysis was performed mea-
suring the average distance of lysosomes to the nucleus and the lysosomal distribution using the
Clark aggregation index (see Material and Methods, section 5.2.5, page 139) [44] (ﬁgure 3.19).
Thereby, in TMEM106B siRNA-transfected cells, lysosomes were clearly more shifted towards
the nucleus and showed a more compact subcellular distribution of lysosomes than the controls
(ﬁgure 3.19).
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Figure 3.19: Quantiﬁcation of the lysosomal clustering phenotype mediated by TMEM106B knock-
down
Immunoﬂuorescence pictures of HeLa cells transfected with TMEM106B siRNA TMEM106B #3 (#3) or
transfection reagent only (Mock) were analysed according to lysosomal positioning by automated quantitative
image analysis. Thereby, the mean distance of the lysosomes to the nucleus was measured and clustering was
quantiﬁed by the Clark aggregation index [44]. In three independent experiments, a total of 510 control cells
and 422 TMEM106B siRNA-treated cells were analysed. Data showed signiﬁcant diﬀerences between control
and knockdown of TMEM106B according to the Mann-Whitney-U-test (***: p < 0.001) [263].
In summary, these data suggest that TMEM106B is involved in lysosomal localization and
traﬃcking.
3.8 Inﬂuence of TMEM106B knockdown on other cellular
organelles and structures
One explanation for the altered lysosomal positioning observed after TMEM106B knockdown
might be a general modiﬁcation of cellular traﬃcking which would then not only aﬀect lysosomes
but other cellular organelles as well. Therefore, I investigated whether TMEM106B knockdown
also inﬂuenced the localization of the ER, the Golgi, mitochondria or early endosomes. Yet,
neither the morphology of the ER nor of the Golgi apparatus showed any obvious diﬀerences
upon TMEM106B knockdown (ﬁgure 3.20 a, b and c). Also, mitochondria did not cluster even
though they might be slightly elongated (ﬁgure 3.20 d). However, interestingly, EEA1-positive
vesicles (early endosomes or amphisomes [69]) seemed to cluster in the same region as lysosomes
(ﬁgure 3.21 a and b) suggesting that TMEM106B inﬂuences not only lysosomal positioning but
might have a broader impact on endocytic vesicle traﬃcking.
Since for vesicle traﬃcking, an intact cytoskeleton is essential, I analysed whether the actin
or microtubule network morphology was altered upon TMEM106B knockdown. Therefore, I
knocked down TMEM106B in HeLa cells and stained for either the actin (phalloidin) or the
microtubule (α-tubulin) cytoskeleton (ﬁgure 3.22). Even though both seemed to be intact, it was
conspicuous that upon TMEM106B knockdown, HeLa cells often presented with an elongated
shape (ﬁgure 3.22).
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Figure 3.20: ER, Golgi and mitochondria morphology was not altered upon TMEM106B knockdown
HeLa cells were transfected with either non-targeting control siRNA or TMEM106B #3 siRNA (#3) to knock-
down TMEM106B and subsequently subjected to immunoﬂuorescence. To visualize successful TMEM106B
knockdown or more precisely, lysosomal clustering, lysosomes were stained with antibodies against LAMP1 or
LAMP2 (red). a) The Golgi apparatus was stained with the cis-Golgi marker antibody anti-giantin (green)
and b) with the trans-Golgi marker antibody anti-golgin-97 (green).
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Figure 3.20 (continued): ER, Golgi and mitochondria morphology was not altered upon TMEM106B
knockdown
c) The ER was stained with the marker antibody anti-calnexin (green) and d) mitochondria were stained with
the marker antibody anti-TOM20 (green). To demonstrate how mitochondrial clustering would look like, HeLa
cells were transfected with a mitofusin2-cDNA construct [214]. Mitochondria were stained with mito-GFP,
respectively.
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Figure 3.21: EEA1-positive vesicles cluster in the perinuclear region upon TMEM106B knockdown
HeLa cells were transfected with either non-targeting control siRNA or TMEM106B #3 siRNA (#3) to
knockdown TMEM106B and subjected to immunoﬂuorescence. a) Cells were co-stained with antibodies
against EEA1 (green) and LAMP2 (red), respectively. b) To conﬁrm the observed clustering of EEA1-positive
vesicles upon TMEM106B knockdown, HeLa cells were stained with a diﬀerent antibody against EEA1 (green)
and co-stained with an anti-LAMP1 antibody (red).
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Figure 3.22: Cytoskeleton morphology is not altered upon TMEM106B knockdown
HeLa cells were transfected with either non-targeting control siRNA or TMEM106B #3 siRNA (#3) to
knockdown TMEM106B and subjected to immunoﬂuorescence. a) Cells were either co-stained with phalloidin
(actin cytoskeleton marker, red), a drug that binds to F-actin, and an anti-LAMP1 antibody (green) b) or with
antibodies against α-tubulin (microtubule marker, green) and LAMP1 (red). Note that upon TMEM106B
knockdown, HeLa cells show a more elongated shape compared to control-treated cells.
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3.9 Clustering is dependent on functional retrograde transport
along microtubules
As already mentioned, microtubules are essential for vesicular transport [177] (see section 1.3.2,
page 26). Thus, it is conceivable that lysosomal clustering would be abolished if the micro-
tubule network was defective. To test whether indeed, the clustering phenotype observed upon
TMEM106B knockdown is dependent on microtubule network integrity, I treated non-targeting
siRNA- or TMEM106B #3 siRNA-transfected HeLa cells with diﬀerent concentrations of noco-
dazole, a drug that interferes with microtubule polymerization as it binds to β-tubulin and
prevents the formation of one of the two interchain disulﬁde linkages [253] (ﬁgure 3.23 a).
Thereby, the lower concentration (0.33 μM) only partly destroyed the microtubule network and
lysosomes were concentrated in the area where microtubules were still intact (ﬁgure 3.23 a).
However, higher nocodazole concentrations (3.3 μM) completely inhibited microtubule network
formation (ﬁgure 3.23 a). Importantly, in TMEM106B #3 siRNA-treated HeLa cells, lysosomes
did not cluster any longer but were distributed throughout the cell like in controls (ﬁgure 3.23 a)
suggesting that an intact microtubule network is indeed essential for the clustering phenotype.
Moreover, motor proteins ensure successful vesicle traﬃcking along the cytoskeleton [260, 115]
and thus play an important role for lysosomal positioning. Thereby, kinesins are the major
motor protein species that mediate anterograde transport towards the plus-end of microtubules
whereas dynein is responsible for the retrograde transport towards the MTOC [260, 111]. To
test whether dyneins inﬂuence the lysosomal positioning in the perinuclear region of the cell
in the TMEM106B knockdown, I inhibited the retrograde transport by dynamitin transfec-
tion. Dynamitin is part of the dynein-dynactin machinery and upon overexpression, it prevents
dynein-dynactin assembly and thus inhibits retrograde transport [121, 33, 181]. Accordingly,
I transfected control or TMEM106B #3 siRNA-treated HeLa cells with a GFP-tagged chicken
dynamitin construct, which is more eﬃcient than human dynamitin in inhibiting dynactin func-
tions [121] (ﬁgure 3.23 b). Dynamitin constructs were either transfected on day 1 or day 2 after
siRNA transfection (see also ﬁgure 3.16, page 68), namely when lysosomes were not yet clustered
(day 1) and when they already were (day 2) (ﬁgure 3.23 b). Interestingly, both earlier and later
transfection of dynamitin resulted in a reversed phenotype, with lysosomes positioned at the
cellular tips (ﬁgure 3.23 b). Hence, lysosomal clustering upon TMEM106B knockdown indeed
is dependent on retrograde transport mediated by the dynein-dynactin complex. Moreover,
the balance between retrograde and anterograde transport might apparently be important for
lysosomal positioning and be inﬂuenced by TMEM106B knockdown (an overview of lysosomal
positioning within the cell with the mentioned treatments is presented in ﬁgure 3.23 c).
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Figure 3.23: A functional microtubule network and retrograde transport are required for lysosomal
clustering upon TMEM106B knockdown
a) HeLa cells were transfected with either non-targeting control siRNA or TMEM106B #3 siRNA (#3) to
knockdown TMEM106B. Before ﬁxation, cells were incubated in 0.33 μM or 3.3 μM nocodazole for 16 h.
Untreated cells served as a control. Subsequently, HeLa cells were subjected to immunoﬂuorescence and
stained for lysosomes (anti-LAMP1 antibody, red) and microtubules (anti-α-tubulin antibody, green).
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Figure 3.23 (continued): A functional microtubule network and retrograde transport are required for
lysosomal clustering upon TMEM106B knockdown
b) On day 1 or day 2 after either control or TMEM106B #3 siRNA transfection, HeLa cells were co-transfected
with a GFP-tagged chicken-dynamitin cDNA construct (chk-dyn) to abolish the assembly of the dynein-
dynactin complex and thus retrograde transport. After the indicated periods of chk-dyn-transfection, cells
were ﬁxed and subjected to immunoﬂuorescence. Lysosomes were stained with an anti-LAMP1 antibody
(red), cells transfected with the GFP-chk-dyn construct ﬂuoresced in green (transfected cells were surrounded
by a dotted line). Note that chk-dyn-transfected cells present with a reversed phenotype with lysosomes
clustered at the tips of the cell. c) Scheme of lysosomal transport along microtubules which shows the control
case, TMEM106B #3 siRNA-treated cells and nocodazole- or dynamitin-treated cells. Impairment is depicted
as lightning and unknown mechanisms as question marks.
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3.10 Lysosomes are still acidic and functional upon
TMEM106B knockdown
As from these data, it is still not conceivable whether TMEM106B has a direct impact on vesic-
ular traﬃcking, I also investigated another possibility which might explain lysosomal clustering,
namely whether clustering upon TMEM106B knockdown represents a cellular stress response to
lysosomal dysfunction (ﬁgure 3.24).
It is known that lysosomes can cluster due to lysosomal stress like amino acid deprivation or
treatment with baﬁlomycin A1 or chloroquine, drugs that impair lysosomal acidiﬁcation (see
section 1.3.4, page 33). Therefore, I investigated whether lysosomal function was altered in
TMEM106B siRNA-treated cells. If TMEM106B knockdown resulted in impaired lysosomal
function, the cell would respond with lysosomal clustering and enhance lysosomal biogenesis
through activating the TFEB pathway (ﬁgure 3.24; see also section 1.3.4, page 33). Hence, to
test lysosomal function, I investigated whether typical lysosomal enzymes like cathepsin B and
D still matured after TMEM106B knockdown, a process that requires acidic conditions (see
section 1.3.1, page 25). However, the knockdown of TMEM106B did not change the maturation
of cathepsin B and D (ﬁgure 3.25 a). Moreover, the cathepsin D activity assay of the cell
lysate of TMEM106B #3 siRNA-treated cells showed the same activity as control lysates (ﬁgure
3.25 b). These results already suggested that lysosomes were still acidic upon TMEM106B
knockdown and thus, that processing and activity of lysosomal enzymes were not impaired. To
verify this ﬁnding, HeLa cells transfected with TMEM106B #3 siRNA were either stained with
lysotracker or DQ-BSA and compared to controls (ﬁgure 3.25 c and d). Lysotracker is a dye
that is incorporated by the cell and accumulates in acidic organelles where its ﬂuorescence is
brightest [219]. In contrast, DQ-BSA is a quenched ﬂuorogenic substrate for proteases which
only ﬂuoresce when it is hydrolysed, a process that requires functional lysosomal enzymes [310].
Upon TMEM106B knockdown, both the lysotracker- and the DQ-BSA-treated cells showed an
intense ﬂuorescent staining arguing for unimpaired lysosomal acidiﬁcation and thus functional
lysosomes (ﬁgure 3.25 c and d).
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Figure 3.24: Lysosomal dysfunction and the lysosomal stress response pathway
BafA1 or CQ treatment as well as amino acid (AA) deprivation are known to result in lysosomal dysfunction
which subsequently causes the induction of the lysosomal stress response pathway. As a consequence, lysosomes
begin to cluster at the MTOC [150]. If TMEM106B knockdown also caused lysosomal dysfunction, this would
explain the clustering phenotype seen upon TMEM106B knockdown.
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Figure 3.25: Lysosomal enzyme activity and lysosomal acidiﬁcation were not impaired upon
TMEM106B knockdown
a) HeLa cells were transfected with non-targeting control (ctrl) siRNA or with TMEM106B #3 siRNA (#3)
and subjected to SDS-PAGE and immunoblotting. Lysosomal enzymes were detected with antibodies against
cathepsin B (CatB) and cathepsin D (CatD). The immature (imm.) and mature (mat.) forms are labelled.
The asterisk (*) represents a probably unspeciﬁc band. β-actin served as loading control and TMEM106B as
control for successful TMEM106B knockdown. b) The graph represents cathepsin D activity analysed by a
cathepsin D activity assay. As assay controls served one sample that only contained the cathepsin D substrate
in the appropriate buﬀer and one sample that had been treated with control siRNA and the cathepsin D
inhibitor pepstatin. Note that there was no diﬀerence in cathepsin D activity between TMEM106B #3 and
control siRNA-treated cells.
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Figure 3.25 (continued): Lysosomal enzyme activity and lysosomal acidiﬁcation were not impaired
upon TMEM106B knockdown
c) HeLa Kyoto cells stably expressing LAMP1-GFP were transfected with either non-targeting control siRNA
or with TMEM106B #3 siRNA (#3). On day 3 after transfection, cells were incubated with lysotracker and
with or without BafA1 and subsequently, life cell imaging was performed. Note that also in TMEM106B #3
siRNA-treated cells, lysosomes were stained with lysotracker. In BafA1-treated controls, lysotracker staining
was abolished as lysosomes were not acidic.
78
3.10 Lysosomes are still acidic and functional upon TMEM106B knockdown
DQ-BSA merge/bright field
 c
on
tro
l
#3
merge/bright fieldDQ-BSA
2h 6h
scale bar: 20 μm
d)
Figure 3.25 (continued): Lysosomal enzyme activity and lysosomal acidiﬁcation were not impaired
upon TMEM106B knockdown
d) Three days after control or TMEM106B #3 siRNA (#3) transfection, HeLa cells were incubated with
DQ-BSA for the indicated periods and subjected to life cell imaging. Note that also in TMEM106B #3 siRNA-
treated cells, the ﬂuorescent signal of DQ-BSA was clearly visible indicating that DQ-BSA was hydrolysed by
functional lysosomal enzymes.
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3.11 Autophagosomal markers are altered upon TMEM106B
knockdown
Lysosomal stress response does not only include lysosomal clustering but also inﬂuences lysoso-
mal biogenesis and autophagy (see section 1.3.4, page 33). As lysosomal function appeared to be
unaﬀected by TMEM106B knockdown, I investigated autophagosomal markers in order to ﬁnd
out whether clustering might be induced by a defect in the autophagic pathway. One of these
markers was p62, a selective autophagy receptor that binds to ubiquitinated proteins and can
mediate phagophore recruitment by binding to LC3 (see section 1.3.3, page 29). In immunoﬂu-
orescence experiments, p62 particles seemed to be increased in TMEM106B #3 siRNA-treated
HeLa cells compared to controls and moreover, in some cells, even huge p62 aggregates/particles
were observed (ﬁgure 3.26 a). To verify this phenotype, another p62 antibody was used (ﬁgure
3.26 b) and particles counted and partitioned into size classes (ﬁgure 3.26 c and d). Thereby,
p62 particle numbers were shown to be signiﬁcantly increased in general (ﬁgure 3.26 d), but
especially in the smaller size classes (ﬁgure 3.26 c). In the larger size groups, diﬀerences were
not signiﬁcant probably due to great variation between single cells, but still it became obvious
that in TMEM106B #3 siRNA-treated cells, larger p62 particles were present in greater quan-
tities than in controls (ﬁgure 3.26 c). Of note, the p62 particle numbers seemed to decrease
again at day 4 after TMEM106B #3 siRNA transfection (data not shown), however, this is only
preliminary data and still has to be conﬁrmed in additional experiments.
Furthermore, p62 levels of TMEM106B #3 siRNA-treated cells were also found to be increased
on immunoblot, however, the diﬀerences even though signiﬁcant, were quite small (about 1.2-
to 1.3-times increased compared to controls; ﬁgure 3.27 a and b). An explanation for the dis-
crepancy between the immunoﬂuorescence experiments and the immunoblot might be that p62
is not suﬃciently extracted from cell lysates. To block p62 degradation, cells were additionally
treated with BafA1 and analysed on immunoblot (ﬁgure 3.27 a). Accordingly, p62 levels were
elevated but the ratio between control and TMEM106B #3 siRNA-treated cells remained the
same (ﬁgure 3.27 b). A second examined autophagic marker was LC3, a protein that binds to au-
tophagosomal membranes (see section 1.3.3, page 29). Like p62, LC3 levels were increased upon
TMEM106B knockdown (ﬁgure 3.28 a). To discriminate whether p62 either mediated proteaso-
mal or lysosomal degradation, I examined LC3 and p62 co-localization in an immunoﬂuorescence
experiment (ﬁgure 3.28 b). Indeed, a huge proportion of p62-positive particles co-stained with
LC3. In addition, LC3 levels were increased on immunoblot (data not shown) conﬁrming a link
between TMEM106B and autophagy. Interestingly, there seemed not only a connection to the
autophagic system but also to the proteasomal degradation system. A staining for polyubiq-
uitin, a marker for proteasomal degradation, revealed co-localization with some very large and
also mid-sized p62 particles (ﬁgure 3.28 c).
In summary, these data suggest an alteration in the degradation systems as both marker proteins
for autophagic and proteasomal degradation were increased upon TMEM106B knockdown.
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Figure 3.26: p62 levels are increased upon TMEM106B knockdown in immunoﬂuorescence
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Figure 3.26 (continued): p62 levels are increased upon TMEM106B knockdown in immunoﬂuores-
cence
a) HeLa cells were transfected with either non-targeting control siRNA or with TMEM106B #3 siRNA (#3)
to knockdown TMEM106B. Subsequently, cells were subjected to immunoﬂuorescence and stained with an
antibody against p62. Note the increased p62 levels in TMEM106B #3 siRNA-treated cells. Field1 shows the
increase of smaller p62 particles whereas ﬁeld2 depicts also the increase in p62 particle size. b) To verify the
results, another anti-p62 antibody was utilized and HeLa cells co-stained with an antibody against LAMP1 to
verify successful TMEM106B knockdown by lysosomal clustering. Two diﬀerent pictures of TMEM106B #3
siRNA-treated cells (#3) are depicted to demonstrate the increase in small p62 particles and the appearance
of large aggregates. c) The bar graph represents the quantiﬁcation of p62 particle numbers and sizes in im-
munoﬂuorescence pictures. In a total of three independent experiments, 287 control and 237 TMEM106B #3
siRNA-treated (#3) HeLa cells were analysed. Data are presented in particle number per 100 cells, partitioned
in particle size groups and depicted as means ± S.D. (n=3; **: p< 0.01, *: p< 0.05 and n.s. by unpaired
student’s t-test). d) The bar graph represents the quantiﬁcation of total p62 particle counts per 100 cells in
immunoﬂuorescence pictures of HeLa cells treated with non-targeting siRNA (ctrl) or TMEM106B #3 siRNA
(#3). In a total of three independent experiments, 287 control and 237 TMEM106B #3 siRNA-treated HeLa
cells were analysed. Data are depicted as means ± S.D. (n=3; **: p< 0.01 by unpaired student’s t-test).
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Figure 3.27: p62 levels are increased upon TMEM106B knockdown in immunoblot
a) HeLa cells were transfected with either non-targeting control siRNA (ctrl) or with TMEM106B #3 siRNA
(#3) to knockdown TMEM106B and treated with or without BafA1 for 3 h before being harvested. Sub-
sequently, cells were lysed in RIPA buﬀer and analysed on immunoblot for p62. β-actin served as loading
control. b) The bar graph represents the quantiﬁcation of the immunoblot by chemiluminescence. Data are
normalized to control siRNA-treated cells without BafA1 treatment and depicted as means ± S.D. (n=3; *:
p< 0.05 by unpaired student’s test).
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Figure 3.28: LC3 and ubiquitin levels are increased upon TMEM106B knockdown in immunoﬂuores-
cence
a) HeLa cells were transfected with either non-targeting control siRNA or with TMEM106B #3 siRNA (#3)
to knockdown TMEM106B. Subsequently, cells were subjected to immunoﬂuorescence and stained with anti-
bodies against LC3 and LAMP1. Note the increase in LC3 levels in TMEM106B #3 siRNA-treated cells. b)
Control and TMEM106B #3 siRNA (#3)-treated HeLa cells were analysed by immunoﬂuorescence for LC3
and p62. Note the increase in both LC3 and p62 levels in TMEM106B #3 siRNA-treated cells. c) HeLa
cells transfected with non-targeting control siRNA and TMEM106B #3 siRNA (#3) were subjected to im-
munoﬂuorescence and stained with antibodies against p62 and lysine 48-linked polyubiquitin (Apu2) which
labels proteins targeted for proteasomal degradation. Note the co-localization of mainly the large p62-positive
particles with ubiquitin in TMEM106B #3 siRNA-treated cells.
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3.12 Starvation reveals an increase in autophagosomal and
lysosomal proteins upon TMEM106B knockdown
Even though some alterations like the p62 increase in immunoﬂuorescence experiments or a slight
increase in LC3 levels on immunoblot were already apparent under normal growth conditions,
so far, an inﬂuence of TMEM106B knockdown on lysosomal protein levels could not be observed
(see section 3.10, page 80 and ﬁgure 3.25 a). However, a “second hit” like additional lysosomal
stress might be needed to reveal diﬀerences between control siRNA- and TMEM106B #3 siRNA-
treated cells.
Therefore, before harvesting, I starved non-targeting control siRNA- and TMEM106B #3
siRNA-treated HeLa cells in OptiMEM for 16 h and analysed the lysates by immunoblot (ﬁg-
ure 3.29 a). Strikingly, in TMEM106B knockdown cells, mature cathepsin D levels were about
2.5-fold increased (ﬁgure 3.29 a and b), a ﬁnding that only became obivous upon starvation but
could not be observed under normal growth conditions (compare with ﬁgure 3.25 a). Further-
more, immature cathepsin D levels also increased, however, to a lesser extent than the mature
ones, which might be attributed to an increase in lysosomal biogenesis.
Moreover, LAMP2 and LC3I and II protein levels were signiﬁcantly increased upon TMEM106B
knockdown following OptiMEM treatment over night (ﬁgure 3.29 a and b). However, a trend
towards elevated LC3 levels had already been observed under normal growth conditions (data
not shown). As both LC3I and LC3II levels were elevated upon TMEM106B knockdown, auto-
phagosomal biogenesis might be enhanced under these conditions.
Together, these data indicate that the knockdown of TMEM106B does not only mediate changes
in lysosomal positioning but also in the expression levels of lysosomal and autophagic proteins.
Moreover, to investigate TMEM106B function, additional stressors seem to be indeed needed, a
ﬁnding which is in line with TMEM106B being a risk factor and not a disease-causing gene.
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Figure 3.29: Lysosomal and autophagosomal proteins are elevated upon TMEM106B knockdown in
immunoblot
a) HeLa cells were either transfected with non-targeting control (ctrl) siRNA or TMEM106B #3 siRNA
(#3) to knockdown TMEM106B. 16 h before harvesting, the cells were incubated in OptiMEM overnight.
Subsequently, cell were lysed and analysed for TMEM106B, LAMP2, LC3 and immature (immat.) and
mature (mat.) cathepsin D (CatD) on immunoblot. The asterisk (*) marks a probably unspeciﬁc band of
the cathepsin D antibody. β-actin served as loading control. Of note, lysates for analysing TMEM106B
were incubated in Laemmli buﬀer at room temperature. b) The bar graphs represent the quantiﬁcation of
the immunoblots by chemiluminescence. Data are normalized to control siRNA-treated cells and depicted as
means ± S.D. (n=3; ****: p< 0.0001, ***: p< 0.001, **: p< 0.01 by unpaired student’s t-test).
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4.1 The molecular weight of TMEM106B
In 2010, TMEM106B was the ﬁrst risk factor to be described for FTLD-TDP [301]. However,
at that time, very little was known about the previously uncharacterised protein. Therefore,
I started my studies with a characterization of its basic biochemical and cell biological fea-
tures. When I analysed TMEM106B on immunoblot after SDS-PAGE, it became evident that
TMEM106B detection in terms of amount and apparent molecular weight depended on the condi-
tions of denaturation, i.e. sample buﬀer composition and temperature. It seems that upon strong
denaturation due to high temperatures and the use of β-mercaptoethanol, low TMEM106B pro-
tein amounts were detected, mainly as monomers. However, upon milder denaturation, i.e.
moderate temperatures and without the use of β-mercaptoethanol, higher levels of TMEM106B
protein were detected in their monomeric as well as in their dimeric form.
More precisely, the very prominent band at about 75 kDa became weaker while increasing the
temperature from 4 ◦C to 95 ◦C. This phenomenon was conﬁrmed by Chen-Plotkin et al. who
also found that the 75 kDa species which they recognized with two diﬀerent anti-TMEM106B
antibodies was very heat-sensitive [39]. Moreover, they observed that at 37 ◦C, more than
50 % of the protein they were able to detect at 4 ◦C was lost [39], a ﬁnding that I also made and
which might be explained by a higher sensitivity of the generated anti-TMEM106B antibodies to
native (maybe dimerized) TMEM106B. Furthermore, the second band at about 40 kDa increased
with rising temperatures [39] conﬁrming my ﬁndings at non-reducing conditions. Brady et al.
were able to show that in immunoblots loaded with protein samples which were not boiled but
incubated at 4 ◦C, TMEM106B appeared at a molecular weight of about 86 kDa [25]. From this,
they concluded that at these temperatures, an SDS-resistant dimer seems to exist [25].
Interestingly, Chen-Plotkin et al. reported that frontal cortex samples of healthy individuals
showed a similar heat-sensitive behaviour than cell lysates, however with the 40 kDa band be-
ing much less prominent [39]. Therefore, for further studies, they decided on incubating their
samples at 4 ◦C [39]. Notably, the 40 kDa band, at least in the brain samples, seemed to be
unaﬀected by temperature elevation, a ﬁnding that I also made concerning reducing conditions.
In contrast, Nicolson et al. showed that at 22 ◦C and reducing conditions, in frontal cortex sam-
ples of healthy individuals, the 40 kDa band was more prominent than the higher molecular
weight band at about 70 kDa to 90 kDa [200]. Moreover, they claim that this higher molecular
weight band is not speciﬁc for TMEM106B as when they incubated their TMEM106B anti-
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body with TMEM106B peptide, this band was still present whereas the lower molecular weight
band disappeared [200]. Thus, they decided on focussing on the 40 kDa band when analysing
TMEM106B.
In summary, until now, it is still not clear which method will represent TMEM106B expression
best. In all biochemical studies about TMEM106B, speciﬁc bands at similar molecular weights
were observed for TMEM106B when using similar denaturation temperatures [200, 263, 155,
39, 25]. However, there are conﬂicting results regarding the molecular weight of TMEM106B in
brain samples.
Moreover, the used anti-TMEM106B antibodies seem to recognize the various TMEM106B
species with a diﬀerent sensitivity. For example, Chen-Plotkin et al. state that their generated
antibody against TMEM106B, N2077, showed a greater aﬃnity for the 75 kDa band than the
commercially available antibody from Bethyl Laboratories [39]. Likewise, the 6F2 antibody I
used in my studies probably is also more sensitive towards the 75 kDa band as detected protein
levels at 4 ◦C were much higher than at 95 ◦C. Furthermore, the 6F2 antibody seems to recognize
TMEM106B better in non-reducing conditions as detected TMEM106B amounts were a lot
higher when β-mercaptoethanol was not added to the protein samples.
Therefore, as it remains uncertain if the 40 kDa or the 75 kDa band should be considered when
analysing TMEM106B, for my studies, I chose to use a condition where both bands could be
detected, namely 65 ◦C under non-reducing conditions.
4.2 TMEM106B is a lysosomal type II transmembrane protein
Having established a method for TMEM106B detection on immunoblot, I further investigated
the biological characteristics of TMEM106B. By sequential membrane extraction, TMEM106B
was shown to be an integral membrane protein (see ﬁgure 3.4 a, page 50) [155]. Furthermore,
I was able to conﬁrm all ﬁve predicted N-glycosylation sites of TMEM106B to be utilized.
Thereby I also demonstrated that TMEM106B adopts a type II membrane orientation as the
most C-terminal N-glycosylation site at position 256 (N5) proved to be glycosylated and thus
to be located in the lumen (see ﬁgures 3.5 and 3.6, pages 51 and 52) [155]. Consistent with
a transport into late secretory compartments, TMEM106B was partially endoglycosidase H-
resistant (see ﬁgure 3.9 a, page 58) and co-localized mainly with lysosomal marker proteins (see
ﬁgure 3.8, pages 54 and 55). This also indicated that TMEM106B is a lysosomal transmembrane
protein [155].
Brady et al. conﬁrmed these data in N2A cells, a mouse neuroblastoma cell line, as they also
showed that TMEM106B was a type II transmembrane protein with a predominantly late endo-
somal/lysosomal localization [25], ﬁndings that were also veriﬁed in neurons [277, 263]. Lysoso-
mal localization was furthermore demonstrated in HeLa cells by Nicholson et al. [200]. Moreover,
Chen-Plotkin et al. conﬁrmed TMEM106B N-glycosylation in HEK293 cells and, more impor-
88
4.3 TMEM106B is degraded in the lysosome but not in the proteasome
tantly, in human brain homogenates [39]. Together, these data strongly suggest that TMEM106B
indeed is an N-glycosylated type II-oriented lysosomal membrane protein [155].
Interestingly, abolishing complex glycosylation resulted in an altered localization of TMEM106B,
namely in either a lamellipodia-like staining (N5 deletion) indicating surface localization of
TMEM106B or in a retainment of TMEM106B in the ER (N4 deletion) suggesting that the
forward transport to lysosomes was impaired (see ﬁgure 3.9 c and d, page 58) [155]. Thus,
complex glycosylation seems to be essential for correct TMEM106B maturation and localization
within the cell [155], a ﬁnding that has been conﬁrmed, at least in part, by Nicholson et al.
[200]. Intriguingly, the TMEM106B coding variant p.T185S, which is in perfect linkage disequi-
librium with the top SNP rs1990622 (see section 1.2, page 21), is located within the N-X-T/S
N-glycosylation consensus motif of the fourth N-glycosylation site of TMEM106B (N4 at posi-
tion 183). In 2013, Nicholson et al. demonstrated that the disease-associated T185 TMEM106B
variant was about two-fold higher expressed than the protective S185 variant which they at-
tributed to a more rapid degradation of the S185 TMEM106B isoform [200]. They claim that
even though complex glycosylation at N4 was not compromised by the serine mutation, a slight
change in the glycan composition and/or complexity modifying the protein stability might still
be a possible explanation for the decrease in S185 TMEM106B protein levels [200]. Support-
ing their hypothesis, Bause et al. reported that a replacement of threonine by serine within
the N-glycosylation motif would result in less eﬃcient N-glycosylation transfer rates [200, 14].
Interestingly, Nicholson et al. reported that the T185 TMEM106B isoform co-localized better
with lysosomal marker proteins than the protective S185 variant [200], which indicates that
protein localization indeed might be altered due to subtle changes in glycan composition. Like
Nicholson et al., I also observed less co-localization of S185 with lysosomal markers compared
to the T185 isoform (data not shown).
In summary, the initial ﬁnding of mutant N4 being retained in the ER stressed the importance of
complex glycosylation at position 183 for TMEM106B localization and maturation and therefore
presented the basis for the ﬁndings of Nicholson et al., namely that diﬀerences in protein stability
probably due to changes in the glycosylation pattern of TMEM106B variants T185 and S185
might modify TMEM106B levels [200].
4.3 TMEM106B is degraded in the lysosome but not in the
proteasome
As TMEM106B seemed to be localized to BafA1-sensitive compartments, I tested whether
inhibition of lysosomal acidiﬁcation or of lysosomal proteases would inﬂuence TMEM106B
levels. In addition, I also investigated whether proteasomal inhibition would have an im-
pact on TMEM106B levels. Interestingly, whereas neither inhibiting lysosomal proteases nor
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proteasomal activity revealed any diﬀerences in TMEM106B protein levels, BafA1 treatment
which inhibits lysosomal acidiﬁcation, strongly increased overexpressed as well as endogenous
TMEM106B protein levels (see ﬁgures 3.12 and 3.13, pages 63 and 64) [155]. Moreover, tran-
scriptional inhibition had no inﬂuence on the BafA1-mediated increase in TMEM106B pro-
tein levels whereas translational inhibition abolished the eﬀect suggesting a predominant post-
transcriptional mechanism to be involved [155]. Brady et al. and Chen-Plotkin et al. conﬁrmed
that TMEM106B levels increase upon inhibition of lysosomal acidiﬁcation [25, 39]. In addition,
Brady et al. were able to show that autophagy inhibition by 3-methyladenine treatment increased
TMEM106B levels [25]. As they also found no eﬀects of proteasome inhibitors on TMEM106B
levels, they concluded that TMEM106B levels are regulated by membrane-traﬃcking events,
but not by the ubiquitin-proteasome pathway [25]. Also, Nicholson et al. could not detect any
inﬂuence of proteasomal degradation on TMEM106B levels [200].
However, in contrast to my ﬁndings, Nicholson et al. observed an increase in TMEM106B lev-
els upon leupeptin treatment, a drug that inhibits lysosomal serine- and cysteine proteases.
Thus, they concluded that the lysosome is the main subcellular compartment to be involved in
TMEM106B degradation [200]. Compared to Nicholson et al. who overexpressed TMEM106B
and were able to detect a modest increase in TMEM106B levels upon leupeptin treatment
[200], I investigated endogenous levels of TMEM106B. Moreover, compared to the increase in
TMEM106B levels I observed after BafA1 treatment, the increase Nicholson et al. observed after
leupeptin treatment was relatively weak. Thus, it might be possible that I was not able to detect
the increase in endogenous TMEM106B levels upon leupeptin treatment.
Very recently, TMEM106B was shown to be lumenally cleaved by lysosomal proteases to gener-
ate an N-terminal fragment that subsequently undergoes regulated intermembrane proteolysis
mediated by SPPL2a thereby generating a highly unstable intracellular domain [26]. RIP is a
process in which a transmembrane protein is consecutively cleaved starting with the shedding of
its ectodomain followed by cleavage within the remaining transmembrane stump of the protein
[161]. Thereby, an ICD as well as a small peptide are released [161]. As the ICD of TMEM106B
was found to be located in the lysosome, but not in the nucleus, the authors concluded that
RIP processing probably served as a quality control system to remove excess TMEM106B pro-
tein rather than having any signalling capacities [26]. These data explain my observation of
TMEM106B levels being increased after BafA1 treatment. As BafA1 inhibits lysosomal acidiﬁ-
cation, concomitantly, it also prohibits the maturation of all lysosomal hydrolases that need an
acidic pH for maturation. Therefore, BafA1 treatment would also impair the cleavage and, con-
sequently, the degradation of TMEM106B thus explaining the increase in TMEM106B protein
levels.
Moreover, BafA1 can potently activate the lysosomal stress response pathway which results in
an increase in lysosomal biogenesis (see section 1.3.4, page 33). The latter is regulated by TFEB,
a transcription factor that recognizes CLEAR motifs in the promotor region of lysosomal and
autophagic genes (see also ﬁgure 1.13, page 34). As TMEM106B is a lysosomal membrane protein
90
4.4 The relationship between TMEM106B and GRN
and has a putative CLEAR motif (GTCACGcGca) in its 5’UTR, it is tempting to speculate that
TMEM106B thus might be a TFEB target. Supporting this assumption, TMEM106B mRNA
levels showed a 1.5-fold increase after BafA1 treatment. This is in line with a reported 1.5- to 5.0-
fold increase in mRNA levels of genes encoding the complex components of H+-ATPase, a known
TFEB target, upon TFEB activation [265]. Hence, the increase of TMEM106B protein levels
upon BafA1 treatment might be explained by an increase in TMEM106B expression possibly
due to the TFEB stress response pathway coupled with decreased TMEM106B degradation due
to impaired lysosomal acidiﬁcation and thus impaired lysosomal enzyme maturation.
Together, my data indicate that the lysosomal but not the proteasomal pathway are important
for TMEM106B degradation [155], a ﬁnding that now has been veriﬁed by others [25, 39, 200,
26].
4.4 The relationship between TMEM106B and GRN
In 2010, van Deerlin et al. published that the risk allele of rs1990622 of TMEM106B was associ-
ated with higher TMEM106B mRNA levels in FTLD-TDP patients carrying a GRN mutation
[301] thereby being the ﬁrst ones to suggest a direct relationship between TMEM106B and
GRN. In subsequent studies, conﬂicting results have been published concerning the matter of
TMEM106B and GRN, as Finch et al. claimed that homozygosity for the protective minor allele
of TMEM106B was associated with an increase in GRN protein levels and a signiﬁcantly delayed
disease onset [72]. In accordance with Finch et al., Cruchaga et al. observed a decrease in the
age-at-onset for the risk allele of TMEM106B as well as lower plasma GRN levels, but were not
able to show any correlation between TMEM106B and GRN mRNA levels [51]. However, van
der Zee et al. were not able to conﬁrm these results [306] (as a summary, see also table 4.1).
Table 4.1: Relationship between FTLD-TDP, TMEM106B and GRN
allele type observations
T (risk; major) • increased TMEM106B mRNA levels in GRN mutation carriers
[301]
• decreased GRN plasma levels [51]
• earlier disease onset [51]
• no correlation between TMEM106B and GRN mRNA levels [51]
• no increase in TMEM106B protein levels [305]
• no association with age-at-onset [306]
• no correlation of TMEM106B levels and FTLD-TDP [306]
C (protective; minor) • 30 % to 50 % reduced risk of developing FTLD [306]
• increased GRN protein levels [72]
• delayed disease onset [72]
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Therefore, in the present study, I used cell lines to analyse whether TMEM106B overexpression
or TMEM106B knockdown had an impact on GRN expression. However, I could not detect
any inﬂuence of TMEM106B on GRN on either transcriptional or translational level [155] in-
dicating that GRN and TMEM106B levels do not inﬂuence each other directly. These ﬁndings
were conﬁrmed by Satoh et al., who overexpressed either GRN or TMEM106B in SK-N-SH
neuroblastoma cells, but did not observe any immediate eﬀect on endogenous levels of either
TMEM106B or GRN mRNA suggesting that TMEM106B is not involved in transcriptional reg-
ulation of GRN and vice versa [257]. Also, Schwenk et al. did not detect any diﬀerences in
GRN protein levels in cell lysates of primary rat cortical neurons transduced with lentiviruses
expressing TMEM106B short hairpin (sh) RNA to knockdown TMEM106B [263]. Furthermore,
in C9orf72 expansion carriers homozygous for either the risk or protective alleles of rs1990622,
plasma GRN levels were not found to be signiﬁcantly diﬀerent from each other [77] even though
TMEM106B was identiﬁed as genetic modiﬁer for FTLD-DPR [299].
In contrast, Brady et al. reported that TMEM106B overexpression in N2a cells resulted in an
increase in intra- and extracellular GRN levels along with an accumulation of GRN in lysosomes
and an enlarged lysosomal phenotype [25]. They therefore concluded that TMEM106B might
regulate GRN levels through its function in the endolysosomal degradation pathway [25]. How-
ever, notably, they were not able to detect any changes in GRN expression upon TMEM106B
knockdown [25]. Nicholson et al. also reported an increase in intra- and extracellular GRN levels,
however, like Brady et al., the diﬀerences between TMEM106B overexpressing cells and controls
were quite small (a less than 1.2- to 1.4-fold increase). Chen-Plotkin et al. also observed abnor-
malities in the endolysosomal pathway upon TMEM106B overexpression represented by enlarged
LAMP1-positive organelles which they showed in several diﬀerent cell lines [39]. Importantly,
they were able to demonstrate that this phenotype resulted from a block in endosomal-lysosomal
fusion and speculated that retrograde transport from the late endosome to the TGN was aﬀected
[39]. Furthermore, they conﬁrmed that intracellular GRN levels increased upon TMEM106B
overexpression (about 1.3-fold), but were not able to detect any diﬀerences in secreted GRN
[39]. These observations might be explained by GRN being internalized and transported to the
lysosome, probably by sortilin [114]. Thereby, GRN binds with high aﬃnity to sortilin and
thus mediates rapid endocytosis [114]. Subsequently, GRN is transported to lysosomes whereas
sortilin is recycled from endosomes and re-transported to the plasma membrane [114]. There-
fore, under normal conditions, GRN would subsequently be degraded in the lysosomal lumen.
However, if TMEM106B overexpression inhibits endosomal-lysosomal fusion, the transport of
GRN to the lysosome would be abolished. Thus, intracellular GRN levels would increase, but
secretion of GRN would probably remain unaﬀected.
The discrepancies between the data of Brady et al., Chen-Plotkin et al. and my data lie within
the experimental set-up. In opposition to my data, Brady et al. and Chen-Plotkin et al. did
not use stable cell lines for TMEM106B overexpression experiments, but transiently transfected
tagged TMEM106B wt constructs (either ﬂag-tagged or GFP-tagged) into various cell lines [25,
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39, 155]. Thus, expression levels of TMEM106B might have been diﬀerent to my experiments,
as I chose a low TMEM106B overexpression clone to analyse the relationship between GRN and
TMEM106B. However, when I transiently transfected HeLa cells with a HA-tagged TMEM106B
wt construct, I also observed enlarged LAMP1-positive vesicles, similar to Brady et al. and Chen-
Plotkin et al. (data not shown). Therefore, the diﬀerences in exogenous TMEM106B levels might
account for the diﬀerent results concerning GRN. Supporting this assumption, Brady et al. re-
ported that endogenous TMEM106B co-localized much better with LAMP1 than overexpressed
TMEM106B which appeared frequently within the lumen of LAMP1-positive vesicles or was mis-
localized to the plasma membrane [25], a ﬁnding that I could conﬁrm (data not shown). Thus,
they concluded that TMEM106B overexpression might cause its mislocalization or the distur-
bance of lysosomal compartments and therefore that expression levels of TMEM106B critically
aﬀect TMEM106B localization [25].
Until now, it has not been ﬁnally clariﬁed whether the increase in lysosomal size is indeed a true
eﬀect or an artefact due to heavy TMEM106B overexpression. It is possible that increasing the
amount of a lysosomal membrane protein might result in expanding lysosomal size. Accordingly,
this increase in lysosomal size might result in decreased acidiﬁcation as the number of H+-
ATPases probably remains unchanged, but the lysosomal lumen is expanded many-fold thereby
diluting the proton concentration. Impaired lysosomal acidiﬁcation might in turn result in a
decreased degradation capacity of the lysosome and thereby also aﬀect the degradation of GRN
which is internalized and transported to the lysosome, probably by sortilin [114]. Therefore, it
is conceivable that TMEM106B overexpression might increase GRN protein levels, however, it
cannot be ruled out that this is due to an overexpression artefact.
Moreover, the observed changes in GRN levels were rather small (about 15 %) [11]. In contrast,
TMEM106B levels were up to 250 % increased upon T185 compared to S185 TMEM106B isoform
expression even though the increase in GRN levels remained the same [11, 200]. Thus, the
diﬀerential abundance of TMEM106B might contribute to a greater extent to disease progression
than the changes in GRN expression [11]. Notably, in FTLD-TDP patients with a GRN mutation
(i.e. GRN levels were up to 50 % reduced), TMEM106B mRNA [39, 301] as well as protein
levels [87] were increased. This ﬁnding was further supported by Götzl et al. who demonstrated
that in Grn knockout mice, TMEM106B protein levels were increased [87]. However, these
ﬁndings are in contrast to the data of Brady et al., Chen-Plotkin et al. and Nicholson et al.
who all demonstrated an increase in GRN levels when TMEM106B was overexpressed [200,
39, 25]. Therefore, a functional relationship rather than a direct inﬂuence on each other on a
transcriptional level is more likely.
Furthermore, as in cortex samples of FTLD-TDP patients lysosomes did not seem to present
with a vacuolation phenotype [34, 39], the in vitro TMEM106B overexpression models might
not represent the disease phenotype. Interestingly, complete loss of GRN had recently been
described to cause NCL, a lysosomal storage disorder, which thus links GRN to lysosomal
function [273]. Moreover, increased TMEM106B levels have been observed in a mouse model
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for NCL [87]. Thus, the observed increased TMEM106B levels in FTLD-TDP patients might
also be explained as a consequence of lysosomal dysfunction.
In summary, it is still under debate whether and, if so, how TMEM106B might aﬀect GRN
levels. As there is accumulating evidence that TMEM106B levels are increased in FTLD-TDP
patients carrying a GRN mutation [39, 301, 87], a relationship between both proteins is quite
certain. However, whether they inﬂuence each other directly or whether they act in a common
pathway still remains to be elucidated.
4.5 TMEM106B inﬂuences lysosomal positioning
As increased TMEM106B levels were reported to be associated with FTLD-TDP by several in-
dependent groups [301, 39, 200], scientists used overexpression models to elucidate TMEM106B
function [25, 39, 155, 200]. Nevertheless, proteins can have misleading actions when they
are overexpressed [11]. This is especially important for TMEM106B as expression levels of
TMEM106B critically aﬀect its localization [25]. Thus, I mainly concentrated on knockdown
experiments to elucidate the endogenous function of TMEM106B.
Upon TMEM106B knockdown, lysosomes changed their intracellular positioning and clustered
at the MTOC (see ﬁgure 3.15, page 67) suggesting that TMEM106B might aﬀect lysosomal
traﬃcking [263]. Transfection of single siRNAs against TMEM106B demonstrated that clus-
tering increased with the knockdown eﬃciency of the used siRNAs (see ﬁgures 3.14 and 3.15,
pages 67 and 66). The quantiﬁcation of the clustering phenotype conﬁrmed that in TMEM106B
#3 siRNA-treated HeLa cells, lysosomes presented with a more compact subcellular distribu-
tion and were signiﬁcantly more shifted towards the nucleus than controls (see ﬁgure 3.19, page
72). Moreover, lysosomal clustering upon TMEM106B knockdown could be rescued by careful
titration of TMEM106B wt levels back to endogenous levels (see ﬁgure 3.17, page 70) thereby
proving the speciﬁcity of the TMEM106B knockdown phenotype. As expected, neither expres-
sion of the empty vector nor of the N4 glycosylation mutant of TMEM106B, which was shown
to be retained in the ER, rescued the clustering phenotype (see ﬁgure 3.17, page 70).
However, Brady et al. were not able to detect any diﬀerences in lysosomal size or morphology
upon TMEM106B knockdown [25] and did not comment on lysosomal positioning. Yet, by
looking at their immunoﬂuorescence pictures, clustering was not discernible upon TMEM106B
knockdown. Compared to my studies, Brady et al. only achieved a knockdown eﬃciency of an
estimated 50 % to 70 % [25] which is probably not enough to see the clustering eﬀect upon
TMEM106B knockdown as I demonstrated that the clustering phenotype correlates with knock-
down eﬃciency (see ﬁgure 3.16, page 68). Moreover, they used N2a cells, a murine neuroblastoma
cell line, instead of HeLa cells for their experiments. Since the clustering eﬀect also seemed less
prominent in human SH-SY5Y cells (see ﬁgure 3.15 b, page 67), it might also be possible that
this phenotype is generally not as evident in neuroblastoma cell lines as in HeLa cells.
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Stagi et al. reported that TMEM106B knockdown reduced lysosomal size and number [277].
Moreover, in contrast to my ﬁndings, they claim that in neurons transduced with TMEM106B
shRNA, lysosomes were distributed more distally throughout the neurites [277]. One possi-
ble explanation are the diﬀerent experimental conditions as well as the diﬀerent models used.
Whereas I worked with HeLa cells, an epithelial cell line, Stagi et al. utilized mouse cortical
neurons [277]. It is known that vesicular transport in neurons diﬀers from the transport in other
cells of the body as microtubules in dendrites present with mixed polarity [132] in contrast to
cells like HeLa cells where microtubules only possess one polarity. Thus, in dendrites, dynein
can move bidirectionally whereas in HeLa cells, it only mediates the retrograde transport. These
diﬀerences might account for the diﬀerent results, however, further investigations are needed.
Conversely, Schwenk et al. demonstrated that TMEM106B knockdown by shRNA in rat cortical
neurons mediates a signiﬁcant increase in dendritic retrograde lysosomal traﬃcking [263] which
would argue against a more distal distribution of lysosomes, as claimed by Stagi et al. [277], and
for the clustering phenotype I observed.
Indirectly supporting my data, Busch et al. and Chen-Plotkin et al. demonstrated that neurons
of FTLD-TDP patients exhibited a more disorganized TMEM106B expression pattern [34] in
which TMEM106B appeared diﬀusely expressed and more widely distributed in the cytoplasm
compared to controls [34, 39]. This would, at least in part, reﬂect my observations in HeLa
cells where lysosomes, upon moderate TMEM106B overexpression, appeared more diﬀuse and
more distributed towards the cellular tips (see ﬁgure 3.17, page 70). Interestingly, Busch et
al. reported that disorganization was especially prominent in GRN mutation carriers where
TMEM106B expression even extended beyond the cell body into neuronal processes [34, 39].
As TMEM106B is localized on lysosomes and, in FTLD-TDP patients, its expression was found
to be increased (with the highest TMEM106B levels detected in GRN mutation carriers) [39,
301], these data implicate that high levels of TMEM106B result in the distribution of lysosomes,
which represents the opposite phenotype of the one I observed upon TMEM106B knockdown,
namely lysosomal clustering.
To summarize, these data together with the data of Schwenk et al. [263], Busch et al. [34] and
Chen-Plotkin et al. [39] therefore suggest that TMEM106B might play a crucial role in lysosomal
transport.
However, TMEM106B might not only inﬂuence lysosomal positioning but might also generally
aﬀect traﬃcking of other cellular organelles either by inﬂuencing the cytoskeleton or motor
proteins. A general disruption of the cellular transport system might impair traﬃcking [112] due
to the loss of transit routes along which motor proteins transport their cargo. Furthermore, it is
known that after the deletion of dynein, the motor protein that regulates retrograde transport,
not only lysosomes but also endosomes and the Golgi are distributed throughout the cytosol
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[100]. Moreover, mitochondria are known to cluster upon impaired kinesin-mediated anterograde
transportation [96], which can be reversed upon knockdown of dynein [180].
Yet, investigation of the morphology of the actin and microtubule cytoskeleton did not reveal
any obvious changes upon TMEM106B knockdown thereby excluding a general disruption of
the cellular transport system. Concomitantly, the Golgi and mitochondria remained unaﬀected
by the knockdown of TMEM106B. Interestinly, however, EEA1-positive vesicles, which are pre-
sumably early endosomes, but might also represent amphisomes [69], clustered near the MTOC
indicating that TMEM106B might speciﬁcally aﬀect the endocytic pathway.
4.6 TMEM106B and microtubule-dependent transport
Microtubules support intracellular transport and are nucleated at the MTOC [88, 177]. As all
types of endosomes as well as lysosomes move actively along microtubules and, upon TMEM106B
knockdown, lysosomes clustered at the MTOC, I examined whether a functional microtubule
network was in fact one of the prerequisites for lysosomal clustering. Therefore, I treated control
and TMEM106B siRNA-transfected cells with nocodazole, a drug that interferes with the poly-
merization of microtubules and thus would abolish vesicular transport. Indeed, as expected, the
inhibition of microtubule network formation by nocodazole treatment compromised lysosomal
clustering upon TMEM106B knockdown.
Lysosomes move bidirectionally along microtubules [88] with a spectrum of diﬀerent kinesins
promoting their anterograde transport while dynein mediates their retrograde transport [29,
88]. These movements are controlled by the intracellular pH as acidiﬁcation disperses lysosomes
into the cytosol whereas alkalinization causes clustering at the MTOC [213, 107].
To determine whether retrograde transport was necessary to cause lysosomal clustering observed
upon TMEM106B knockdown, the dynein-dynactin complex formation was impaired by dyna-
mitin overexpression, a known tool to inhibit dynein-dynactin assembly and thus retrograde
transport [121, 33, 181] (see also 3.9, page 77).
Interestingly, dynamitin overexpression reversed the TMEM106B knockdown phenotype irre-
spective of whether lysosomes had already been clustered at the time of transfection or not.
Hence, on the one hand, a functional retrograde transport is indeed the second prerequisite for
lysosomal clustering upon TMEM106B knockdown. On the other hand, anterograde transport
was most likely not impaired by the knockdown of TMEM106B. This is because, in case of
TMEM106B knockdown combined with dynamitin transfection on day 2, lysosomes, which at
that point are normally already clustered at the MTOC, were redistributed from the cluster at
the MTOC to the cellular tips.
Together, these data indicate that perinuclear lysosomal clustering upon TMEM106B knock-
down is dependent on an intact microtubule network as well as on functional dynein-dynactin-
mediated retrograde transport, the essential components of retrograde microtubular transport
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[298]. Morevoer, TMEM106B knockdown does not seem to inﬂuence the anterograde transport
of lysosomes, however, more experiments are needed for conﬁrmation.
One possible explanation for lysosomal clustering upon TMEM106B knockdown is that either
TMEM106B promotes the anterograde transport or inhibits the retrograde transport of lyso-
somes. Conversely, in case of reduced TMEM106B expression, the anterograde transport would
not be promoted any more or the retrograde transport would be restored resulting in overall
increased retrograde transportation of lysosomes towards the MTOC (ﬁgure 4.1).
If the hypothesis that TMEM106B promotes the anterograde transport holds true, I would have
expected that upon TMEM106B knockdown and dynamitin expression, lysosomes are clustered
at the cellular tips as retrograde transport is abolished, but not so tightly as anterograde trans-
port is also not promoted any longer. However, if the hypothesis that TMEM106B inhibits the
retrograde transport holds true, lysosomes should tightly cluster at the cellular tips upon the
inhibition of the retrograde transport by dynamitin as the anterograde transport is still intact.
Since in TMEM106B siRNA-transfected cells expressing dynamitin, lysosomes seemed to be as
tightly clustered at the cellular tips as lysosomes of control siRNA-transfected cells expressing
dynamitin (see ﬁgure 3.23 b, page 78), TMEM106B probably inhibits the retrograde transport
of lysosomes rather than promotes the anterograde transport (ﬁgure 4.1).
This assumption was supported by the data of Schwenk et al. who reported that under nor-
mal conditions, the binding of TMEM106B to MAP6 inhibited active retrograde transport of
lysosomes along dendrites [263]. Importantly, they showed that knocking down TMEM106B
increased the number and speed of retrogradely moving lysosomes in dendrites resulting in im-
paired dendritic branching [263]. Moreover, promoting anterograde lysosomal transport rescued
this phenotype in TMEM106B knockdown cells [263]. Additionally, Stagi et al. claimed that
TMEM106B suppression in neurons increased the fraction of moving lysosomes by 30 % further
indicating that TMEM106B is involved in lysosomal transport [277].
Together with my data, this suggests that TMEM106B might indeed aﬀect lysosomal transport
probably by limiting retrograde traﬃcking of lysosomes.
Functional traﬃcking is especially important for neurons as it ensures neuronal survival and
diﬀerentiation [60]. Neurons need to transport their cellular waste over long distances towards
the cell body, where the majority of lysosomes is located [205] (see also 1.4, page 35). More-
over, vesicular traﬃcking allows for a rapid cellular adaptation to the changing extracellular
environment [144, 73].
Accordingly, impaired axonal transport is implicated in neurodegeneration as evidenced by the
identiﬁcation of mutations in motor protein genes like KIF1B, which causes Charcot-Marie-
Tooth Disease Type 2A, or DCTN1 , encoding for a dynactin subunit, which is associated with
97
4 Discussion
TMEM106B knockdown
b) TMEM106B limits
    the retrograde transport
TMEM106B knockdown + dynamitin
a) TMEM106B promotes
    the anterograde transport
lysosome
microtubule
X X
X
X
X
X
X
Figure 4.1: Hypotheses of how TMEM106B might inﬂuence microtubule-dependent transport
The hypotheses for the inﬂuence of TMEM106B on microtubule-dependent transport are depicted for
TMEM106B knockdown and TMEM106B knockdown combined with concomitant dynamitin expression. The
crosses represent an abolishment of transport, the lightnings an impairment.
motor neuron degeneration in an Alabama kindred as well as with ALS and FTLD [40, 190,
279, 112, 154, 119]. Interestingly, key components of the retrograde transport routes, which
are responsible for targeting neurotrophins and their survival signals to the soma, have been
especially associated with motor neuron disease [94, 60, 119, 154].
However, not only motor proteins but also lysosomal membrane proteins which may inﬂuence
lysosomal positioning have been described to be implicated in neurodegeneration. One exam-
ple is ceroid-lipofuscinosis, neuronal 3 (CLN3), an endosomal/lysosomal transmembrane protein
which had been reported to interact with several motor components, but especially with Rab7
and RILP. Mutations in CLN3 that are causative for juvenile NCL (Batten disease) were associ-
ated with an imbalanced Rab7 GTP/GDP cycle and a loss of Rab7 and CLN3 interaction. This
subsequently resulted in defects in neuronal endocytic traﬃcking and autophagic processes ulti-
mately leading to neurodegeneration [298]. Other examples are the lysosomal membrane proteins
LAMP1 and LAMP2 (see also section 1.3.1, page 25), the latter of which is implicated in Danon
disease, another lysosomal storage disorder. Cells lacking both proteins showed a more diﬀuse
distribution of lysosomes in the cytosol which is caused by a defective dynein-mediated transport.
In a cell culture model for phagocytosis, this resulted in impaired lysosome-phagosome fusion
probably due to the reduced ability of phagosomes and lysosomes to move towards the MTOC
precluding their interaction [117]. Similarly, autopohagosome maturation and their fusion with
lysosomes might be impaired by the delayed migration towards the MTOC [248].
Interestingly, neurons of FTLD-TDP patients have been reported to present with a diﬀuse
distribution of TMEM106B-positive vesicles which are probably lysosomes [34, 39]. Thus, the
lysosomal phenotype might be comparable to LAMP1/LAMP2 knockout cells. Since increased
TMEM106B levels might, like in LAMP1/2 double-knockout, impair the retrograde transport of
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lysosomes, it is tempting to speculate that as a result, phagocytosis and autophagy are likewise
inhibited thereby promoting neurodegeneration. Moreover, it is probable that both too high
and too low TMEM106B levels are detrimental to neurons, as both might lead to an imbalance
in lysosomal traﬃcking which would result in axonal transport deﬁcits and in impaired dendrite
and synapse stability [263, 40, 190, 279, 112, 154, 119].
4.7 The autophagic pathway is inﬂuenced by TMEM106B
knockdown
Clustering of lysosomes might not only be caused by defective lysosomal transportation but also
be the result of a cellular stress response caused by impaired lysosomal function [150]. There-
fore, I analysed whether lysosomal acidiﬁcation and the processing and activity of lysosomal
enzymes were aﬀected by TMEM106B knockdown. However, no changes between control and
TMEM106B siRNA-treated cells were detected arguing for fully functional lysosomes. Thus,
if, upon TMEM106B knockdown, lysosomal clustering was indeed a lysosomal stress response
and the stress did not result from lysosomal dysfunction, it might instead have been caused by
inhibited fusion of lysosomes and autophagosomes or endosomes, i.e. from impaired autophagy.
It has been demonstrated that lysosomal clustering can inﬂuence the autophagic pathway in
two diﬀerent ways, namely by enhancing the autophagic ﬂux and by increasing the expression of
autophagosomal and lysosomal genes [150] (see section1.3.4, page 33). I therefore investigated
whether upon TMEM106B knockdown, autophagosomal or lysosomal markers were altered.
Indeed, p62 protein levels were increased upon TMEM106B knockdown, however, only to a mild
extent. Interestingly though, Korolchuk et al. also showed an only 1.2- to 1.3-fold increase in p62
levels upon Atg7 knockdown which abolishes autophagy and is known to be suﬃcient to cause
neurodegeneration (see also section 1.4, page 35). Thus, even though the autophagic pathway
is compromised, p62 levels might not be heavily elevated as a consequence [149].
Yet, upon TMEM106B knockdown, the number of p62 particles increased signiﬁcantly. More-
over, these particles co-localized with both LC3, a marker for autophagosomes, and Apu2, a
marker for lysine 48-linked polyubiquitin suggesting that autophagic turnover and maybe also
proteasomal degradation might be impaired. Interestingly, it has been shown that excess p62
inhibits the clearance of ubiquitinated proteins destined for proteasomal degradation due to a
delay in their delivery to proteasomal proteases mediated by reduced autophagic activity [149].
Hence, inhibition of autophagy might also inhibit the ubiquitin-proteasome system [149] thereby
explaining the increase in both LC3 and lysine 48-linked polyubiquitin under the paradigm that,
upon TMEM106B knockdown, autophagy is impaired. Moreover, Filimonenko et al. speculated
that polyubiquitinated proteins might also be autophagic substrates which could be directed
to the autophagic pathway by p62 [71]. However, the increase in p62 levels still has to be
re-evaluated with diﬀerent siRNAs against TMEM106B to exclude siRNA-speciﬁc side eﬀects.
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Moreover, whether autophagy is the only degradation pathway to be aﬀected or whether the
ubiquitin-proteasome system is also inﬂuenced by TMEM106B remains to be determined.
Another protein that was found to be increased upon TMEM106B knockdown was LC3, an au-
tophagic marker protein. Interestingly, both soluble LC3I and membrane-bound, PE-conjugated
LC3II protein levels were elevated indicating an increase in LC3 expression rather than just a
conversion of LC3I into LC3II. These results were also obtained upon starvation and thus acti-
vation of autophagy, where the quantiﬁcation of protein levels revealed a 2.0- (LC3I) to 2.3-fold
(LC3II) increase in LC3 protein levels upon TMEM106B knockdown.
Strikingly, upon starvation, not only diﬀerences in LC3 levels but also in lysosomal protein levels
were revealed that had not been apparent under normal growth conditions. Accordingly, protein
levels of LAMP2, a lysosomal membrane protein, and of cathepsin D, a lysosomal enzyme, were
signiﬁcantly elevated upon TMEM106B knockdown. The increase in immature as well as mature
cathepsin D levels suggests that in TMEM106B #3 siRNA-treated cells, lysosomal biogenesis
might have been activated faster or earlier than in control siRNA-transfected cells. Moreover,
a reduced turnover might also explain the increased cathepsin D and LAMP2 protein levels.
Therefore, determining the mRNA levels of both proteins might elucidate which of these two
scenarios reﬂects the truth.
Together, these data implicate that TMEM106B aﬀects, even though probably mildly, the lyso-
somal and autophagic pathway. Furthermore, applying additional stress, like starvation, in
an experimental set-up might be crucial to reveal the consequences of TMEM106B loss as, by
challenge, diﬀerences between protein levels might become more apparent.
Inhibition of the autophagic pathway is suﬃcient to cause neurodegeneration as functional au-
tophagy is crucial for neuronal survival [99] (see also sections 1.3.3, page 29 and 1.4, page 35).
As TMEM106B is not a disease-causing gene but a risk factor, it might only have a minor impact
on cellular function under normal conditions. However, a second hit like stress in addition to
TMEM106B dysfunction might accelerate neurodegeneration in FTLD-TDP.
Supporting this assumption, the risk allele of TMEM106B had been found to be especially as-
sociated with GRN mutation carriers. Interestingly, a homozygous GRN mutation has recently
been identiﬁed to cause NCL, a lysosomal storage disorder, thereby strongly arguing for GRN
playing a crucial role in lysosomal function [273]. Moreover, lysosomal proteins were demon-
strated to be increased in Grn knockout mice [87, 286] as well as in brain lysates of FTLD-TDP
patients carrying a GRN mutation [87] possibly due to decreased mTORC1 activity and thus
increased lysosomal biogenesis [286]. Tanaka et al. claim that this increase in lysosomal proteins
subsequently resulted in exacerbated neuronal damage [286] (see also section 1.1.3.1.2, page 12).
Thus, it is tempting to speculate that even though GRN probably aﬀects lysosomal function in-
dependently of TMEM106B, however, both proteins might have an impact on the same pathway,
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namely lysosomal biogenesis and autophagy, which would thereby accelerate disease progression
if both a GRN mutation and the risk allele of TMEM106B were present.
4.8 Hypotheses of how TMEM106B might inﬂuence the
pathogenesis of FTLD-TDP
Both transport and autophagy have been inextricably linked with neurodegeneration. As already
mentioned, neurons are highly dependent on functional transportation due to the fact that axons
can represent more than 99 % of the cellular volume whereas protein and lipid synthesis occur
almost exclusively in the cell body [112]. Thus, active transport is required for supplying the
neuron with newly synthesized material [112]. Moreover, the large expanses of dendritic and
axonal cytosol result in long transport routes of cellular waste towards the cell body, where the
majority of lysosomes is located [205, 234] (see also 1.4, page 35). Together with the fact that
neurons cannot dilute their toxic burden by cell division [235, 319, 158], this is why neurons are
especially vulnerable to any defects in cellular transport.
As microtubule motors function interdependently of each other [112], both the anterograde and
the retrograde transport machinery have to work properly to ensure neuronal survival [60].
Interestingly, the data of this study indicate, that TMEM106B might play a role in one or
both of these pathways as TMEM106B seems to inﬂuences lysosomal transport and to aﬀect
the lysosomal degradation pathway. However, there are several options to explain the observed
phenotypes after TMEM106B knockdown. In a ﬁrst hypothesis, TMEM106B directly aﬀects
lysosomal transport by either promoting the anterograde transport or by inhibiting the retro-
grade transport machinery (ﬁgure 4.2, upper panel), the latter of which is more likely due to
evidence from Schwenk et al. [263] (see also section 4.6, page 101). The second hypothesis is
that TMEM106B might promote the fusion process between autophagosomes and lysosomes, i.e.
autophagy (ﬁgure 4.2, lower panel). Supporting the latter hypothesis, Stagi et al. reported that
TMEM106B might interact with Vps11, a class C protein of the HOPS complex. Interestingly,
in 2014, Vps11 has been reported to mediate autophagosome-lysosome fusion [122]. However,
whether TMEM106B indeed interacts with Vps11 and whether this interaction might inﬂuence
autophagosome-lysosome fusion remains to be elucidated.
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Figure 4.2: Hypotheses why lysosomes cluster upon TMEM106B knockdown
Upon TMEM106B knockdown, lysosomes cluster at the MTOC. One possible explanation for this phenotype
is that TMEM106B aﬀects lysosomal transport (see upper panel). Thereby, it could either promote the
anterograde transport (see upper panel, a) or limit the retrograde transport (see upper panel, b). Another
possibility is that TMEM106B inﬂuences the lysosomal stress response pathway (see lower panel). As lysosomes
are still acidic and lysosomal enzymes still functional upon TMEM106B knockdown, lysosomal dysfunction is
very unlikely. However, the fusion between autophagosomes and lysosomes might be impaired thus inducing
the lysosomal stress response pathway which, as a consequence, results in clustering of lysosomes (see lower
panel).
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Derived from theses hypotheses, there are two diﬀerent scenarios of how TMEM106B might af-
fect neurodegeneration (ﬁgure 4.3), namely by impaired lysosomal transportation or an impaired
fusion of lysosomes and autophagosomes. Concomitantly, following the fusion hypothesis, im-
paired TMEM106B function might result in a loss-of-TMEM106B-function which may cause a
decrease in the fusion capacity of autophagosomes and lysosomes (see also ﬁgure 4.2, lower panel,
page 107). This is supported by the fact that p62 accumulates upon TMEM106B knockdown.
Consequently, autophagosomes and thus dysfunctional proteins or organelles would accumulate,
further compromising the autophagic degradation system. Moreover, impaired autophagy would
subsequently also inhibit the proteasomal degradation machinery [149] resulting in accelerated
neurodegeneration as both degradation machineries would be impaired. In addition, the accu-
mulation of autophagosomes would probably activate the lysosomal stress response pathway to
compensate for the decreased autophagic ﬂux explaining the increase in LC3, cathepsin D and
LAMP2 protein levels as well as lysosomal clustering upon TMEM106B knockdown. Interest-
ingly, in some LSDs like Niemann-Pick type C, late endosomes and lysosomes were also found
to cluster at the MTOC [298, 242].
Together, over a long period of time, this would mean a constantly activated lysosomal stress
response pathway combined with impaired autophagy which likely would result in neurodegen-
eration [99, 286] (ﬁgure 4.3, left panel).
In the second scenario, the transport hypothesis, impaired TMEM106B function might result
in increased TMEM106B levels and/or a gain-of-function mechanism which may subsequently
decrease the retrograde transport within the cell. This is supported by the fact that in FTLD-
TDP patients, TMEM106B levels were indeed found to be increased [301, 87] accompanied by
a more diﬀuse distribution of TMEM106B-positive vesicles (i.e. probably lysosomes) in the cell
periphery [34, 39]. Moreover, the latter presents the opposite phenotype of which could be
observed upon TMEM106B knockdown. A decrease in retrograde transport would subsequently
lead to an imbalanced axonal transport combined with decreased dendritic branching [277]
and synaptic plasticity [40, 112], the latter of which has been reported in FTLD patients [43].
Moreover, the fusion of autophagosomes and lysosomes would be impaired [234] resulting in
an accumulation of misfolded or dysfunctional proteins over time. In addition, due to higher
TMEM106B expression, lysosomes would not as eﬃciently be transported to the MTOC as
in healthy individuals, the lysosomal stress response pathway would probably be impaired.
mTORC1 would remain active due to the predominant positioning of lysosomes in the cell
periphery [150] mediating TFEB phosphorylation which concomitantly would inhibit autophagic
and lysosomal biogenesis [40]. Upon TMEM106B knockdown, the opposite phenotype, namely
an increase in LC3, p62, cathepsin D and LAMP2 was detected supporting this hypothesis.
In summary, both a direct inﬂuence of TMEM106B on autophagy as well as an impact of
TMEM106B on the retrograde transport machinery would, in case of TMEM106B malfunction-
ing, lead to an inhibition of the autophagic ﬂux resulting in an accumulation of dysfunctional
proteins, and a compromised stress response pathway, which might render neurons more suscep-
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tible to cellular stress [215, 40]. All these mechanisms would ultimately promote neurodegen-
eration (ﬁgure 4.3, right panel). Notably, a similar mechanism was described in neurons where
snapin, a protein implicated in linking late endosomes to the dynein motor, was knocked out
[36]. Thereby, retrograde transport was impaired, late endosomes clustered and autophagy was
inhibited leading to neurodegeneration, thus providing a mechanistic link between retrograde
transport, lysosomal maturation and autophagy [36]. Hence, it is tempting to speculate that
a similar disease mechanism might apply for FTLD-TDP where the TMEM106B risk allele is
present.
impaired TMEM106B function
due to increased TMEM106B levels
decreased retrograde transport
imbalanced axonal transport,
reduced autophagic flux,
impaired lysosomal stress response
accumulation of dysfunctional proteins,
cells more susceptible to cellular stress
neurodegeneration
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increased accumulation of dysfunctional proteins
as autophagosome-lysosome fusion 
remains compromised
decreased fusion of 
autophagosomes and lysosomes
Two hypotheses of how TMEM106B might affect neurodegeneration
Figure 4.3: Scheme of how TMEM106B might aﬀect neurodegeneration
On the left (in pink), disease progression under the paradigm that TMEM106B aﬀects autophagosome-
lysosome fusion is depicted. On the right (in blue), disease progression under the paradigm that TMEM106B
inhibits the retrograde transport is depicted.
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At present, it has not yet been conclusively determined which of both hypotheses might hold
true. Thus, further investigation is crucial to elucidate TMEM106B function, i.e. to delineate
whether TMEM106B might indeed aﬀect cellular traﬃcking directly or inﬂuence autophagosome-
lysosome fusion. However, TMEM106B might also be involved in both pathways as, interestingly,
van der Kant et al. recently published that lysosomal tethering and transport are combined pro-
cesses [302]. Moreover, to resolve whether a TMEM106B gain- or a loss-of-function mechanism
promotes FTLD-TDP disease progression will be intriguing.
4.9 Is an increase in TMEM106B levels detrimental or
beneﬁcial for FTLD-TDP disease progression?
Until now, the question of whether the observed increase in TMEM106B levels in FTLD-TDP
patients is a cause or a consequence, i.e. detrimental or beneﬁcial, could not be suﬃciently clar-
iﬁed. On the one hand, Stagi et al. stated that elevated TMEM106B levels would constantly
activate TFEB resulting in a greater lysosomal and autophagic function, which might be protec-
tive for TDP-43 pathology [277, 12]. Yet, if elevated TMEM106B levels activate the lysosomal
stress response pathway that strongly, this would more likely suggest that TMEM106B overex-
pression would cause lysosomal dysfunction rather than exert a positive eﬀect on cells. This is
in line with the ﬁndings of Brady et al. and Chen-Plotkin et al. who reported that TMEM106B
overexpression caused an increase in lysosomal size accompanied by poor lysosomal acidiﬁcation
and a subsequent impairment of endolysosomal degradation [39, 25]. Moreover, Nicholson et
al. claimed that the disease-associated TMEM106B variant (T185) was more stable than the
protective variant (S185) [200], again arguing for increased TMEM106B levels to be detrimental.
Schwenk et al. observed that dendritic branching was inhibited upon TMEM106B knockdown,
suggesting that overexpression of TMEM106B might positively aﬀect dendrite morphology [263].
However, they claimed that TMEM106B might limit retrograde traﬃcking and thus that the
dendritic phenotype was caused by lysosomal misrouting [263]. Thus, both too much and too
little TMEM106B expression would result in imbalanced cellular transportation and therefore
be detrimental to neurons.
On the other hand, the observed increase in TMEM106B levels in FTLD-TDP could represent a
rescue attempt of the cells to compensate for impaired lysosomal function due to GRN reduction.
GRN was implicated to play a role in lysosomal function [273, 15] and GRN haploinsuﬃciency
might therefore result in dysfunctional lysosomes. Accordingly, Tanaka et al. demonstrated
that GRN deﬁciency in a mouse model resulted in an increased activity of the lysosomal stress
response pathway accompanied by an elevation in lysosome-related gene expression [286]. Götzl
el al. also observed an increase in lysosomal proteins in Grn knockout mice, one of which
was TMEM106B [87]. As TMEM106B levels also increased in Ctsd knockout mice, an NCL
mouse model, they argued that TMEM106B along with other lysosomal membrane proteins was
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increased due to the enlargement of lysosomes which were unable to cope with the accumulation
of cellular debris [87].
In summary, it is still under debate whether the increase in TMEM106B levels observed in
FTLD-TDP patients is a cause or a consequence of disease progression which stresses the need for
further investigations to elucidate TMEM106B function. One attempt might be the use of better
models like TMEM106B knock-in mice instead of using transient TMEM106B overexpression in
cell lines. Moreover, as additional stressors might be necessary to reveal the probably mild eﬀects
of TMEM106B on lysosomal function, TMEM106B mice might be crossed with Grn knockout
mice and/or additionally treated with autophagy inducers or inhibitors.
4.10 Impaired traﬃcking and autophagy as common disease
mechanisms in FTLD?
Multiple FTLD-causative or -associated genes are linked to vesicle transport and autophagy. For
instance, tau mutations, the cause for FTLD-tau, destabilize microtubules along which vesicles
are transported. This results in impaired axonal transport in addition to tau ﬁlament aggrega-
tion [239, 270]. Moreover, mutations in CHMP2B identiﬁed in FTLD-UPS patients have been
reported to disrupt endocytic traﬃcking by a gain-of-function mechanism [295]. Thereby, mu-
tant CHMP2B constitutively binds to MVBs concomitantly preventing Rab7 recruitment [295].
Rab7, however, is crucial for anterograde and retrograde transportation of late endosomes [242,
314], autophagosome maturation and endosome-lysosome fusion [118]. Accordingly, CHMP2B
mutants displayed a decrease in axonal traﬃcking along with an altered dendritic spine mor-
phology [83], increased neuroinﬂammation [83] and an accumulation of autophagosomes and
p62-positive aggregates [71] due to impaired autophagy [295, 71].
Another protein known to be causative for FTLD is VCP. This protein had been demonstrated
to impair autophagy at diﬀerent stages like autophagosome formation [152] and fusion with
lysosomes [131]. Recently, also C9orf72 was added to the list of FTLD-causing genes [61, 238].
Interestingly, it was reported to be structurally associated with the DENN protein family [49,
77] which regulates Rab GTPase function and thus membrane traﬃcking [49, 77]. Accordingly,
Farg et al. were able to show that C9orf72 interacted with several diﬀerent Rabs, actin and
ubiquilin-2 [70]. Furthermore, C9orf72 knockdown was demonstrated to inhibit endocytosis and
autophagy further indicating that C9orf72, like tau, CHMP2B and VCP, is involved in intracel-
lular traﬃcking pathways linked to protein degradation [70]. Interestingly, my data suggest that
TMEM106B either alters lysosomal traﬃcking probably by slowing down the retrograde trans-
port or that it aﬀects autophagy presumably by promoting autophagosome-lysosome fusion.
Hence, the FTLD risk factor TMEM106B would ﬁt in well into the general picture of impaired
transport and autophagy being common disease mechanisms in FTLD. However, which func-
tions exactly are performed by TMEM106B and which other proteins are involved remains to
be elucidated.
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4.11 Concluding remarks
Together, in this study, TMEM106B has been demonstrated to be a lysosomal type II transmem-
brane protein with three non-complex and two complex N-glycosylation sites, the latter of which
are important for correct TMEM106B localisation within the cell. Moreover, even though no
direct association with GRN could be detected, an indirect relationship between those proteins
was suggested as both proteins seem to aﬀect the lysosomal degradation pathway. Strikingly,
TMEM106B knockdown presented with tight lysosomal clustering and an increase in autophago-
somal and lysosomal proteins. Thus, two possible disease mechanisms were proposed in which
either impaired traﬃcking or autophagy was suggested to be the origin of disease progression.
Hence, this study provides the ﬁrst thorough biochemical characterization of TMEM106B along
with strong indications of how TMEM106B might inﬂuence FTLD pathology. Moreover, it
stresses the importance of the role of lysosomes in the development and progression of neurode-
generative diseases. Interestingly, lysosomes are the proteolytic system probably most aﬀected
by ageing [103] as during ageing, they become more and more susceptible to free radical ox-
idative stress [8]. However, also the activity of the proteasomal system is known to decrease
during ageing adding to the accumulation of misfolded proteins and, as a consequence, promot-
ing neurodegeneration [164, 134, 41]. Thus, during ageing, both proteolytic machineries, the
proteasome and the lysosome, are increasingly impaired [41].
Bahr et al. speculated that the gradual alterations in the lysosomal system during ageing might
be the cause for ageing being the primary risk factor for many neurodegenerative diseases [8].
This might explain why mutations in GRN, even though they probably aﬀect lysosomes only
mildly, cause neurodegeneration and also why TMEM106B might accelerate this process. Possi-
bly, during ageing, lysosomes at some point cannot compensate any longer for the ever-growing
decrease in lysosomal degradation that is further aggravated by mutations in GRN which conse-
quently would result in neurodegeneration. TMEM106B mutations might accelerate this process
as they might very mildly aﬀect the same pathway.
However, TMEM106B was not only implicated in FTLD-TDP with GRN mutations and FTLD-
DPR with C9orf72 hexanucleotide expansions, but also in other neurodegenerative diseases
like ALS and AD as well as in a general risk for cognitive decline (see section 1.2, page 21).
Hence, TMEM106B might inﬂuence neurodegeneration on a broader level. Interestingly, not
only FTLD, but also AD, PD, ALS and HD show a strong autophagic/lysosomal component
along with traﬃcking defects (see also 1.4, page 35). For instance, in AD, autophagic vesicles
accumulate and, as a consequence, intracellular traﬃcking is impaired [176], linking vesicular
transport and autophagy. Moreover, in PD, LRRK2 mutations were associated with endosomal-
lysosomal traﬃcking and lysosomal pH, again linking transport and autophagy [220, 176, 175].
Familial ALS can be caused by mutations in DCTN1, a subunit of dynactin which is part of the
dynein-dynactin complex responsible for retrograde transport [189, 190]. Transgenic mice which
express the mutant protein have been reported to have increased LC3II levels and accumulated
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ubiquitin-positive aggregates along with autophagic vacuoles in aﬀected neurons [153]. Interest-
ingly, it was also shown that mutant but not normal superoxide dismutase 1 (SOD1), causative
for ALS and degraded by autophagy, co-localizes with the dynein-dynactin complex. This seems
to inhibit retrograde vesicular transport and to promote neurodegeneration [325, 283]. In HD,
huntingtin, which normally helps to link cargo to actin and coordinates the switch between
actin and microtubules in preparation for dynein-dependent movement [88], is mutated and
thus not functional. Furthermore, after inhibiting the UPS [62], mutant huntingtin aggregates
can recruit beclin-1 which in turn would impair autophagosome formation and thus autophagy
[269]. These examples demonstrate, that traﬃcking and autophagy are cellular mechanisms
that are often linked with each other and are implicated in various neurodegenerative diseases.
Therefore, if TMEM106B inﬂuences one or even both mechanisms, it would be conceivable that
TMEM106B does not only play an important role for FTLD, but might constitute a general risk
for neurodegeneration.
Elucidating TMEM106B’s biochemical characteristics along with understanding the mechanisms
of how TMEM106B aﬀects cellular pathways might therefore aid the development of strategies
to slow down disease progression of various neurodegenerative diseases.
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5.1 Material
5.1.1 Laboratory equipment and chemicals
All experiments were performed using standard laboratory equipment. Chemicals were pur-
chased from the companies Merck Millipore, Roth and Sigma-Aldrich with analytical grade pro
analysi (p.a.) unless otherwise stated. The compositions of solutions and buﬀers are listed in
the respective methods part.
5.1.2 Primers
Primers were synthesized by Thermo Fisher Scientiﬁc, puriﬁed by high performance liquid chro-
matography and lyophilized. Stock solutions of 100 μM (100 pmol/μl) were prepared in double
distilled water (ddH2O) and stored at −20 ◦C. The list of primers with name, construct used for
and sequence from 5’ to 3’ end is given in table 5.1 (Fwd indicates forward primer, Rev indicates
reverse primer and mut means mutated).
Table 5.1: Primer list
primer name construct sequence
TMEM106B_Glyc_NIT1(S) Fwd TM_NIT1mut GTT ATG ATG TTC AGA AGC GTA CAA TTT ATT TAA GTA TCA
CAA ACA CAC T
TMEM106B_Glyc_NIT1(S) Rev AGT GTG TTT GTG ATA CTT AAA TAA ATT GTA CGC TTC TGA
ACA TCA TAA C
TMEM106B_Glyc_NIT2(S) Fwd TM_NIT1-2mut CAC AAA CAC ACT AAG TAT AAC AAA CAA TAA CTA TTA CTC
TGT CGA AGT TG
TMEM106B_Glyc_NIT2(S) Rev CAA CTT CGA CAG AGT AAT AGT TAT TGT TTG TTA TAC TTA
GTG TGT TTG TG
TMEM106B_Glyc_NIT3(S) Fwd TM_NIT1-3mut CTA TTA CTC TGT CGA AGT TGA AAG CAT CAC TGC CCA AGT
TCA ATT TTC
TMEM106B_Glyc_NIT3(S) Rev GAA AAT TGA ACT TGG GCA GTG ATG CTT TCA ACT TCG ACA
GAG TAA TAG
TMEM106B_Glyc_NIT4(S) Fwd TM_NIT1-4mut/
siRNA TM3-
resistent N4
GGA AAG GCA CGC TTA AAC AGC ATA ACC ATT ATT GGT CCA
CTT G
TMEM106B_Glyc_NIT4(S) Rev CAA GTG GAC CAA TAA TGG TTA TGC TGT TTA AGC GTG CCT
TTC C
109
5 Material and Methods
Table 5.1: Primer list
primer name construct sequence
TMEM106B_Glyc_NTT5(S) Fwd TM_NIT1-5mut GTA TGT CGA CTG TGG AAG AAG CAC AAC TTA TCA GTT GG
TMEM106B_Glyc_NTT5(S) Rev CCA ACT GAT AAG TTG TGC TTC TTC CAC AGT CGA CAT AC
TMEMsiRNA3 Fwd TM3
siRNA-resistent
HA-TMEM106B
CCA TAT AGT GAC CAA CGA TTA CGG CCG AGA AG
TMEMsiRNA3 Rev CTT CTC GGC CGT AAT CGT TGG TCA CTA TAT GG
HA-TMEM106B (BamHI) Fwd HA-TM/
HA-TM pcDNA6
CGC GGA TCC GCC ACC ATG TAC CCA TAC GAC GTC CCA GAC
TAC GCT GGA AAG TCT CTT TCT CAT TTG
TMEM106B STOP (XhoI) Rev CCG CTC GAG TTA CTG TTG TGG CTG AAG TAC ATT TAA ATA
TMEM106B (BamHI) Fwd TM-HA CGC GGA TCC TCA GAC ATG GGA AAG TCT CTT TCT CAT TTG
TMEM106B-HA-Stop (XhoI) Rev CCG CTC GAG TTA AGC GTA GTC TGG GAC GTC GTA TGG GTA
CTG TTG TGG CTG AAG TAC ATT TAA ATA TTC
In table 5.2, the TaqMan primers used for real-time PCR are depicted.
Table 5.2: TaqMan primer list
target name provider
human GAPDH 4326317E Applied Biosystems
human TMEM106B Hs00998849 (exon boundary 7-8) Applied Biosystems
human GRN Hs00173570 (exon boundary 1-2) Applied Biosystems
5.1.3 Constructs
Vectors and plasmids used in this study are depicted in table 5.3. Furthermore, it is stated how
the plasmids were cloned. Notably, in this study, when TMEM106B is mentioned, the T185
isoform of TMEM106B is meant (the protective S185 isoform was termed T185S, but data are
not shown in this study).
*Aﬃliations: Serge Bénichou, Institut Cochin, Paris; Marino Zerial, Max Planck Institute of Molecular Cell
Biology and Genetics, Dresden; Nicole Exner, Ludwig-Maximilians-University Munich, Adolf Butenandt Institute,
Munich.
Table 5.3: Constructs
construct
abbreviation
construct name vector backbone cloning provider
IMAGE full length clone
IRATp970G1031D
human TMEM106B cDNA pBluescriptR SalI + XhoI imaGenes
GmbH
HA-TM pcDNA6 pcDNA6/V5-His STOP
HA-TMEM106B
pcDNA6/V5-HisA (Life
Technologies)
BamHI + XhoI lab
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Table 5.3: Constructs
construct
abbreviation
construct name vector backbone cloning provider
HA-TM pcDNA 4 /TO/myc
HA-TMEM106B
pcDNA4/TO/myc (Life
Technologies)
BamHI + XhoI Christina
Lang
TM-HA pcDNA3.1
TMEM106B-HA
pcDNA 3.1 Hygro (Life
Technologies)
BamHI + XhoI Christina
Lang
TM_NIT1mut TM_NIT1 pcDNA6/V5-HisA (Life
Technologies)
site-directed mutagenesis
on HA-TM pcDNA6
Christina
Lang
TM_NIT1-2mut TM_NIT1-2 (NIT2) pcDNA6/V5-HisA (Life
Technologies)
site-directed mutagenesis
on TM_NIT1mut
Christina
Lang
TM_NIT1-3mut TM_NIT1-3 (NIT3) pcDNA6/V5-HisA (Life
Technologies)
site-directed mutagenesis
on TM_NIT1-2mut
Christina
Lang
TM_NIT1-4mut TM_NIT1-4 (NIT4) pcDNA6/V5-HisA (Life
Technologies)
site-directed mutagenesis
on TM_NIT1-3mut
Christina
Lang
TM_NIT1-5mut TM_NIT1-5 (NIT5) pcDNA6/V5-HisA (Life
Technologies)
site-directed mutagenesis
on TM_NIT1-4mut
Christina
Lang
N3 (HA-TMEM) N3 only (HA-TMEM) HA-TM in
pcDNA4/TO/myc (Life
Technologies)
site-directed mutagenesis
on HA-TM
lab
N4 (HA-TMEM) N4 only (HA-TMEM) HA-TM in
pcDNA4/TO/myc (Life
Technologies)
site-directed mutagenesis
on HA-TM
lab
N5 (HA-TMEM) N5 only (HA-TMEM) HA-TM in
pcDNA4/TO/myc (Life
Technologies)
site-directed mutagenesis
on HA-TM
lab
N3 TMEM-HA N3 only TMEM-HA pcDNA 3.1 Hygro (Life
Technologies)
site-directed mutagenesis
on TM-HA
Christina
Lang
N4 TMEM-HA N4 only TMEM-HA pcDNA 3.1 Hygro (Life
Technologies)
site-directed mutagenesis
on TM-HA
Christina
Lang
N5 TMEM-HA N5 only TMEM-HA pcDNA 3.1 Hygro (Life
Technologies)
site-directed mutagenesis
on TM-HA
Christina
Lang
NIT4+5 NIT4+5only HA-TM in
pcDNA4/TO/myc
site-directed mutagenesis
on HA-TM
Christina
Lang
LAMP1-mGFP addgene plasmid 34831 pEGFP-N EcoRI + SalI addgene
TM3 siRNA-resistent
HA-TMEM106B
TM3 siRNA-resistent
HA-TMEM106B
pcDNA4/TO/myc (Life
Technologies)
site-directed mutagenesis
on HA-TMEM
Christina
Lang
siRNA TM3-resistent N4 siRNA TM3-resistent N4
only HA-TMEM106B
pcDNA4/TO/myc (Life
Technologies)
site-directed mutagenesis
on N4 (HA-TMEM)
Christina
Lang
chk-dyn 0347-pEGFPC2-DynChk
(GFP-chicken dynamitin)
pEGFP-C2 (Clonetech) EcoR1 Serge
Benichou*
[121]
Rab4-GFP Rab4-GFP pEGFP-Vektor (Clonetech) HindIII+XhoI Marino
Zerial* [287]
Rab5a-GFP Rab5a-GFP pEGFP-Vektor (Clonetech) HindIII+Pst Marino
Zerial* [240]
Rab7-GFP Rab7-GFP pEGFP-Vektor (Clonetech) BamHI Marino
Zerial* [240]
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Table 5.3: Constructs
construct
abbreviation
construct name vector backbone cloning provider
Rab11-GFP Rab11-GFP pEGFP-Vektor (Clonetech) HindIII+XhoI Marino
Zerial* [318]
Mfn2 Mitofusin2 pcDNA 3.1 (Life
Technologies)
BamHI + HindIII Nicole Exner*
[198]
Mito-GFP CellLightR©
Mitochondria-GFP,
BacMam 2.0
Life
Technologies
5.1.4 Small interfering RNAs
For RNA interference, the siRNAs depicted in table 5.4 were used. Moreover, the abbreviations
that I have given them in this study, their sequence (if known) and their provider are listed.
Table 5.4: siRNA sequences
abbreviation name sequence provider
TMEM106B pool SMART pool
siGENOME
TMEM106B siRNA
D-020307-01
TM2,TM3,TM4 +
TM17
GE Healthcare
Dharmacon RNAi &
Gene Expression
TMEM106B #2
(#2)
individual siGENOME
TMEM106B siRNA
D-020307-02
GGA AUG GAC
UGG UUA AUA G
GE Healthcare
Dharmacon RNAi &
Gene Expression
TMEM106B #3
(#3)
individual siGENOME
TMEM106B siRNA
D-020307-03
GAU CAG AGA
UUA AGG CCA A
GE Healthcare
Dharmacon RNAi &
Gene Expression
TMEM106B #4
(#4)
individual siGENOME
TMEM106B siRNA
D-020307-04
GCU CUA UCG
ACG UGA AAU A
GE Healthcare
Dharmacon RNAi &
Gene Expression
TMEM106B #17
(#17)
individual siGENOME
TMEM106B siRNA
D-020307-17
GUA GCU GGG
UUG AGA UUA A
GE Healthcare
Dharmacon RNAi &
Gene Expression
Neg1 (control for
pool)
siGENOME
Non-Targeting siRNA
Pool #1
D-001206-13-05
not given GE Healthcare
Dharmacon RNAi &
Gene Expression
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Table 5.4: siRNA sequences
abbreviation name sequence provider
Neg4 (control for
single siRNAs)
siGENOME
Non-Targeting siRNA
#4 D-001210-04
not given GE Healthcare
Dharmacon RNAi &
Gene Expression
5.1.5 Drugs and ﬂuorescent dyes
In table 5.5, all drugs used in this study are listed giving the used concentration, treatment
duration, provider and a brief description of the target or function.
Table 5.5: Drug treatment
drug concentration time provider description
actinomycin D 20 μg/ml 16 h Sigma-Aldrich transcription
inhibitor
cycloheximide 20 μg/ml 16 h Sigma-Aldrich translation inhibitor
leupeptin
hemisulfate
10 μM 16 h Merck Millipore serine/cystein
protease inhibitor
E-64 10 μM 16 h Biomol cystein protease
inhibitor
antipain
hydrocholride
5 μM 16 h Calbiochem serine/cystein
protease inhibitor
epoxomycin 1 μM 16 h Sigma-Aldrich proteasome inhibitor
baﬁlomycin A1
(BafA1)
30 nM 6h to
16 h
Merck Millipore H+-ATPase
inhibitor
tunicamycin 10 μg/ml 16 h Sigma-Aldrich N-glycosylation
inhibitor
nocodazole 0.33 μM, 3.3 μM 16 h Sigma-Aldrich microtubule
polymerization
inhibitor
rapamycin 1mM 6h Life Technologies autophagy inducer
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In table 5.6, all ﬂuorescent dyes used in this study are listed giving the used concentration,
treatment duration, provider and a brief description of the target or function.
Table 5.6: Dyes
dye concentration time provider description
LysoTracker Red
DND-99
75 nM 30min Life Technologies stains acidic
organelles
DQTMRed BSA
(DQ-BSA)
100 ng/ml 5 h Molecular Probes ﬂuorogenic
substreate for
proteases
Alexa Fluor R©
555 Phalloidin
1:200 30min Life Technologies stains F-actin
4’,6-diamidino-2-
phenylindole
(DAPI)
1:5,000 15min Vector
Laboratories
stains DNA
5.1.6 Cell lines
In this study, the cell lines depicted in table 5.7 were used and cultured as described in section
5.2.2.1.
Table 5.7: Cell lines
name description resistance culture medium
HEK293T human embryonic kidney (HEK) cells (DSMZ #
ACC 305)
non DMEM high glucose + GlutaMAX (Life
Technologies), penicillin/stretomycin
(P/S) (50U/ml / 50 μg/ml; PAA
laboratories), 10 % fetal calf serum
(FCS; Life Technologies)
SH-SY5Y human neuroblastoma cell line (DSMZ # ACC
209)
non DMEM F12 (Life Technologies), P/S
(50U/ml / 50 μg/ml), 1 % non-essential
amino acids (NEAA), 15 % FCS
T-RExTM
HEK293
human embryonic kidney cells stably expressing
the tetracycline repressor protein (ATCC
CRL-1573)
blasticidine DMEM high glucose + GlutaMAX,
P/S (50U/ml / 50 μg/ml), 10 % FCS,
5 μg/ml blasticidine
HeLa human cervical carcinoma cells (DSMZ # ACC
57)
non DMEM high glucose + GlutaMAX,
P/S (50U/ml / 50 μg/ml), 10 % FCS
HeLa Kyoto human cervical carcinoma cells non DMEM high glucose + GlutaMAX,
P/S (50U/ml / 50 μg/ml), 10 % FCS
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5.1.7 The T-RExTM system
The T-RExTM system (Life Technologies) is a mammalian expression system regulated
by tetracycline. Importantly, it consists of an inducible expression plasmid (for example
pcDNA4/TO/myc, ﬁgure 5.1) containing two copies of the tet operator 2 (TetO2) sequence,
which is a regulatory element from the E. coli TN10-encoded tetracycline (Tet) resistance operon
[108, 109].
HA-TMEM106B
Figure 5.1: Cloning of pcDNA4-HA-TMEM106B
The puriﬁed HA-TM PCR product as well as the pcDNA4/TO/myc vector were digested with BamHI and
XhoI and ligated to create the HA-TM construct that was used for the generation of T-RExTM 293 cells stably
expressing wt HA-TMEM106B.
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HA-TMEM106B
HA-TMEM106B
HA-TMEM106B
Figure 5.2: Mechanism of repression in the T-RExTM system
This scheme was taken and modiﬁed from the T-RExTM System User Guide (Revision date: 8th November
2011, Publication Part number 25-0271, Life Technologies). It depicts the mechanism of repression of the
T-RExTM system.
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Moreover, a second plasmid is needed that contains the pcDNA6/TR regulatory vector which
is responsible for the expression of the Tet repressor.
In this study, T-RExTM 293 cells were used which stably express the pcDNA6/TR regulatory
vector resulting in high expression levels of the TetR gene, encoding for the Tet repressor [222].
In the absence of tetracyline, the Tet repressor dimerizes and binds to the TetO2 sequence
in the promoter region of the inducible expression plasmid (pcDNA4/TO/myc HA-TMEM)
[108] thereby repressing the transcription of the gene of interest, in this case HA-TMEM106B.
However, when tetracycline is added to the cell culture medium, it binds to the Tet repressor
dimer leading to a conformational change of the repressor which makes it unable to bind to
the Tet operator. Thus, the repressor-tetracycline complex dissociates from the Tet operator
allowing for HA-TMEM106B transcription (ﬁgure 5.2).
5.1.8 Antibodies
All antibodies used for immunoﬂuorescence (IF), western blotting (WB) or immunoprecipitation
(IP) are listed in table 5.8 along with their host, provider and dilution used in this study.
Furthermore, in table 5.9, the secondary antibodies used in this study are depicted along with
the provider and the used dilution.
*Aﬃliations: Prof. Dr. Dieter Edbauer, German Center for Neurodegenerative Diseases (DZNE), Ludwig-
Maximilians-University Munich, Munich, Germany; Dr. Dorothee Dormann, Institute of Cell Biology, Ludwig-
Maximilians-University Munich, Munich, Germany; Dr. Anja Capell, Ludwig-Maximilians-University Munich,
Adolf Butenandt Institute, Munich, Germany; Dr. Elisabeth Kremmer, Institute of Molecular Immunology,
Helmholtz Center, Munich, Germany.
Table 5.8: Antibody list
antibodies host provider dilution
Anti-HA High Aﬃnity (clone 3F10) rat Roche Applied Sciences IF: 1:200
Anti-Grp78/Bip (KDEL) mouse StressGen IF: 1:200
Giantin, mAb (G1/133) mouse Enzo Life Sciences, Inc. IF: 1:600
LAMP1 (clone H4A3) mouse Developmental Studies
Hybridoma Bank
IF: 1:400
LAMP2 (clone H4B4) mouse Developmental Studies
Hybridoma Bank
IF: 1:400
LAMP1 (D2D11) XPR© Rabbit
mAb #9091
rabbit Cell Signaling IF: 1:400
Anti-β-catenin rabbit Sigma-Aldrich IF: 1:400
Anti-γ-tubulin Clone GTU-88 rabbit Sigma-Aldrich IF: 1:200
Puriﬁed Mouse Anti-Tom20 mouse Santa Cruz IF: 1:1,000
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Table 5.8: Antibody list
antibodies host provider dilution
Anti-α-tubulin mouse Sigma-Aldrich IF: 1:500
Calnexin Polyclonal Antibody rabbit StressGen IF: 1:2,000
Golgin-97 (D8P2K) Rabbit mAb rabbit Cell Signaling IF: 1:100
EEA1 (C45B10) Rabbit mAb rabbit Cell Signaling IF: 1:250
Puriﬁed Mouse Anti-EEA1 Clone
14/EEA1 (RUO)
mouse BD Transduction
LaboratoriesTM
IF: 1:100
Anti-p62 (SQSTM1) pAb rabbit MBL IF: 1:1,000
Puriﬁed Mouse Anti-p62 Ick ligand mouse BD Biosciences IF: 1:100
Monoclonal antibody to LC3
(microtubule-associated protein 1
light chain 3B)
mouse Nanotools IF: 1:200
Anti-Ubiquitin, Lys48-Speciﬁc,
clone Apu2
mouse Millipore IF: 1:100
anti-TMEM 344 rabbit Dieter Edbauer*,
Eurogentic [155]
IF: 1:43
Anti-HA-Peroxidase, High Aﬃnity
(3F10)
rat Roche Applied Sciences WB: 1:1000
PCDGF Polyclonal Antibody,
Rabbit (anti-GRN)
rabbit Life Technologies WB: 1:700
Monoclonal Anti-β-Actin antibody
produced in mouse clone AC-74
mouse Sigma-Aldrich WB: 1:2,000
cathepsin D (C-20): sc-6486 mouse Santa Cruz WB: 1:400
cathepsin B (FL-339): sc-13985 rabbit Santa Cruz WB: 1:1,000
LC3 rabbit Dorothee Dormann* [261] WB: 1:4,000
14-3-3 β (C-20): sc-628 mouse Santa Cruz WB: 1:200
6F2 anti-TMEM106B rat Anja Capell*, Elisabeth
Kremmer* [155]
WB: 1:10 -
1:50
anti-TMEM 345 rabbit Dieter Edbauer*,
Eurogentic [263]
WB:
1 μg/ml
LAMP2 (clone H4B4) mouse Developmental Studies
Hybridoma Bank
WB: 1:2,000
Anti-p62 (SQSTM1) pAb rabbit MBL WB: 1:1,000
Anti-HA antibody rabbit Sigma-Aldrich IP: 1:250
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Table 5.9: Secondary antibodies
Secondary antibodies provider dilution
Alexa 555/488/647-conjugated anti-mouse IgG Life Technologies IF: 1:500
Alexa 555/488/647-conjugated anti-rabbit IgG Life Technologies IF: 1:500
Alexa 555/488/647-conjugated anti-rat IgG Life Technologies IF: 1:500
horse-radish peroxidase (HRP)-conjugated
anti-mouse IgG
Promega WB: 1:10,000
HRP-conjugated anti-rabbit IgG Promega WB: 1:10,000
HRP-conjugated anti-rat IgG Promega WB: 1:10,000
HRP-conjugated anti-goat IgG Promega WB: 1:5,000
HRP-conjugated anti-rat 2c IgG Elisabeth Kremmer* WB: 1:1,000
5.1.9 Validation of the anti-TMEM106B antibody 6F2
The monoclonal antibody against TMEM106B 6F2 was validated by immunoblot (ﬁgure 5.3).
Therefore, SH-SY5Y cells were either transfected with the siRNA pool against TMEM106B for
TMEM106B knockdown (KD), control siRNA for endogenous TMEM106B expression (/) or
with a HA-tagged wt TMEM106B cDNA construct for TMEM106B overexpression (OE). As
the overexpression construct was tagged, the proteins ran a little bit higher than endogenous
TMEM106B (ﬁgure 5.3). The protein bands marked with an asterisk probably represent aggre-
gated or dimerized TMEM106B (ﬁgure 5.3). As these bands do not appear in the knockdown
lane, they are TMEM106B-speciﬁc.
kDa KD / OE
TMEM106B
HA-TMEM106B
TMEM106B*
HA-TMEM106B*
250
148
98
50
64
Figure 5.3: Validation of the anti-TMEM106B antibody 6F2 in SH-SY5Y cells
SH-SY5Y cells were either not transfected or transfected with a non-targeting control siRNA or with an siRNA
pool against TMEM106B on day 0. On day 2 after siRNA transfection, the untransfected cells were transfected
with a HA-tagged wt TMEM106B cDNA construct. On day 3, cells were harvested and analysed by SDS-PAGE
and subsequent immunoblotting with the anti-TMEM106B antibody 6F2. Probably aggregated or dimerized
TMEM106B is marked with an asterisk (*).
119
5 Material and Methods
5.2 Methods
5.2.1 Molecular biology and nucleic acid techniques
5.2.1.1 Polymerase chain reaction (PCR)
PCRs were performed with the aforementioned primers and appropriate cDNA plasmids as
templates (see sections 5.1.2, page 115 and 5.1.3, page 116). Thereby, Pwo polymerase from
Pyrococcus woesei was used owing to its proofreading activity. A typical experimental set-up is
presented below.
10x reaction buﬀer for Pwo complete (PeqLab) 5 μl
template DNA (10 ng/μl) 1 μl
forward primer (10 pmol/μl) 1 μl
reverse primer (10 pmol/μl) 1 μl
dNTP-Mix (10mM, Roche Applied Science) 2 μl
ddH2O 39μl
Pwo polymerase (1U/μl, peqLab) 1 μl
50 μl
All PCR reactions were prepared on ice and performed in a pre-heated thermocycler using
the PCR programme depicted below. Of note, the annealing temperature was adjusted to the
melting temperature of the primers starting usually with 5 ◦C below the respective melting
temperature.
step temperature time
initial denaturation 95 ◦C 5min
denaturation 95 ◦C 30 s ⎤
⎥⎦30 xannealing 52 ◦C to 72 ◦C 30 s
elongation 72 ◦C 250 bp/min
ﬁnal extension 72 ◦C 7min
storage 4 ◦C hold
5.2.1.2 Site-directed mutagenesis
To introduce point mutations into a plasmid, the QuikChangeR© Site-Directed Mutagenesis Kit
(Stratagene) was used according to the manufacturer’s instructions. Brieﬂy, primers were de-
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signed that contained the desired mutation according to the guidelines listed in the kit’s manual.
Then, a PCR was performed using the following set-up:
10x reaction buﬀer for Pfu Turbo 5 μl
template DNA (10 ng/μl) 1.3 μl
forward primer (125 ng) 1.3 μl
reverse primer (125 ng) 1.3 μl
dNTP-Mix (10mM, Roche Applied Science) 2 μl
ddH2O 38.1 μl
Pfu Turbo polymerase (1U/μl) 1 μl
50 μl
All PCR reactions were prepared on ice and performed in a pre-heated thermocycler using the
cycling parameters depicted below.
step temperature time
initial denaturation 95 ◦C 30 s
denaturation 95 ◦C 30 s ⎤
⎥⎥⎥⎦16 x
annealing 55 ◦C 1min
elongation 68 ◦C 1min/kb
of plasmid length
ﬁnal extension 68 ◦C 7min
storage 4 ◦C hold
Subsequently, 1 μl of DpnI restriction enzyme was added to the ampliﬁcation reaction and
incubated at 37 ◦C for 3 h to digest the non-mutated, methylated template DNA. Following
digestion, the remaining mutated DNA was transformed into chemically competent DH5α E.coli
as described in section 5.2.1.7.
5.2.1.3 Restriction digest
Restriction enzymes, the appropriate buﬀers and additives were purchased from Fermentas,
Roche Applied Science or New England Biolabs (NEB) and used according to the manufacturers’
instructions. Usually, 1 μg of plasmid DNA or 10 μl of puriﬁed PCR product were used and
mixed with 5U of restriction enzyme(s) together with the appropriate buﬀer in a ﬁnal volume
of 20 μl. For an analytical digest, 5 μl of “Miniprep”-DNA were utilized (see section 5.2.1.8.1,
page 129). Subsequently, the reaction mix was incubated for 1 h to 3 h at 37 ◦C. Digested PCR
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products were puriﬁed by using the NucleoSpinR© Extract II kit (Macherey-Nagel) according to
the manufacturer’s instructions whereas digested plasmids were separated on an agarose gel,
ﬁrst (see section 5.2.1.4). Subsequently, digested DNA was subjected to ligation (see section
5.2.1.5).
5.2.1.4 Agarose gel electrophoresis and gel extraction of DNA
TBE buﬀer (10x) 0.9M Tris (pH 8.3), 0.9M boric acid, 20mM ethylenediaminetetraacetic acid
(EDTA; pH 8.0) in ddH2O
DNA loading buﬀer (10x) 100mM Tris (pH 9.0), 10mM EDTA, 50 % (volume/volume; v/v) glycerol, 0.5 %
(mass/volume; w/v) Orange G in ddH2O (pH 9.0)
Agarose gel electorphoresis was used to separate DNA. Thereby, ultrapure agarose (Life Tech-
nologies) was dissolved in 1x TBE buﬀer and 0.3 μg/ml of ethidium bromide were added prior to
casting the 1 % to 2 % agarose gel (depending on the DNA size analysed) in order to visualize
DNA under UV light. DNA samples were mixed with 6x DNA loading buﬀer and electrophoresis
was performed in 1x TBE buﬀer at 120V. A 1 kb-DNA ladder (Life Technologies) served as
standard. Subsequently, DNA was visualized under UV light and, if required, cut and extracted
from the gel by using the NucleoSpinR© Extract II kit (Macherey-Nagel) which was done ac-
cording to the manufacturer’s instructions. However, DNA was eluted in ddH2O instead of NE
buﬀer.
5.2.1.5 Ligation
After purifying the digested DNA, PCR products or DNA fragments were ligated into linearized
vectors using the T4 DNA ligase (Thermo Scientiﬁc). Typically, a 1:5 ratio between vector and
insert DNA was used in a total volume of 30 μl together with 5U of T4 DNA ligase. As controls,
a reaction mix was either prepared without the insert or without both the insert and the ligase.
After incubating at room temperature for 2 h or at 4 ◦C over night (o/n) , 20 μl of the ligation
mix were used to transform competent E.coli (see section 5.2.1.7).
5.2.1.6 Preparation of competent bacteria
Transformation buﬀer 50mM CaCl2, 10mM PIPES (pH 6.6), 15 % (v/v) glycerol in ddH2O
(sterile-ﬁltered)
LB0 medium 1 % (w/v) Bacto Tryptone (Becton Dickinson), 0.5 % (w/v) yeast extract (Becton
Dickinson), 17.25mM NaCl in ddH2O (pH 7.0), autoclaved at 1.2 bar, 120 ◦C for
20min
To prepare chemically competent Escherichia coli (E.coli) DH5α, bacteria of a glycerol stock
were plated on agar plates without antibiotics and incubated at 37 ◦C o/n. The next day, 2ml of
LB0 medium were inoculated with a fresh E.coli clone and incubated o/n at 37 ◦C. Subsequently,
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200ml of LB0 medium were inoculated with the pre-culture and grown to an optical density of
OD600 = 0.2. Then, bacteria were put on ice for 10min before being centrifuged at 800 g and 4 ◦C
for 10min. The cell pellet was resuspended in ice-cold transformation buﬀer and incubated on ice
for 20min. Again, cells were centrifuged at 800 g and 4 ◦C for 10min before being resuspended
in 10ml ice-cold transformation buﬀer. Subsequently, aliquots of 100 μl and 300 μl were frozen
in liquid nitrogen before being stored at −80 ◦C.
5.2.1.7 Transformation of bacteria
LB0 medium 1 % (w/v) Bacto Tryptone (Becton Dickinson), 0.5 % (w/v) yeast extract (Becton
Dickinson), 17.25mM NaCl in ddH2O (pH 7.0), autoclaved at 1.2 bar, 120 ◦C for
20min
LB agar plates LB medium supplemented with 15 % agar (15 g/l, Becton Dickinson), autoclaved at
1.2 bar, 120 ◦C for 20min. If needed, either kanamycin or ampicillin were added
after cooling.
kanamycin A stock solution of 50mg/ml was prepared in ddH2O (sterile-ﬁltered; 0.2 μm). For
the working concentration, the stock was diluted 1:1,000.
ampicillin A stock solution of 100mg/ml was prepared in ddH2O (sterile-ﬁltered; 0.2 μm). For
the working concentration, the stock was diluted 1:1,000.
To transform bacteria, a 100 μl-aliquot of competent E.coli (see section 5.2.1.6) was thawed on
ice before adding 20 μl of ligation mix or 0.5 μg of plasmid DNA (re-trafo). The suspension
was incubated on ice for 30min. Then, heat-shock was applied for 2min at 42 ◦C followed by a
2min-incubation step on ice. Afterwards, 1ml of room temperature-LB0 medium was added to
the bacteria. The suspension was subsequently incubated for 1 h at 37 ◦C with agitation. The
bacteria were pelleted by very short centrifugation (15 s) and resuspended in 50 μl of LB0 medium
before being plated on agar plates containing the appropriate selection antibiotic (typically
ampicillin (Roth) or kanamycin (Roth)). The plates were incubated at 37 ◦C until single colonies
appeared, usually o/n.
Clones were selected and ampliﬁed by inoculating 6ml of LB medium containing the appropriate
selection antibiotic with single colonies picked from the agar plate. Positive clones were identiﬁed
by analytical digest (see section 5.2.1.3) and sequencing (see section 5.2.1.9).
5.2.1.8 Plasmid DNA preparation
5.2.1.8.1 Small scale, analytical plasmid preparation ("Miniprep")
To analyse whether cloning had been successful, small amounts of plasmid DNA were puriﬁed
out of 5ml of 6ml of pre-culture (LB medium that was inoculated with the respective bacterial
colony (see section 5.2.1.7)). The remaining 1ml of pre-culture was used for large scale plasmid
preparation after the clone proved to be correct (see below). For small scale plasmid prepara-
tion, the NucleoSpinR© Plasmid kit (Macherey-Nagel) was used according to the manufacturer’s
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instructions. Plasmid DNA was eluted in ddH2O instead of AE buﬀer to allow sequencing (see
section 5.2.1.9).
5.2.1.8.2 Large scale, preparative plasmid preparation ("Midiprep" or "Maxiprep")
For subsequent cloning or transfection into cell lines, suﬃcient amounts of plasmid DNA were
needed and obtained by large scale, preparative plasmid preparation. Thereby, 200ml of LB
medium containing the appropriate selection antibiotic were inoculated with 1ml of pre-culture
left from small scale plasmid preparation (see above). Alternatively, 200ml of LB medium con-
taining the appropriate selection antibiotic were directly inoculated with a clone picked from a
selection plate (usually done when a plasmid was re-transformed). After incubating the inocu-
lated LB medium at 37 ◦C o/n (with agitation), bacteria were harvested by centrifugation and
plasmid DNA extracted by using the NucleoBondR© Xtra Midi/Maxi plasmid DNA puriﬁcation
kit (Macherey-Nagel) according to the manufacturer’s instructions. DNA was eluted in ddH2O
and diluted to a ﬁnal concentration of about 1 μg/μl. Thereby, DNA concentration and purity
were determined by photometric measurement using a NanoDrop photospectrometer (PeqLab).
Thereby, the absorption at 260 nm (DNA concentration) and the adsorption at 280 nm (conta-
mination with protein) of the DNA solution were determined. The ratio of A260/A280 should
at least be 1.8.
5.2.1.9 Sequencing of DNA
DNA sequencing was performed by the GATC Biotech AG using Sanger sequencing on a Sanger
ABI 3730xl DNA analyzer (Applied Biosystems). Sequencing data was analysed and processed
with the CLC Main Workbench 6.6 software (CLC bio).
5.2.1.10 Isolation of cellular RNA
Isolation of cellular RNA was performed with the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. Brieﬂy, cells were harvested and pelleted as described in section
5.2.3.1. Subsequently, the cells were resuspended in RTL lysis buﬀer (provided by the kit) before
being homogenized by using the QIAshredder kit (Qiagen) according to the manufacturer’s
instructions. To avoid DNA contamination, samples were treated with the enzyme DNase I
(RNase-Free DNase Set, Quiagen) according to the manufacturer’s instructions. RNA was
eluted in RNase-free water (provided by the kit) and either put on ice until further processing or
stored at −80 ◦C. RNA concentration and purity were determined by photometric measurement
using a NanoDrop photospectrometer (PeqLab). Thereby, the absorption at 260 nm (RNA
concentration) and the adsorption at 280 nm (contamination with protein) of the RNA solution
were determined. A ratio of A260/A280 ∼ 2.0 was usually accepted for pure RNA.
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5.2.1.11 Reverse transcription of RNA
Transcription of RNA into cDNA was performed using M-MLV reverse transcriptase (Promega)
together with the appropriate buﬀers according to the manufacturer’s instructions. Thereby,
2 μg of RNA were transcribed into cDNA by the use of oligo dTs, dNTPs and M-MLV reverse
transcriptase. The resulting cDNA was analysed by real-time PCR.
5.2.1.12 Real-time PCR
To determine mRNA expression levels, real-time PCR was performed using TaqMan technology.
Thereby, 1 μl of TaqMan primers (see TaqMan primer list, table 5.2) was mixed with 10 μl of
TaqMan Universal PCR Master mix (2x, ROX, Applied Biosystems) and pipetted into fast
optical 96-well reaction plates (Applied Biosystems). Subsequently, 0.1 μg/μl of sample cDNA
were mixed with 8 μl of ddH2O and added to the TaqMan primer mix. For analysis, the 96-well
plate was sealed with adhesive foil, brieﬂy centrifuged and put into the 7500 Fast Real-Time
PCR system (Applied Biosystems) for measuring. Usually, samples were measured in triplicates
and normalized to GAPDH cDNA levels according to the ΔΔCt method using the following
equation: 2−(CtTMEM106B−CtGAPDH)treatment−(CtTMEM106B−CtGAPDH)control .
5.2.2 Cell culture methods
5.2.2.1 Cultivation of continuous cell lines
Phosphate-buﬀered saline
(PBS)
140mM NaCl, 10mM Na2HPO4, 1.75mM KH2PO4, 2.7mM KCl in ddH2O
(pH 7.4), autoclaved at 1.2 bar, 120 ◦C for 20min
Trypsin-EDTA solution
(Life Technologies)
0.05 % (w/v) trypsin, 0.53mM EDTA-4NA, 0.025mM phenol-red
Penicillin/streptomycin
(PAA laboratories)
5000 units/ml penicillin, 5mg/ml streptomycin
ZeocinTM selection
reagent (Life
Technologies)
200 ng/μl to 400 ng/μl working concentration
GeniticinTM selective
antibiotic (G418 sulfate,
Life Technologies)
200 ng/μl to 500 ng/μl working concentration
Blasticidine 5 μg/ml working concentration
Human cervical carcinoma (HeLa and HeLa Kyoto) cells and human embryonic kidney (HEK
293T) cells were cultured in Dulbecco’s Modiﬁed Eagle Medium (DMEM) with Glutamax I
(Life Technologies) supplemented with 10 % (v/v) fetal calf serum (FCS, Life Technologies)
and 1% (v/v) P/S (PAA laboratories). Human neuroblastoma SH-SY5Y cells were cultured in
Dulbecco’s Modiﬁed Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) (Life Technologies)
supplemented with 15 % (v/v) FCS (Life Technologies), 1 % (v/v) non-essential amino acids
(NEAA; Life Technologies) and 1% (v/v) P/S (PAA laboratories). All cell lines were cultured
in a standard incubator which was set to 37 ◦C, 5 % CO2 and 95 % relative humidity. For
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passaging, cells were washed with autoclaved PBS once and were incubated in trypsin solution
until the cell layer detached from the culture dish. Subsequently, cells were suspended in culture
medium and transferred in a dilution of 1:3 to 1:20 to new cell culture dishes containing the
appropriate culture medium.
5.2.2.2 Preparation of stable cell lines
A stable cell line for TMEM106B overexpression was obtained through transfection of the
pcDNA4/TO-HA-TMEM106B wt construct (N-terminally tagged) into a T-RExTM-293 cell line
(Life Technologies). A stable cell line was obtained by selection in DMEM with Glutamax I
supplemented with 10 % (v/v) FCS, 1% (v/v) P/S and 400 ng/μl of ZeocinTM (Life Technolo-
gies) and single cell clones were picked. After selection, the Zeocin concentration was reduced
to 200 ng/μl. To induce TMEM106B expression, stable cell clones were treated with 0.2 ng/μl
tetracycline (Sigma-Aldrich) for 12 h to 24 h (see also supplement 5.1.7).
Stable cell lines for LAMP1 overexpression were gained by transient transfection of the plas-
mid 34831: LAMP1-mGFP (Addgene) into a HeLa Kyoto cell line. Cells were selected as
described above, but with 300 ng/μl to 500 ng/μl G418 as selection antibiotic, and single cell
clones picked.
5.2.2.3 Cryopreservation of cell lines
Freezing medium Fetal calf serum (Life Technologies) supplemented with 10 % (v/v) DMSO
For cryopreservation, cells grown to a conﬂuency of about 80% to 90% in a 10 cm dish were
trypsinised (trypsin-EDTA; Life Technologies) and pelleted by centrifugation (5min, 1000 g at
RT). Subsequently, cells were resuspended in 0.5ml freezing medium and transferred into a
micro cryotube (Sarstedt). Cells were frozen at −80 ◦C using an isopropanol cryo 1 ◦C freezing
container (Nalgene).
For thawing, cells in a micro cryotube were shortly placed into a 37 ◦C water bath and immedi-
ately afterwards diluted in 10ml of culture medium. After six to eight hours, the medium was
replaced.
5.2.2.4 Transfection of cells via lipofection
Transient transfection of cells was carried out using either LipofectamineTM 2000 (Life Tech-
nologies), Fugene R©HD (Roche Applied Science) transfection reagent or X-tremeGENE 9 DNA
(Roche Applied Science) transfection reagent according to the manufacturers’ protocols. Brieﬂy,
cells were plated and transfected at 60 % to 80 % conﬂuency. Thereby, DNA and transfection
reagent were prepared in OptiMEM (Life Technologies), incubated for 20min and added to the
cells. After six to 16 h, medium was replaced by fresh medium and cells were incubated for at
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least 24 h in total before being harvested. Usually, FugeneR©HD or X-tremeGENE 9 DNA trans-
fection reagent were used for HeLa cells wereas LipofectamineTM 2000 was used for SH-SY5Y
cells and HEK293T cells.
For RNA interference experiments, 10 nM siRNA were mixed with LipofectaminR© RNAiMAX
reagent (Life Technologies) in OptiMEM (Life Technologies) according to the manufacturer’s
instructions. After 15min, cells were reversely transfected and subseqently incubated for 72 h
before analysis (if not stated diﬀerently in the text). After 24 h of siRNA treatment, new medium
was added to the cell culture dishes to dilute the transfection reagent and after 48 h, the medium
was replaced by new culture medium, respectively.
To rescue the TMEM106B knockdown phenotype, a TM3 siRNA-resistant HA-TMEM106B
construct or the empty vector were additionally transfected after 48 h of siRNA transfection,
using X-tremeGENE 9 DNA reagent (Roche Applied Science).
5.2.2.5 Drug treatment
The drugs used in this study are listed in section 5.1.5, table 5.5. To inhibit transcription,
cells were treated with 1 μM actinomycin D whereas translation was inhibited by 20 μg/ml cy-
cloheximide. Lysosomal degradation was inhibited by 10 μM leupeptin or a mixture of 10 μM
leupeptin, 10 μM E-64 and 5 μM antipain. Proteasomal degradation was blocked by 1 μM epox-
omicin (Sigma-Aldrich). All treatments mentioned above were carried out for 16 h at 37 ◦C.
H+-ATPase and thus lysosomal acidiﬁcation was inhibited by treating the cells for 6 h to 16 h
with 30 nM baﬁlomycin A1 (BafA1) (Merck Millipore) at 37 ◦C. For inhibiting microtubule
polymerization, cell were treated with 0.33 μM and 3.3 μM for 16 h, respectively.
5.2.3 Protein biochemistry
5.2.3.1 Collection of media and cell harvest
PBS 140mM NaCl, 10mM Na2HPO4, 1.75mM KH2PO4, 2.7mM KCl in ddH2O
(pH 7.4)
For analysing the cell media, cells were incubated in OptiMEM (Life Technologies) 16 h prior to
cell harvest. Then, cells were put on ice and the supernatant was collected in an Eppendorf tube.
Cellular debris was removed by centrifugation at 10,000 g for 10min at 4 ◦C. If not analysed
directly, the supernatant was stored at −20 ◦C. To harvest the cells, the cell monolayer was
washed three times with PBS and scraped in 1ml PBS. The cell suspension was transferred to
an Eppendorf tube and cells were pelleted by centrifugation (5min, 1.000 g, 4 ◦C), respectively.
The cells were either stored at −80 ◦C or lysed directly afterwards.
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5.2.3.2 Preparation of total cell lysates
Phosphatase and
protease inhibitors
Na3VO4 A stock solution of 100mM Na3VO4 was prepared in ddH2O. For the working
concentration, the stock solution was diluted 1:50.
NaF A stock solution of 1M NaF was prepared in ddH2O. For the working
concentration, the stock solution was diluted 1:1,000.
protease inhibitor cocktail
(Roche Applied Sciences)
The stock solution was diluted 1:500.
Lysis buﬀers
RIPA 150mM NaCl, 10mM Tris (pH 7.2), 0.1 % (w/v) SDS, 1 % (v/v) TritonX 100,
1 % (w/v) deoxycholate, 5mM EDTA in dH2O
STEN 50mM Tris (pH 7.6), 150mM NaCl, 2mM EDTA (pH 8.0), 1 % (v/v) NP-40 in
dH2O
Depending on the size of the cell pellet, cells were lysed in 50 μl to 500 μl of lysis buﬀer supple-
mented with phosphatase and protease inhibitors. After incubating on ice for 30min, the cell
lysate was centrifuged at 10,000 g for 30min at 4 ◦C to remove undissolved cell debris and, in
the case of STEN lysis, the nuclei. If cells were lysed with RIPA lysis buﬀer, the cell lysate was
additionally soniﬁcated before centrifugation to shear the DNA. Subsequently, cell lysates were
analysed on immunoblot or stored at −20 ◦C.
5.2.3.3 Measurement of the protein concentration
The protein concentration of cell lysates was determined by applying the colorimetric bicin-
choninic acid (BCA) method (Thermo Scientiﬁc, Pierce) according to the manufacturer’s in-
structions. Brieﬂy, the assay was performed in a 96-well plate in a total volume of 200 μl.
Usually, 198 μl of the BCA solution were added to 2 μl of the cell lysate. As standard served
serial dilutions of bovine serum albumin (BSA, included in the kit). After incubating for 30min
at 37 ◦C, the samples were analysed by measuring the absorbance at 562 nm using an ELISA
reader (PowerWave XS, BioTek).
5.2.3.4 Membrane preparation
RSB buﬀer 10mM Tris (pH 7.6), 1mM EDTA, 1mM ethylene glycol tetraacetic acid (EGTA)
in dH2O
Carbonate buﬀer 0.1M Na2CO3 (pH 11.5) in dH2O, 10mM dithiothreitol (DTT) added freshly
Laemmli buﬀer (4x) 4 g sodium dodecyl sulfate (SDS) ultra pure, 7.5ml dH2O, 12.5ml Tris (1M,
pH 6.8), 20ml glycerol, 1 spatula of bromophenol blue
Laemmli buﬀer (2x) 800 μl Laemmli buﬀer, 200 μl β-mercaptoethanol (freshly added), 1ml dH2O
Urea Laemmli buﬀer (2x) 1ml Laemmli buﬀer, 1ml urea solution (8M)
Cells were scraped and pelleted as described above. Then, they were lysed for 30min on ice in
RSB buﬀer supplemented with protease and phosphatase inhibitors. Subsequently, lysates were
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needled (20 times; needle size 0.6 x 30 mm) and centrifuged for 10min at 4 ◦C and 1,500 g to sep-
arate the cell debris from the nuclear fraction. The resulting supernatant was ultra-centrifuged
for 1 h at 4 ◦C and 100,000 g. The pellet contained all membrane proteins whereas the super-
natant comprised all cytosolic proteins. To distinguish between integral membrane proteins and
membrane-associated proteins, a carbonate extraction was subsequently performed by incubat-
ing the pellet in carbonate buﬀer supplemented with protease and phosphatase inhibitors on
ice for 30min. Then, the sample was ultra-centrifuged as described above. The resulting pellet
contained the integral membrane proteins whereas the supernatant comprised the membrane-
associated ones. For immunoblot analysis of TMEM106B, pellets were directly resuspended in
2x urea Laemmli sample buﬀer and incubated at 65 ◦C for 15min before being loaded on a urea
gel containing 12 % of acrylamide (see section 5.2.3.7).
5.2.3.5 Direct deglycosylation with N-glycosidase F
N-glycosidase F buﬀer 100mM sodium phosphate (pH 8.0), 25mM EDTA, 0.1 % (v/v) TritonX 100,
2.5mM phenylmethylsulfonylﬂuoride (PMSF)
STEN-lysates were mixed in a ratio of 1:5 with N-glycosidase F buﬀer. N-glycosidase F (Roche
Applied Sciences) was added and the samples incubated o/n at 37 ◦C on a shaker. The next
day, the samples were mixed with urea loading buﬀer and loaded on urea gels containing 12 %
of acrylamide (see section 5.2.3.7).
5.2.3.6 Immunoprecipitation and Deglycosylation
STEN-NaCl buﬀer 50mM Tris (pH 7.6), 500mM NaCl, 2mM EDTA (pH 8.0), 0.2 % (v/v) NP-40
STEN-SDS buﬀer 50mM Tris (pH 7.6), 150mM NaCl, 2mM EDTA (pH 8.0), 0.2 % (v/v) NP-40,
0.1 % (w/v) SDS
STEN wash buﬀer 50mM Tris (pH 7.6), 150mM NaCl, 2mM EDTA (pH 8.0), 0.2 % (v/v) NP-40
beads elution buﬀer 100mM Tris pH (7.4), 1 % (w/v) SDS, 1 % (v/v) β-mercaptoethanol
N-glycosidase F buﬀer 100mM sodium phosphate (pH 8.0), 25mM EDTA, 0.1 % (v/v) TritonX 100,
2.5mM PMSF, 1 % (v/v) β-mercaptoethanol, 1 % (w/v) SDS
endoglycosidase H buﬀer 200mM sodium citrate (pH 5.8), 2.5mM PMSF
STEN-lysates were pre-cleared for 30min at 4 ◦C. Then, Protein A Sepharose 4 Fast Flow beads
(GE Healthcare) and 1 μl of rabbit polyclonal anti-HA antibody (Sigma-Aldrich) were added to
pull down HA-tagged TMEM106B. After 2 h of incubation at 4 ◦C on a shaker, samples were
centrifuged for 5min at 4 ◦C and 3,500 g. The supernatant was discarded and the beads were
subsequently washed with STEN-NaCl buﬀer, STEN-SDS buﬀer and STEN wash buﬀer. The
proteins were separated from the beads by adding the beads elution buﬀer and incubating
the mixture at 65 ◦C for 5min. After 2min of centrifugation at 17,000 g, the supernatant
was taken oﬀ and mixed with either N-glycosidase F or endoglycosidase H buﬀer to dilute the
SDS concentration to 0.1 %. Then, the enzymes N-glycosidase F (Roche Applied Sciences) or
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endoglycosidase H (Roche Applied Sciences) were added and the samples incubated at 37 ◦C
o/n on a shaker. Subsequently, proteins were precipitated with trichloroacetic acid (100 %,
w/v). The protein pellet was re-suspended in STEN lysis buﬀer supplemented with phosphatase
and protease inhibitors. Subsequently, samples were subjected to urea SDS-PAGE (see section
5.2.3.7).
5.2.3.7 Sodium dodecyl sulfate polyacrylamid gel electrophoresis (SDS-PAGE)
Lower Tris (4x) 1.5M Tris (pH 8.8), 0.4 % (w/v) SDS in dH2O
Upper Tris (4x) 0.5M Tris (pH 6.8), 0.4 % (w/v) SDS in dH2O
Acrylamide 40 % (w/v) acrylamide-BIS-acrylamide 37, 5:1 in dH2O
10 % ammoniumpersulfate
(APS)
10 % APS (w/v) in dH2O
Laemmli buﬀer (4x) 8% SDS ultra pure, 0.25M Tris (pH 6.8), 40% glycerol, 1 spatula of bromophenol
blue in dH2O
Laemmli buﬀer (2x) 800 μl Laemmli buﬀer (4x), 200 μl β-mercaptoethanol (freshly added), 1ml dH2O
Urea Laemmli buﬀer (2x) 1ml Laemmli buﬀer (4x), 1ml urea solution (8M)
Tris-glycine buﬀer 25mM Tris, 190mM glycine, 0.1 % (v/v) SDS in ddH2O
Proteins were analysed under denaturing conditions by utilizing SDS-PAGE. Therefore, poly-
acrylamide gels containing a separating and a stacking gel were cast according to table 5.21.
Table 5.21: Protocol for one thick (1.5mm) SDS gel
step 8 % gel 10 % gel 12 % gel 15 % gel stacking gel
H2O [ml] 4.4 4.0 3.6 3.0 3.3
40 % Acrylamid [ml] 1.6 2.0 2.4 3.0 0.5
Lower Tris [ml] 2.0 2.0 2.0 2.0 1.25 (Upper Tris!)
TEMED [μl] 15 15 15 15 15
10 % APS [μl] 15 15 15 15 15
To analyse TMEM106B, in the stacking and separation gel, water was substituted by an 8M
urea solution to reach a ﬁnal urea concentration of at least 4M in the gels. To prepare the
samples for loading on SDS gels, cell lysates were mixed with 2x Laemmli buﬀer and boiled
at 95 ◦C for 5min. Samples (not frozen before) for TMEM106B analysis were mixed with 2x
urea Laemmli buﬀer and either heated to 65 ◦C for 15min or incubated at room temperature for
30min. To analyse LC3, (fresh) cell lysates were put into the 65 ◦C-heating block before directly
adding 2x Laemmli buﬀer without β-mercaptoethanol and incubating the samples for 10min.
After short centrifugation, equal amounts of protein were loaded on the gel together with 6 μl
of the SeeBlue Plus2 Prestained Molecular Weight Standard (Life Technologies) which served
as molecular weight standard. Electrophoresis was performed in a Tris-glycine buﬀer system
using the Mini-PROTEAN system (BIORAD). Gels were run at 120V for 90min to 120min
depending on the acrylamid concentration of the gel.
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5.2.3.8 Western blotting and immunodetection
Transfer buﬀer (1x) 25mM Tris, 0.2M glycine in dH2O
TBS-T buﬀer 0.3M NaCl, 10mM Tris-HCl (pH 7.6), 0.3 % (v/v) TritonX 100 in dH2O
I-Block solution 0.2 % (w/v) Tropix I-Block (Applied Biosystems), 0.1 % (v/v) Tween 20 in PBS
After SDS-PAGE, proteins were transferred onto polyvenylidene ﬂuoride (PVDF) membranes
(0.45 μm; Immobilon-P Transfer Membrane, Merck Millipore) using the Mini Trans-Blot cell
system (BIORAD). Thereby, membranes were activated in isopropanol followed by three washes
in dH2O and a 10min-incubation step in transfer buﬀer to equilibrate the membrane. WB was
performed in transfer buﬀer for 1 h at a constant current of 400mA. Subsequently, membranes
were incubated in I-Block solution for 1 h at room temperature. After blocking, membranes were
incubated in primary antibodies diluted in I-Block solution at 4 ◦C o/n or alternatively, at room
temperature for 2 h (with agitation). Then, membranes were washed with TBS-T several times
in a time frame of 1 h before they were incubated in HRP-coupled secondary antibodies diluted
in I-Block solution for 1 h (with agitation). Again, membranes were washed with TBS-T for 1 h
before proteins were detected using enhanced chemiluminescence (ECL). Thereby, membranes
were incubated in 2ml of HRP substrate (ECL, GE Healthchare or ECL Plus, Thermo Scientiﬁc)
at room temperature for 1min to 5min before being developed by using X-ray ﬁlms (Super RX
Medical X-Ray, Fujiﬁlm Life Science) and an automated ﬁlm developer (CAWOMAT 2000 IR,
CAWO).
To quantify protein levels, WB signals were detected by the Luminescent Image Analyzer LAS-
4000 (Fujiﬁlm Life Science) and subsequently analysed by using the Multi Gauge software version
3.0 (Fujiﬁlm Life Science).
5.2.3.9 Cathepsin D activity assay
To meassure the cathepsin D activity, the Cathepsin D Activity Assay Kit (Abnova) was used
according to the manufacturer’s instructions. Brieﬂy, HeLa cells grown in 6-well plates were lysed
in 200 μl of cathepsin D lysis buﬀer, incubated on ice for 20min and centrifuged at 16,000 g
for 15min at 4 ◦C. The supernatant was adjusted to 1 μg of protein in 50 μl of lysis buﬀer.
Subsequently, 50 μl of reaction buﬀer together with 2 μl of substrate were added. Immediately
afterwards, the samples were meassured every ten minutes over a period of 110min while at 37 ◦C
in a ﬂuorometer. As controls of speciﬁcity served a sample that only contained the cathepsin D
substrate in the appropriate buﬀer and a sample that had been treated with 5 μM cathepsin D
inhibitor pepstatin (Calbiochem).
5.2.3.10 Enzyme-linked immunosorbent assay (ELISA) for human GRN
Secreted GRN in conditioned media was quantiﬁed in a sandwich ELISA as described in Capell
et al. [37].
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5.2.4 Microscopy
5.2.4.1 Immunoﬂuorescence
Poly-L-lysine 1% (v/v) poly-L-lysine hydrobromide (Sigma-Aldrich) in dH2O
Paraformaldehyde (PFA) 4 % PFA (w/v) and 4 % (w/v) sucrose in PBS
NH4Cl solution 0.2 % (v/v) Triton X 100, 50mM NH4Cl in PBS
blocking buﬀer 5 % (w/v) bovine serum albumin (BSA) in PBS
10 % (w/v) saponin 2 g saponin in 20ml sterile dH2O
PBS-S 0.01 % (w/v) saponin in PBS
Transfected HeLa, transfected SH-SY5Y or transfected HEK293T cells, T-RExTM-293 cells sta-
bly expressing HA-TMEM106B or HeLa Kyoto cells stably expressing LAMP1-GFP were grown
on glass cover slips. In the case of HEK cells, the cover slips were additionally coated with poly-
L-lysine for better attachment. Usually, 24 h after transient plasmid transfection or induction
of HA-TMEM106B expression or 72 h after siRNA transfection, cells were washed in PBS and
either ﬁxed with ice-cold methanol for 5min at −20 ◦C or with PFA for 20min with subsequent
permeabilization with 0.2 % (v/v) Triton X 100 for 10min at 25 ◦C. Then, cells were blocked
in blocking buﬀer for 30min followed by an incubation with the indicated ﬁrst antibodies for
60min at 25 ◦C. After washing with PBS-S for six times, cells were incubated in Alexa-488-
and Alexa-555-coupled secondary anti-mouse, anti-rat or anti-rabbit antibodies (Life Technolo-
gies) diluted in blocking buﬀer for 30min at room temperature. For F-actin staining, cells were
incubated in phalloidin conjugated with a ﬂuorophore diluted in blocking buﬀer before being
washed and nuclei stained with DAPI for 15min at 25 ◦C. Subsequently, cells were washed in
PBS-S six times and in dH2O once before the cover slips were mounted on glass slides using
ProLongR©Gold Antifade Reagent (Life Technologies). Images were taken on a Zeiss LSM 510 or
710 laser scanning microscope using the 63x oil objective (Plan Apochromat) with a numerical
aperture of 1.4 (diﬀerential interference contrast (DIC)). Images were processed with the LSM
software v3.5 (Carl Zeiss MicroImaging) or the ZEN software (Carl Zeiss MicroImaging).
5.2.4.2 DQ-BSA and lysotracker staining
To analyse whether lysosomal enzymes were proteolytically active, cells were stained with DQ-
BSA, a quenched ﬂuorogenic substrate for proteases which only ﬂuoresce when it is hydrolysed
[310] (see section 5.1.5, table 5.6). Thereby, HeLa cells seeded on coverslips were incubated in
DMEM high glucose and GlutaMAX and 1 % (v/v) P/S, but only 1 % (v/v) FCS for 30min.
Subsequently, 100 ng/ml DQ-BSA were added for 2 h to 6 h according to the manufacturer’s
instructions. Then, life-cell imaging was performed with the Zeiss LSM 710 laser scanning
microscope as described before.
To determine whether lysosomes were acidic upon TMEM106B knockdown, cells were stained
with lysotracker (see section 5.1.5, table 5.6) and life-cell imaging was performed. Thereby, HeLa
cells stably expressing LAMP1-GFP were used for this experiment and seeded on coverslips.
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75 nM lysotracker were added to the cells 30min prior to life-cell imaging according the the
manufacturer’s instructions.
5.2.5 Quantiﬁcation of lysosomal clustering
For the quantiﬁcation of the lysosomal clustering phenotype observed upon TMEM106B knock-
down, immunoﬂuorescence experiments were performed in HeLa cells. Thereby, TMEM106B #3
siRNA-treated HeLa cells and mock controls were stained with antibodies against LAMP2 and
β-catenin. Nuclei were stained with DAPI. Images were taken on a Zeiss LSM 710 laser scanning
confocal microscope by using z-stacks. Subsequently, lysosomal positioning was determined by
automated quantitative image analysis measuring the mean distance of the lysosomes to the
nucleus, done by Christoph Moehl (Image and Data Analysis Facility, DZNE Bonn). More-
over, lysosomal distribution was illustrated by using the Clark aggregation index (CAI) [44] (see
equations 5.1, 5.2 and 5.3):
CAI = observed mean distanceexpected mean distance (5.1)
whereas
observed mean distance =
∑
D(x)
N(x) (5.2)
and
expected mean distance = 1
2
√
N(x)
A
(5.3)
D(x) is the spatial distance to the next neighbour of pixels belonging to the lysosome region,
N(x) is the number of pixels belonging to the lysosome region and A is the number of pixels of
the cell object (area). In total, 510 control cells and 422 TMEM106B siRNA-treated cells were
analysed.
5.2.6 Statistics
Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software) or ImageJ
[231]. All statistical data are represented as mean ± standard deviation (S.D.). If more than
two groups were compared, one-way analysis of variance (ANOVA) followed by the Dunnett’s test
or the Tukey’s test was applied. If only two groups were compared, an unpaired student’s t-test
was used with a signiﬁcance level α of 0.05 (p-values: *: p < 0.05, **: p < 0.01, ***: p < 0.001,
****: p < 0.0001). Usually, data was normalized and set to 1.0 as indicated in the ﬁgures.
Calculations were performed with Excel 2010 (Microsoft).
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